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1. Introduction
1.1. Filarial nematodes
Filarial nematodes belong to the phylum Nematoda (round worms), which comprises
the largest number of parasites that cause disease and damage to humans, animals
and plants. Within the nematodes the family of the Onchocercidae comprises the
filarial parasites. These thread-like worms infest various tissues of their primary
hosts (but never the intestine), have a distinct gender dimorphism and give birth to
larvae which occupy different parts of the body than the adults (Hiepe et al., 2006).
Three out of the eight filarial parasites which infect humans are responsible for most
of the disease caused by their infection: Wuchereria bancrofti and Brugia malayi
are the major agents that cause lymphatic filariasis and Onchocerca volvulus causes
onchocerciasis. They are not only responsible for enormous health problems and
disability, but also, as a consequence, bear a great socio-economic burden (Addiss
and Brady, 2007; Basanez et al., 2006). The successful activity of several anti-filarial
control programmes diminished the number of affected people, nevertheless, many
million people still suffer from these diseases, which are far from being eliminated
(Hoerauf, 2010; WHO, 2010b).
1.1.1. Biology and epidemiology
1.1.1.1. Wuchereria bancrofti and Brugia spp.
Lymphatic filariasis, caused by W. bancrofti, B. malayi and B. timori, is the second
largest cause for long term disability in the world. More than 1.3 billion people live
at risk of infection and 120 million in 83 countries are affected. 90 % of these cases
are due to infection by W. bancrofti, which is widely distributed in sub-Saharan
Africa, India, Southeast Asia, some parts of South America, the Caribbean and the
South Pacific. B. malayi is found in Southeast Asia and B. timori is restricted to
minor foci in South Eastern Indonesia. 40 million people suffer from the disease and
are not only disfigured but also excluded from social life and normal working which
increases the risk of living in poverty. The adult female and male worms live in the
1
Chapter 1. Introduction
lymphatic vessels, mostly of the extremities and male genitals, where they cause
inflammation leading to lymphoedema and hydrocele, respectively. They can be
reproductively active for 5-8 years, in this time they produce millions of microfilariae
(L1 larvae) which circulate in the blood. Different mosquito species, depending on
the geographical location, act as intermediate host and ensure transmission of the
disease between humans. They take up microfilariae by blood feeding and enable the
development of the L1 larvae to the third stage larvae. The peak concentrations of
the microfilariae in the peripheral blood match to the feeding activities of the insect
vector, ensuring effective transmission of larvae. Infective L3 larvae are transmitted
by another blood feeding from the mosquito to humans, where they develop after two
other moults into adult worms. Culex is distributed in urban and semi-urban areas,
whereas Anopheles transmits the disease mainly in rural areas and Aedes mainly in
the Pacific (Addiss and Brady, 2007; Pfarr et al., 2009; Taylor et al., 2010; WHO,
2010b) (Figure 1.1).
1.1.1.2. Onchocerca volvulus
Nearly 37 million people in 34 countries are affected by onchocerciasis caused by
infection with O. volvulus (Taylor et al., 2010). The disease is most abundant
in Africa where > 100 million people in 19 endemic countries are living at high
risk of infection (WHO, 2010a). Smaller foci with prevalence of O. volvulus are
also in Southern and Central America. The transmission of the infective agent to
humans occurs by black flies of the family Simulium. The most important vector
is S. damnosum, widely distributed in Africa and Yemen, which breeds in fast-
flowing oxygenated rivers and streams (Boatin and Richards, 2006). Onchocerciasis
is commonly named river blindness, as people living or working nearby the breeding
habitats are at highest risk of getting bitten by black flies and suffering from the
disease. Furthermore, people often are forced to leave the river valleys in order to
avoid infections and high blindness rates make these fertile countries economically
non-viable. (Hoerauf, 2011). During a blood meal the black fly takes up microfilariae
from the skin and after two moults within the insect the L3 larvae develops. This
infective larvae is transmitted during another blood meal from the intermediate to
the human host. Within one year, after another two moults, the mature adult worms
develop. The females reside in subcutaneous nodules (Onchocercomata) which are
located near the biting sites of the black flies, whereas the male worms can move
freely from one nodule to an other. The adults are long-lived and can reach an
age of 12-15 years, in this time producing millions of microfilariae which migrate
through the skin and the eye. Microfilariae can live up to 2 years and their death
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causes inflammation leading to dermatitis and eye lesions (Boatin and Richards,
2006; Udall, 2007; Taylor et al., 2010).
Figure 1.1.: Life cycle of Wuchereria bancrofti. The infective 3rd stage larvae enters
the human host during a blood meal of the insect vector in different species of Culex,
Anopheles, Aedes and Mansonia (1). After two moults the infective larvae develop into
female and male adults, which reside in the lymphatics, commonly of the limbs and males
genitals (2). There they produce thousands of microfilariae, which migrate through the
blood and lymphatic vessels with nocturnal periodicity which coincides with the biting
activity of the mosquitoes (3). During another blood meal microfilariae are taken up
(4) and migrate from the mosquito midgut to the thoracic muscles (5). There they again
moult twice from the L1 (6) to the infective L3 larvae (7). After migrating to the proboscis
(8) the infective larvae can be transmitted to a human host, thereby closing the cycle (1).
Source: Centers of Disease Control and Prevention, http://www.dpd.cdc.gov/dpdx
1.1.2. Pathogenesis and disease
1.1.2.1. Lymphatic Filariasis
One third of the infected people develop clinical disease of lymphatic filariasis. The
remaining have asymptomatic infections, characterized by high worm loads and mi-
crofilaraemia. The worms actively down-regulate the host immune responses and
3
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thereby ensure their survival (Hoerauf et al., 2005). On the other hand, patients
that develop lymphoedema or hydrocele have only few or no parasites but vigor-
ous specific immune reactions. Frequency of infections and genetic predisposition
seem to play a role in the outcome of the disease (Debrah et al., 2006). In the
non-permissive form, inflammatory responses to dying worms in the lymphatic ves-
sels lead to lymphadenitis and filarial fever and temporal immobilisation can occur.
Antigenic stimulation promotes the up-regulation of vascular endothelial growth fac-
tors (VEGFs), which mediate lymphangiogenesis and dilation of lymphatic vessels.
Antigens of the endosymbiotic Wolbachia (Chapter 1.2.4) greatly contribute to the
pro-inflammatory stimulation. Then the damaged and enlarged lymph vessels are
no longer capable of efficiently transporting lymph fluids, making them suscepti-
ble for secondary infections. This further promotes lymphangiogenesis, resulting
in fluid extravasation and lymphoedema. The severest outcome, elephantiasis, is
characterized by a painful massive swelling of the legs with thickened and fissured
skin (Figure 1.2 A). Lymphoedema can also occur in breast and arms. A second
clinical manifestation of LF in men is hydrocele, the accumulation of lymph fluid in
the scrotum (Pfarr et al., 2009; Taylor et al., 2010).
1.1.2.2. Onchocerciasis
Onchocerciasis mainly presents as dermatitis and keratitis due to host inflammatory
reactions provoked by the death of microfilariae. The manifestation of the disease
starts a year after infection, the time when adult female worms start producing
microfilariae (Boatin and Richards, 2006). Severity of symptoms differs greatly be-
tween individuals, depending on infection intensity and predisposition of the host
with associated immune responsiveness. Patients with generalized onchocerciasis
have many parasites and a high microfilarial load, but they develop only weak der-
matitis due to down-regulated host pro-inflammatory responses. Death of skin mi-
crofilariae causes skin irritations with intense itching (Figure 1.2 B). The dermal
lesions range from papular dermatitis and degeneration of skin (atrophy) to sev-
erer outcomes with depigmentation and edema of the limb (Sowda). The latter is
a form of hyperreactive onchocerciasis dominated by strong pro-inflammatory im-
mune responses. Microfilariae also migrate through the eye conjuntiva, where, upon
chronic exposure, stimulation of immune responses leads to sclerosing keratitis caus-
ing visual impairment that may eventually result in blindness (Figure 1.2 C). As in
lymphatic filariasis Wolbachia bacteria play a role in this clinical outcome (Chapter
1.2.4) (Taylor et al., 2010; Hoerauf, 2011).
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Figure 1.2.: Examples of pathological outcomes of lymphatic filariasis and onchocerci-
asis. (A) Patient with elephantiasis, the severest form of lymphoedema. Image taken
from Debrah et al. (2006). (B) Lichenified onchodermatitis. Image taken from Hoerauf
(2011). (C) Patient with ocular lesions due to O. volvulus infection. Image courtesy of
WHO/TDR/Mark Edwards.
1.1.3. Anti-filarial treatment
The basis for the WHO control programmes to eliminate filariasis is mass drug
administration (MDA) using the three drugs ivermectin (IVM), albendazole and
diethylcarbamizine (DEC). The Global Programme to Eliminate Lymphatic Filar-
iasis (GPELF) has the goal to eliminate LF by 2020 by breaking transmission.
Fiftyone of the 81 endemic countries have launched the programme and annually
distribute either 200-400 µg/kg IVM + 400 mg albendazole or, in countries without
co-endemicity with O. volvulus, 600 µg/kg DEC + 400 mg albendazole. Since 2000
1.9 million treatments have been provided by the GPELF, thereby preventing 32
million disability-adjusted life years. China and Korea became the first countries
declared to have eliminated LF in 2008 due to MDA programmes and in many coun-
tries the microfilariae rates have been reduced to less than 1 % (Taylor et al., 2010;
WHO, 2008).
Several control programmes improved onchocerciasis in the Americas and Africa.
The Onchocerciasis Elimination Program for the Americas (OEPA) uses twice yearly
mass treatment with IVM and thereby covers 85 % of the affected communities.
Early strategies to combat onchocerciasis in Africa, carried out by the Onchocer-
ciasis Control Programme (OCP), relied on extensive vector control using aerial
larviciding (Boatin and Richards, 2006; Hoerauf, 2010). The OCP success is contin-
ued by the African Programme for Onchocerciasis Control (APOC) that relies on
community-directed treatment of 150 µg/kg IVM given annually to break transmis-
sion of the disease in African endemic countries by 2015. This programme intends to
cover > 90 million people with treatment (WHO, 2010a). DEC is contraindicated for
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onchocerciasis due to side effects induced by killing of microfilariae in the eye. IVM,
on the other hand, does not cause ocular damage. The drug blocks postsynaptic
glutamate-gated chloride channels and thereby paralyses the worm, the immobilized
microfilariae are transported to other parts of the body and are not killed within the
eye. Slight skin irritations and fever occur only at high microfilarial loads or higher
doses of IVM (Hoerauf, 2011). Although IVM as well as DEC and albendazole
kill microfilariae and late embryonic stages, they only have a little macrofilaricidal
effect. Because the adult female worms are only temporally sterilized, microfilar-
iae reappear in the skin after ca. 6 month. Repeated treatments for the worm’s
life span are therefore necessary to break transmission (Udall, 2007). Other drugs
considered for anti-filarial treatment include moxidectin and suramin. Moxidectin
has shown to be very efficient in reducing microfilariae numbers, but also does not
have macrofilaricidal properties. Suramin is a macrofilaricidal drug, but the delivery
mode (injections for several weeks) is inconvenient and it has immense side effects,
making it unsuitable for MDA and also very unpopular for individual treatment
(Hoerauf, 2008; Udall, 2007).
The control programmes of the recent years had a great success in preventing
many cases of disease and greatly reduced transmission in several countries (Ottesen
et al., 2008; WHO, 2010a). Sustaining and further promoting these achievements
is important. Thus, reports of IVM resistance are a great concern, as IVM is the
sole drug available for MDA against onchocerciasis. An introduction of a new drug,
which is suitable for MDA, is therefore urgently needed prior to resistant strains
spreading (Bourguinat et al., 2007; Osei-Atweneboana et al., 2007; Bourguinat et al.,
2008). An ideal drug against onchocerciasis would be macrofilaricidal or have a long
term sterilizing effect. For treatment of LF, a macrofilaricidal effect should not lead
to rapid death of the adult worms, which would cause adverse reactions. Ideally,
symptoms of lymphoedema and hydrocele would be reversed. A new promising
anti-filarial strategy that uses doxycycline to target the endosymbiont Wolbachia
has proven to show many of these features of an ideal drug (Hoerauf, 2008). The
principle is introduced in detail in Chapter 1.2.5.
1.2. Wolbachia
Wolbachia bacteria were first discovered by Hertig and Wolbach (1924), who de-
scribed them as Rickettsia-like bacteria in Culex pipiens. The establishment of
the genus Wolbachia followed a few years later (Hertig, 1936). In the 1970s unusual
bodies within microfilariae and developmental stages of filarial nematodes have been
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identified as bacteria by electron microscopy (Kozek, 1977; Kozek and Marroquin,
1977; McLaren et al., 1975). Unaware of the importance of these bacteria for the
filarial biology they were forgotten for the next 20 years until the rediscovery of
bacterial sequences in filaria in the 1990s in the course of filarial genome sequencing
projects. The sequences were first considered as contaminants but quickly shown
to derive from Wolbachia bacteria. Sironi et al. (1995) first described Wolbachia as
the endosymbiont of the filaria nematode Dirofilaria immitis.
1.2.1. Distribution and Phylogeny
Wolbachia are gram-negative α-Proteobacteria of the order Rickettsiales. Close rela-
tives are Anaplasma, Ehrlichia and Rickettsia (O’Neill et al., 1992). They are found
in an estimated number of 66 % of insect species (Hilgenboecker et al., 2008) and in
other arthropods like spiders, butterflies, scorpions and termites (Baldo et al., 2007;
Bordenstein and Rosengaus, 2005; Hiroki et al., 2004; Rowley et al., 2004) where
they are commonly known as reproductive parasites. Wolbachia are an extremely
abundant bacterial group, considering the great diversity of insect species and more
than 1 million of them harbouring Wolbachia (Werren and Windsor, 2000). Further-
more, Wolbachia are found in 90 % of filarial nematodes, where they are mutualistic
symbionts (in contrast to their lifestyle in arthropods). Filarial species containing
Wolbachia include the medical important species B. malayi, B. timori, Wuchereria
bancrofti, Onchocerca volvulus, Mansonella sp. and Dirofilaria immitis. Notable
exceptions are Loa Loa, Acanthocheilonema viteae, O. flexuosa and Setaria spp.
(Bandi et al., 1998; Taylor and Hoerauf, 1999; Bu¨ttner et al., 2003; Keiser et al.,
2008).
Phylogenetic analysis based on Wolbachia 16S rRNA, ftsZ, groEL, gltA, dnaA,
ftsZ and Wolbachia surface protein (wsp) sequences, divides Wolbachia into eight
supergroups A-H, with supergroup G tentative. Supergroups C and D are comprised
of Wolbachia that are found in filarial nematodes. The other supergroups comprise
Wolbachia from arthropods with supergroup A and B the most abundant ones. Su-
pergroup F includes Wolbachia from arthropods and filariae (Casiraghi et al., 2005;
Lo et al., 2007; Werren et al., 2008) (Figure 1.3). Interestingly, the phylogeny of
the filarial nematodes is in concordance with the phylogeny of the Wolbachia they
harbour, suggesting a co-evolution of the filarial host with its endosymbiont. In
contrast, phylogeny of the arthropod host is not in concordance with their Wol-
bachia, indicating horizontal transmission of Wolbachia between arthropod species.
Due to the close association filarial larvae have with the intracellular environment
of their insect vectors, a transmission of Wolbachia from insects to nematodes, or
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vice versa, after the separation of nematodes and arthropods has been suggested.
Nevertheless, data are missing to resolve the ancestry of parasitic and mutualistic
Wolbachia (Bandi et al., 1998; Bordenstein et al., 2009).
Figure 1.3.: The phylogenetic tree of Wolbachia. Various phylogenetic studies divided
Wolbachia into 8 clades, named supergroups A-H. Figure taken from Lo et al. (2007).
1.2.2. Morphology and Localisation
Wolbachia are rod shaped bacteria with a length of around 1 µm. They are obligate
intracellularly and live in various tissues of different arthropod species, but notably
are found in their female reproductive organs. In filarial nematodes Wolbachia are
located in the ovaries, oocytes, embryos and microfilariae, but they are absent from
the male reproductive organs. Additionally, they are found in varying amounts in the
lateral hypodermal chords of both female and male worms. On electron microscopic
photos 3 membranes can be distinguished by which Wolbachia are surrounded: the
two inner layers are thought to be the inner and outer bacterial membrane, whereas
the third outermost layer represents an vacuole with membrane derived from the
host (Taylor and Hoerauf, 1999) (Figure 1.4). It is yet not clear which organelle
contributes to forming this vacuole. One study describes a Wolbachia strain in
association with the endoplasmatic reticulum (Serbus et al., 2008; Voronin et al.,
2004).
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Figure 1.4.: Cross-sections of filarial nematodes showing endosymbiotic Wolbachia bac-
teria. Electron micrograph of Wuchereria bancrofti, with a cluster of 5 bacteria (arrows)
(A). Wolbachia with the characteristic double membrane (arrow) within a vacuole (v) in
the lateral chord of an adult female Brugia malayi (B). Cross-section of a female adult
Onchocerca volvulus filaria with a staining against bacterial hsp60 (red). Wolbachia are
seen in the hypodermis (h) but not in the cuticle (c), the musculature (m), the intestine
(i), and the uterus epithelium (u). Arrows indicate unspecific hsp-60 staining, possibly
against nematode hsp60 (C). Figures A and B are taken from Taylor and Hoerauf (1999)
and Figure C from Hoerauf et al. (2000).
1.2.3. Role of Wolbachia in arthropods
Reproductive alterations In arthropods Wolbachia mostly behave as parasitic
endosymbionts, causing a range of reproductive phenotypes which all enhance the
production or survival of female offspring. As Wolbachia are transmitted vertically
via the maternal germline these alterations increase the number of infected females
with a reproductive advantage and promote spreading of Wolbachia into insect pop-
ulations (Serbus et al., 2008).
The most common effect Wolbachia induces in insects is cytoplasmatic incom-
patibility (CI). Here, Wolbachia-infected females can mate with infected (with the
same Wolbachia supergroup) and uninfected males, but crosses between uninfected
females with infected males are incompatible and do not produce any offspring. The
cytological mechanisms underlying this phenotype are defects in the embryonic mi-
tosis: male and female pronuclei have an asynchronous development, which is due
to a delayed nuclear envelope breakdown and chromosome condensation of the male
pronuclei. This again can be explained by a delayed activity of Cdk1 kinase and
associated failure of histone deposition to the male pronucleus (Landmann et al.,
2009).
Other phenotypes that are induced by Wolbachia and promote female offspring,
although not as common as CI, are parthenogenesis (females instead of males develop
from unfertilized eggs), feminization (genetic males develop as females) and male
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killing, which results in increased food supply for the surviving female offspring
(Werren et al., 2008).
Transmission strategies The success of Wolbachia in arthropods can, besides
these reproductive alterations, also be explained by highly efficient transmission
strategies. Transmission rates are 97 % in the wild and even 100 % in the laboratory.
Wolbachia have evolved mechanisms which guarantee their incorporation into the
germline stem cells during embryogenesis. This involves specific localisation patterns
of Wolbachia in the oocyte, which seems to be achieved by dynein and kinesin
dependent transport along microtubuli (Ferree et al., 2005; Serbus and Sullivan,
2007). Little is known about how Wolbachia is able to interact with the host’s
cytoskeleton, but the annotated genome of Wolbachia from Drosophila melanogaster
(wMel) allows one to make some assumptions, like a role for the many Ankyrin
repeat domain proteins encoded by wMel in these processes (Fenn and Blaxter,
2006; Iturbe-Ormaetxe et al., 2005; Walker et al., 2007).
Fitness benefits for insects Recent research led to the assumption that the
highly efficient invasion of Wolbachia into insect populations can not only be ex-
plained by their reproductive parasitism, as some Wolbachia strains do not induce
CI, yet they are able to invade the host population. A role of Wolbachia for iron
metabolism and tolerance of oxidative stress indicates that the endosymbiont can
function as a nutrional mutualist in insects. Besides altering reproductive mecha-
nisms, fitness benefits provided by Wolbachia to their insect host might be a second
basis for establishment of infection (Brennan et al., 2008; Brownlie et al., 2009;
Kremer et al., 2009).
Wolbachia-mediated pest control Another beneficial effect of Wolbachia for
insects is the induction of resistance to infection by several viruses (Hedges et al.,
2008; Teixeira et al., 2008; Frentiu et al., 2010). This offers a great potential for
new pest control strategies. Additionally, Wolbachia has a life shortening effect in
Aedes aeygypti, the vector of dengue virus. An invasion of this Wolbachia strain
into Aedes mosquitoes could be an efficient approach to control dengue (McMeni-
man et al., 2009).
Although Wolbachia of arthropods have a different lifestyle than the nematode
Wolbachia, many of the host-endobacteria interactions may be based on a similar
machinery, e.g. the strategies of transmission via the maternal germline (Landmann
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et al., 2010). Thus, knowledge of the mechanisms of the insect-Wolbachia associa-
tion and the genes and pathways involved might also provide information to better
understand the molecular mechanisms of the nematode-Wolbachia symbiosis, which
is yet not well understood.
1.2.4. Role of Wolbachia in filarial nematodes
Role for filarial biology The rediscovery of Wolbachia bacteria in filarial ne-
matodes in the 1990s awoke a great interest, as this provided a new approach in
filarial research to control filarial infections. Wolbachia were until then known as
reproductive manipulators in arthropods and one could assume that they somehow
might influence the filarial biology as well. Subsequent in vitro and in vivo studies as
well as human trials proved that Wolbachia not only influence the development and
survival, but are essential for their filarial host (in contrast to the insect-Wolbachia).
Treatment of filaria with anti-rickettsial antibiotics like doxycycline leads to deple-
tion of the bacteria and results in embryonic blockade, degenerate embryos and larval
moulting defects. Wolbachia depletion also leads to sterility and finally to the death
of adult worms (Hoerauf et al., 2000, 2001b, 2008; Langworthy et al., 2000; Taylor
et al., 2005). These observations are a direct consequence of Wolbachia depletion, as
treatment of the Wolbachia-free filarial nematode A. viteae with the same antibiotics
does not alter worm development or survival (Hoerauf et al., 1999). This indicates
that Wolbachia provides its host with essential nutrients and functions and that
the filaria-Wolbachia symbiosis is of obligatory mutualistic nature. Wolbachia are
transmitted vertically via the maternal germline, as shown by crossing experiments
with B. malayi and B. pahangi (Taylor et al., 1999). Recent microscopic studies
by Landmann et al. (2010) brought the understanding of the mechanism forward:
similar to the transmission in insects, Wolbachia have a posterior concentration in
the Brugia oocyte and show an asymmetric segregation pattern in embryogenesis
which guarantees their incorporation into the female germline.
Role for pathology Wolbachia bacteria play an important role for the pathology
of filarial infections. Wolbachia-associated products, such as Wolbachia Surface Pro-
tein (WSP) are inducers of pro-inflammatory cytokines (Brattig et al., 2004; Taylor
et al., 2000) which can also regulate the expression of VEGF-A and VEGF-C (Asano-
Kato et al., 2005; Ristima¨ki et al., 1998). Up-regulation of VEGFs then can lead
to lymph vessel growth and thereby mediates lymphatic pathology (Debrah et al.,
2006). A direct connection between Wolbachia products and pathological outcome
has also been shown in onchocerciasis. In an experimental model of keratitis, filarial
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antigen induces the infiltration of neutrophils into the eye and this is not seen with
Wolbachia-free filarial antigen (Gillette-Ferguson et al., 2004; v Saint Andre et al.,
2002). Toll-like receptor 2 (TLR-2) has been shown to mediate Wolbachia-antigen
recognition (Daehnel et al., 2007; Hise et al., 2007). Specifically, the Diacyl Wol-
bachia lipoprotein (WoLP) induces innate and adaptive inflammatory responses in
a TLR2 and 6 dependent manner (Turner et al., 2009). The host immune system is
exposed to Wolbachia immunogenic materials e.g. during the uptake of degenerate
larvae or dead worms by macrophages. In the event of a rapid death of microfilariae,
e.g. upon treatment with DEC, the immune system is confronted with high amounts
of Wolbachia antigens leading to adverse reactions (Pfarr et al., 2009).
1.2.5. Wolbachia as a target for filariasis control
The essential function of Wolbachia for filarial development and survival as well as
their impact on the pathological outcome of filarial infections makes them potential
targets for treating filariasis. A new anti-filarial chemotherapy using doxycycline
or rifampicin to clear Wolbachia from worms has been proven to be successful in
several clinical trials (Debrah et al., 2011; Hoerauf et al., 2000, 2001b; Supali et al.,
2008; Taylor et al., 2005). A 4-6 week course of 200 mg doxycycline/day depleted
Wolbachia from W. bancrofti and led to clearance of microfilariae from blood, to a
long-term sterilization of females and eventually to the death of the adult worms.
Equally, onchocerciasis treatment for 4-6 weeks with 100-200 mg doxycycline per day
has both micro- and macrofilaricidal effects. With the 6-week course of 200 mg/day,
60 % of female worms were dead at the end of the observation period. The slow
killing of the worms prevents the sudden release of great amounts of Wolbachia and
thereby also the adverse reactions seen, e.g. with DEC. This makes doxycycline the
only macrofilaricidal drug without major side effects. Furthermore, doxycycline has
been shown to improve disease symptoms in lymphatic filariasis, which is another
great advantage over the currently used anti-filarial drugs. Severity of lymphoedema
and hydrocele can be reversed, which is thought to be due to the Wolbachia clearing
and associated decrease in pro-inflammatory stimuli. Indeed, the decrease of plasma
VEGF levels after Wolbachia depletion precedes the amelioration of the disease
(Debrah et al., 2006; Mand et al., 2009).
Doxycycline is suitable for individual therapy and is being considered for ”endgame”
control efforts in foci where transmission has stopped, but where a few individuals
are still infected. However, it is not suitable for MDA due to the long period of ad-
ministration and the contraindications for children under 9 years, and breastfeeding
and pregnant women (Hoerauf, 2008; Taylor et al., 2010).
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Targeting Wolbachia fulfils many of the requirements for a new anti-filarial drug
and as there is a greater genetic divergence of the bacteria from the human host than
that of the nematodes, chances are increased to specifically target the endosymbiont
without interfering with human functions. Therefore, a great effort is made by the
Anti-Wolbachia Consortium (A-WOL) (http://A-WOL.com) to identify potential
endosymbiont genes for a new anti-Wolbachia chemotherapy which is compatible
with the MDA programmes (Slatko et al., 2010).
1.3. Insights from the decoding and annotation of
the filarial and Wolbachia genome
The sequencing of the genome of B. malayi, initiated by the Filarial Genome Project,
was undertaken to further research on the parasitic life style and the interactions
with the host. B. malayi was chosen as representative for a human filarial parasite
because a sufficient supply of material is available and the nematode can be main-
tained in a rodent as well as ex vivo. The sequencing of its endosymbiont Wolbachia
facilitated research on the molecular dependencies of the symbiosis by revealing
metabolic gaps in both genomes (Foster et al., 2005; Ghedin et al., 2004).
1.3.1. The genome of B. malayi
The genome of B. malayi is 95 Mb and is encoded on 5 chromosomes, including an
XY sex determination pair. Additionally, the nematode contains a 14 kb mitochon-
drial genome and the 1 Mb endosymbiont genome. The Brugia genome has been
sequenced at 9-fold coverage with 90 % of the genome being assembled. Closing
the gaps between scaffolds is complicated by the many repetitive elements, which
make up 14 % of the genome. B. malayi is estimated to have 14.500 -17.800 protein
coding genes which is a lower number than reported for the free-living non-parasitic
nematode C. elegans. The comparative analysis with the genome of C. elegans is
informative for finding genes relevant for the parasitic life style (adaption to the
mosquito and mammalian environment) and for symbiotic mechanisms with the en-
dosymbiont Wolbachia. Whereas genes and genome structures that are shared by
both organisms indicate common core elements for nematodes, dissimilarities might
guide to specific adaptations which have evolved under the pressure of parasitism
and the presence of Wolbachia. The two nematode genomes are more distinct than
previously thought. Although linkage of genes has been conserved, the gene order
within linked genes differs between B. malayi and C. elegans. Furthermore, C. el-
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egans seems to have lost many genes which have been retained in Brugia; these
genes might encode proteins needed for the parasitic life style. Approximately 50 %
of the Brugia genes have orthologs in C. elegans, and 20 % of the predicted genes
are specific to B. malayi because they have no identities in any database (Ghedin
et al., 2007).
While the sequencing of the genome gives information about filaria specific genes
and pathways, which are likely targets for intervention (for example genes involved
in moulting and cuticle formation, neuronal signalling and reproductive biology), it
also reveals metabolic gaps in the genome which might be the basis for the mutu-
alistic symbiosis with Wolbachia: 9 of 10 genes needed for de novo purine synthesis
are missing, only one gene needed to synthesise heme and no genes for riboflavin
synthesis are found in the genome (Ghedin et al., 2007; Scott and Ghedin, 2009).
1.3.2. The genome of Wolbachia of B. malayi
The genome of Wolbachia from B. malayi (wBm) was the first sequenced Wol-
bachia genome of a parasitic nematode (Foster et al., 2005) (Figure 1.5) and had
been published shortly after the genome of Wolbachia from Drosophila melanogaster
(wMel) (Wu et al., 2004). Beside these, the genomes of wPip, the endosymbiont
of Culex pipientis (Klasson et al., 2008) as well as parts of the Wolbachia genomes
from several Drosophila hosts and filarial nematodes have been sequenced (Salzberg
et al., 2005; Scott et al., 2011). Thus, comparative analysis of the genomes of the
different Wolbachia strains is possible and can help to unravel the genomic basis of
mutualistic and parasitic symbiosis (Fenn and Blaxter, 2006).
The circular genome of wBm has a size of 1.1 Mb (Foster et al., 2005) and thus
is smaller than the genomes of free-living α-Proteobacteria (> 3 Mb). Reduced
genomes and gene losses are a common characteristic of obligate intracellular bac-
teria and reflect the adaption to the host (Moran, 2003; Sun et al., 2001). 806
protein coding genes were identified and one copy for each ribosomal RNA. The
amount of repetitive DNA in the wBm genome is much lower (5.4 %) than in the
wMel genome (14 %). Furthermore, in contrast to the wMel genome, wBm does not
contain prophages (Foster et al., 2005; Wu et al., 2004). The large amount of repet-
itive DNA and prophages in the insect Wolbachia genomes are suggested to reflect
a genome plasticity and the ability to adapt to the cellular environment of novel
host species, which is not necessary in the strictly vertically transmitted Wolbachia
from nematodes. Frequent genome rearrangements in arthropod Wolbachia would
also explain the missing colinearity between the wMel and wBm genomes (Brownlie
and O’Neill, 2005; Foster et al., 2005).
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Figure 1.5.: The genome of Wolbachia from B. malayi. Figure taken from Foster et al.
(2005).
The Wolbachia genome encodes proteins for translational processes, the biogenesis
of cytochrome c oxidase and c-type chromosomes, most genes for DNA replication
and repair, as well as genes for protection from oxidative damage. The enzymatic
machinery to counter deleterious effects may reflect the adaptation of the bacteria
to the intracellular environment of the host. The retention of enzymes for transla-
tional processes together with the DNA repair systems could also reflect mechanisms
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to reduce deleterious mutations due to repeated bottlenecking during transmission
of Wolbachia. Most of the signal transduction machinery has been lost from the
genome, except some genes for stress response and cell-cycle regulation. Further-
more, transcriptional regulators are not retained in the genome, indicating that
Wolbachia genes are constitutively expressed (Brownlie et al., 2007; Foster et al.,
2005; Slatko et al., 2010). Wolbachia has lost several genes for peptidoglycan syn-
thesis, likely because a cell wall is not needed for osmotic stabilization in the host
vesicle. Nevertheless, the precursor lipid II can be synthesised and is functional.
The role of lipid II in a cell wall-less bacteria is not yet clear but might play a vital
role for cell division (Foster et al., 2005; Henrichfreise et al., 2009). As evidenced by
the genome information, LPS cannot be synthesised by wBm, despite immunologi-
cal data indicate an LPS-like molecule to be important in the immune responses in
filarial infections. Besides the stimulation of the immune system by WSP (Brattig
et al., 2004), a lipoprotein associated with the unusual peptidoglycan structure of
wBm (PAL) contributes to the inflammatory responses against Wolbachia (Turner
et al., 2009).
1.3.2.1. Metabolic capacities that indicate Wolbachia-host dependencies
Wolbachia has reduced metabolic pathways, which likely makes them dependent
upon their host. wBm is incapable of synthesising many cofactors and vitamins.
Pathways for de novo synthesis of Coenzyme A, NAD, biotin, lipoic acid, ubiquinone,
folate and pyridoxal phosphate are missing. Strikingly, wBm has lost genes for the
synthesis of all amino acids, except meso-diaminopimelate.
Metabolic pathways that have been retained in the wBm genome are especially
interesting, since they may indicate mechanisms which make filarial nematodes de-
pendent upon their endosymbionts. Since Wolbachia is capable of de novo synthesis
of purines and pyrimidines, the bacteria might supply the filarial host with addi-
tional nucleotides in periods of high DNA requirements (e.g embryogenesis). This
is highly likely, since the B. malayi genome indicates that the worms have incom-
plete purine and pyrimidine biosynthetic pathways encoded in the nematode genome
(Ghedin et al., 2007). Furthermore, the pathways for biosynthesis of isoprenoids,
fatty acids and phospholipids are retained in the wBm genome. The presence of the
complete pathway for riboflavin biosynthesis is interesting, as B. malayi lacks the
enzymes for its synthesis, therefore Wolbachia could be an important source for this
essential cofactor. The Wolbachia genome encodes enzymes for the biosynthesis of
glutathione, which either might be used for oxidative stress reduction in the Wol-
bachia vesicle or is provided to the host. Glycolytic enzymes are found in wBm with
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only two enzymes missing for glycolysis. Nevertheless, the reverse reaction, gluco-
neogenenis, using the enzymes fructose-1,6-biphosphatase and pyruvate phosphate
dikinase (PPDK) may occur in Wolbachia. Intermediates for the citric acid cycle,
which is present in Wolbachia, might serve as growth substrates, because they might
be easily obtained by the proteolysis of host proteins. Pyruvate, which is abundant
in the worm, is also a likely substrate for Wolbachia as it can be metabolised via
the gluconeogenetic pathway. The final product, fructose-6-phosphate, can enter the
pentose phosphate pathway, thereby producing the substrates for the biosynthesis
of nucleotides, riboflavin and FAD (Brownlie et al., 2007; Fenn and Blaxter, 2006;
Foster et al., 2005; Slatko et al., 2010).
Heme biosynthesis One pathway of special interest encoded by Wolbachia bac-
teria is the heme biosynthesis pathway. Heme is an essential cofactor needed in
catalases, hemoglobins, cytochromes and peroxidases and is involved in important
biological processes like oxidative phosphorylation and electron transport.
Wolbachia encode all but one enzyme to synthesise the cofactor heme. The
missing gene is protoporphyrinogen oxidase, a gene that is absent in many alpha-
proteobacteria, but very likely complemented by another gene (Narita et al., 1999).
B. malayi, on the other hand, lacks most of the genes needed to produce heme
(Foster et al., 2005). The only gene that is encoded by the B. malayi genome is
ferrochelatase, which catalyses the last step of heme synthesis, the conversion of
protoporphyrin IX into heme. Therefore B. malayi either takes up heme from the
environment or is provided by its Wolbachia endosymbiont (Slatko et al., 2010).
Recent findings by Wu et al. (2009) indicate that the latter case might be true:
the inhibition of heme biosynthesis performed in an ex vivo study led to immobil-
ity and degenerate tissue of B. malayi worms, although hemin was provided in the
culture medium. One phenotype observed after depletion of Wolbachia from filar-
ial nematodes is the inability of larval moulting, which could be a consequence of
heme deprivation. Ecdysteroid-like hormones are important for moulting and re-
production and ecdysone signalling is required in Brugia malayi (Tzertzinis et al.,
2010). These hormones are synthesised in Drosophila, in part, by cytochrome P450
mono-oxygenases (Petryk et al., 2003). A loss of function of these heme dependent
enzymes after Wolbachia depletion may therefore account for the impairment of de-
velopmental processes in the worm (Negri et al., 2010).
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1.3.2.2. Further predicted Wolbachia-host interactions
Secretion and transport machineries are important for the communication of intra-
cellular bacteria with their host and bacterial persistence within the host cell. Both
the arthropod Wolbachia and wBm contain a complete gene set to form a functional
type IV secretion system (T4SS). This secretion system has been shown to deliver
effector proteins, DNA and virulence factors via the bacterial membrane (Masui
et al., 2000; Foster et al., 2005; Pichon et al., 2009). It is unknown which molecules
are secreted by Wolbachia but the Ankyrin domain proteins might be a candidate
(Rikihisa and Lin, 2010). Five ANK proteins are found in wBm and 23 in wMel. In
eukaryonts ankyrins mediate protein-protein interactions, e.g. to the cytoskeleton
(Mosavi et al., 2004). In Anaplasma phagocytophilum an Ank protein is secreted and
binds to host chromatin (Caturegli et al., 2000; Foster et al., 2005; Iturbe-Ormaetxe
et al., 2005). Wolbachia Ank proteins might therefore interact with the host cell
cytoskeleton or play a role in regulation of host cell cycle and gene expression (Fenn
and Blaxter, 2006).
1.4. Litomosoides sigmodontis - an animal model
for filariasis
In order to study immunology and genetics of filarial infections, Petit et al. (1992)
introduced the L. sigmodontis experimental model. They identified the BALB/c
mouse strain as fully permissive to L. sigmodontis, making it the only filarial worm
that can complete its life cycle and that develops a patent microfilaremia in an
inbred mouse strain. L. sigmodontis is closely related to the human filaria Brugia
spp., O. volvulus, and W. bancrofti and is therefore widely used to study filariasis
(Allen et al., 2000; Hoerauf et al., 2001a; Allen et al., 2008). Like most filarial
species, L. sigmodontis harbours Wolbachia bacteria and depletion of bacteria with
tetracycline leads to a block in embryogenesis (Hoerauf et al., 1999), making this
filarid a suitable model to study symbiosis (Heider et al., 2006).
1.4.1. The life cycle of L. sigmodontis
The natural host of L. sigmodontis is the cotton rat Sigmodon hispidus. The adults
reside in the pleural cavity and at high infection rates also in the coelomic cavity.
Mature female worms release microfilariae, the L1 larvae, which circulate in the pe-
ripheral blood, where they can be taken up during a blood meal of the intermediate
host, the tropical rat mite Ornithonyssus bacoti. Within 10-12 days the L1 larvae
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Figure 1.6.: Life cycle of L. sigmodontis. During a blood meal, mites take up microfilariae
from the peripheral blood of the cotton rat Sigmodon hispidus. The larvae molt twice,
resulting in the infective L3 larvae. These are used to either infect new cotton rats or
BALB/c IL-5 ko mice, which were used for performing experiments in this study.
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undergoes two moults into the infective third stage larvae (L3) which is transmitted
by another blood feeding from the mite to the definite host, the cotton rat. Within
22-28 days the L3 larvae undergoes two other moults resulting in the juvenile adult
worms, which at this time have migrated to the pleural cavity. At this final destina-
tion they mate and produce microfilariae which can be detected in the blood around
day 55 p.i. (Hoffmann et al., 2000). Female adult worms have a length of up to 13
cm whereas male worms are only around 3 cm in length and can therefore easily be
distinguished from each other. The laboratory life cycle is maintained in the cotton
rat, as microfilariae concentrations are higher and adult worms live longer in the
natural host compared to mice. In order to perform experiments the infective larvae
can then be transmitted to BALB/c mice (Figure 1.6).
Th2 immune responses help to control filarial infections. The interleukin (IL) 5
cytokine influences development and number of L. sigmodontis in the mice (Saeftel
et al., 2003; Volkmann et al., 2003). IL-5 knock out (ko) mice have higher worm
burdens and a prolonged patency, which is especially important when treating mice
harbouring adult worms over a long period of time, as carried out in this study.
An additional advantage of using BALB/c IL-5 ko mice is the reduced formation of
inflammatory nodules around the worms.
1.5. Tools for analysing the host-Wolbachia
interactions
The first experiments that revealed the importance of Wolbachia endosymbionts for
their filarial host came from assessing the worm phenotype after depletion of the
bacteria with antibiotics (Bandi et al., 1999). The Wolbachia-free filaria A. viteae
is used as a control for unspecific effects of the antibiotics or drugs (Heider et al.,
2006; Hoerauf et al., 1999).
Research of Wolbachia is greatly hindered by the fact that the bacteria cannot
be maintained outside their filarial host or insects cells, respectively, which makes
classic genetic manipulation tools impossible. Attempts to culture W. pipientis in
cell-free media showed that the bacteria can survive in amino acid-rich media for at
least one week and that they were still able to re-infect the insect cells. If the exact
molecular composition can be defined, i.e. molecules needed for Wolbachia to repli-
cate, transformation of Wolbachia and deletion of specific genes might be possible
in the near future (Rasgon et al., 2006). This would greatly ease the way to analyse
the role of specific genes for symbiosis. Nevertheless, infection of Wolbachia-cured
filaria with a genetically manipulated Wolbachia will be difficult, as curing of the
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worm of the endosymbiont results in developmental defects. Such attempts would
therefore be restricted to investigations on insect-Wolbachia. However, Wolbachia
from insects contain a similar set of genes like filarial Wolbachia and many symbi-
otic strategies might work on a similar basis. Investigating the (mostly) parasitic
symbiosis of Wolbachia from arthropods might therefore also shed light on the mech-
anism of the mutualistic filaria-Wolbachia symbiosis. The cultivation of Wolbachia
in an insect cell culture inables easy testing of susceptibilities to antibiotics, which
can be preselected before moving them into in vivo studies (Fenollar et al., 2003).
Furthermore, Wolbachia from insect cell cultures can be used as a source for Wol-
bachia membranes and proteins and verification of their functionality by using in
vitro activity assays (Henrichfreise et al., 2009). Functioning of specific Wolbachia
proteins can also be confirmed by complementation assays in mutant E. coli strains
(Wu et al., 2009). Microscopic techniques greatly help in investigating Wolbachia
interactions with host cell structures, Wolbachia localisation patterns or identifica-
tion of up-regulation of proteins (Ferree et al., 2005; Fischer et al., 2011; Landmann
et al., 2009; Pfarr et al., 2008; Serbus and Sullivan, 2007). Other techniques that can
help to understand the basis of the Wolbachia-host symbiosis include the analysis of
differentially expressed genes upon anti-Wolbachia treatment (Heider et al., 2006),
filarial ex vivo culture to asses worm phenotypes upon drug treatment or inhibition
of specific pathways (Johnston et al., 2010; Townson et al., 2006; Wu et al., 2009)
and the proteomic analysis of the secretome or different developmental stages of
Brugia (Bennuru et al., 2011; Hewitson et al., 2008). Upcoming studies that are
going to use GST-tagged Wolbachia proteins to identify interactors from B. malayi
proteins extracts in a pull-down assay have a great potential to identify molecules
important for symbiosis (Slatko et al., 2010).
A powerful tool to reveal molecular mechanisms of the Wolbachia-filaria relation-
ship is provided by the genome information of B. malayi and wBm. It enables the
prediction of symbiotic dependencies by comparing presence and absence of genes
for metabolic pathways (Foster et al., 2005). Genome information also enables com-
parison of the Brugia genome with the genome of Wolbachia-free filarial species to
eventually identify essential genes for filarial biology which have been lost in Brugia
due to their compensation by Wolbachia or have been transferred to Wolbachia-free
filaria, in case they were infected by Wolbachia earlier in evolution (McNulty et al.,
2010). The sequencing and annotation of the Brugia genome has facilitated the de-
velopment of a filarial microarray, which offers a great potential for filarial research.
It has for example been used for identification of gender regulated genes and genes
that are important for the infectivity of the third stage larvae (Li et al., 2005, 2009)
21
Chapter 1. Introduction
and is now another tool for analysing molecular mechanisms of the filaria-Wolbachia
symbiosis (Figure 1.7).
Figure 1.7.: Microarray experiment to identify differential expressed genes after depletion
of Wolbachia endosymbionts from filaria.
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1.6. Objectives
Lymphatic filariasis and onchocerciasis are the second leading causes for disability
in the world and lead to enormous health and socio-economic problems in the de-
veloping countries. Mass drug treatments for many years have averted many cases
of infections and in some countries a stop of transmission of the disease has been
announced. Nevertheless, as the currently used drugs only have a microfilaricidal
effect, they have to be given over many years to stop transmission. There is a strong
need for the development of a new drug against filarial infections before resistance
against ivermectin (the most widely used drug by anti-filarial programmes) spreads,
which could revert the success of the control programmes. The endosymbiotic mu-
tualistic bacteria Wolbachia are excellent targets for filariasis control, as Wolbachia
depletion with antibiotics results in embryogenic blockade, sterility and death of the
worms. Furthermore, worms are killed slowly which prevents adverse effects evoked
by a sudden release of worm and Wolbachia antigens. However, the most active
antibiotic, doxycyline, has to be given over many weeks and cannot be administered
to young children and pregnant women and is therefore not suitable for MDA. A
well-directed development of new drugs would be possible with the knowledge of the
molecular mechanisms of the filaria-Wolbachia symbiosis, as blocking the symbiotic
interactions should lead to the same detrimental effects for the worm, as seen after
depleting the bacteria. The genomic information of the genome of B. malayi and
wBm together with a well-established and widely used model organism for filariasis
provides the basis to address the questions of the molecular interactions between
Wolbachia and filarial nematodes and to promote target identification for drugs
against filariasis. The following goals were therefore addressed in the present study:
1. Identification of differentially expressed genes in L. sigmodontis after Wol-
bachia depletion using cross-hybridisation to the Brugia microarray to ascer-
tain genes and pathways important for symbiosis.
2. Establishment of an ex vivo culture for the model filarial L. sigmodontis to
enable testing of drugs and inhibition of specific pathways and evaluation of
function of genes important for the Wolbachia-filaria symbiosis.
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2. Materials and Methods
2.1. Materials
Chemicals and molecular biology reagents used in this study are listed. Specific
instruments or commercial kits which are not specified here will be mentioned in
the corresponding sections.
Chemicals
Agarose Fermentas, St. Leon-Rot, Germany
5-aminolevulinic acid Sigma-Aldrich, Munich, Germany
Ampicillin Sigma-Aldrich, Munich, Germany
1-bromo-3-chloro-propane Sigma-Aldrich, Munich, Germany
Boric acid Sigma-Aldrich, Munich, Germany
Disodium hydrogen phosphate Merck, Darmstadt, Germany
Dimethyl Sulfoxide (DMSO) Roche, Mannheim, Germany
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)
Roth, Karlsruhe, Germany
Ethanol Merck, Darmstadt, Germany
Ethidium bromide Biomol, Hamburg, Germany
EDTA, Disodium Salt, Dihydrate Sigma-Aldrich, Munich, Germany
HEPES Merck, Darmstadt, Germany
Hydrochloric acid Sigma-Aldrich, Munich, Germany
IPTG Sigma-Aldrich, Munich, Germany
Isoforene Abbot, Wiesbaden, Germany
Isopropanol Merck, Darmstadt, Germany
Ketanest Parke-Davis, Berlin, Germany
LB Agar Sigma-Aldrich, Munich, Germany
Sodium Chloride Roth, Karlsruhe, Germany
Sodium Hydroxide Merck, Darmstadt, Germany
Potassium dihydrogen phosphate Merck, Darmstadt, Germany
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Potassium chloride Merck, Darmstadt, Germany
RedSafeTM Chembio, Hertfordshire, United Kingdom
Rompun Bayer, Leverkusen, Germany
SOC medium Invitrogen, Karlsruhe, Germany
Succinylacetone Sigma-Aldrich, Munich, Germany
Tris Roth, Karlsruhe, Germany
Trizol Invitrogen, Karlsruhe, Germany
wALADin1 (Wolbachia aminolevu-
linic acid inhibitor 1)
ChemBridge, San Diego, USA
X-Gal Roth, Karlsruhe, Germany
Molecular biology reagents
Custom Primers Invitrogen, Darmstadt, Germany
Biomers, Ulm, Germany
DNA ladders New England Biolabs, Ipswich, USA
Invitrogen, Darmstadt, Germany
10 x DNase I buffer Applied Biosystems, Foster City, USA
dNTPs (40 mM) Qiagen, Hilden , Germany
HotStar Taq Polymerase Qiagen, Hilden , Germany
Linear acrylamid Applied Biosystems, Foster City, USA
MgCl2 Qiagen, Hilden , Germany
Oligo-dT primer Qiagen, Hilden, Germany
10 x PCR buffer Qiagen, Hilden , Germany
RNase free DNase I Applied Biosystems, Foster City, USA
RNase Inhibitor Peqlab, Erlangen, Germany
Invitrogen, Karlsruhe, Germany
Sybr Green Roche, Mannheim, Germany
Taqman Hybridisation Probe Operon Biotechnologies, Cologne, Ger-
many
10 x Yellow SubTM Geneo BioTechProducts, Hamburg, Ger-
many
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Cell culture reagents
Fetal Calf Serum PAA, Pasching, Austria
L-glutamin PAA, Pasching, Austria
Minimum essential medium with
earls salts (MEM)
PAA, Pasching, Austria
PBS for cell culture PAA, Pasching, Austria
Penicillin/Streptomycin PAA, Pasching, Austria
RPMI-1640 PAA, Pasching, Austria
Trypsin/EDTA 10 x PAA, Pasching, Austria
2.2. Animals and parasitological methods
2.2.1. Maintenance of animals
Cotton rats (Sigmodon hispidus) and jirds (Meriones unguiculatis) were maintained
at the animal facilities of the Institute for Medical Microbiology, Immunology and
Parasitology (IMMIP), University Clinic Bonn, Germany. IL-5 deficient BALB/c
mice were bred at the Haus fu¨r Experimentelle Therapie (HET) and afterwards
maintained under Specific Pathogen Free (SPF) conditions in the IMMIP. Ethical
clearance for animal handling was approved by the regional authority in Cologne,
Germany (AZ 50.203.2-BN15,40/04).
2.2.2. Animal model
The natural host of L. sigmodontis, the cotton rat S. hispidus, was used to maintain
the life cycle of L. sigmodontis as described in Chapter 1.4.1. For the experiments
described in this study we used BALB/c mice which are deficient for the Th2 cy-
tokine IL-5 (BALB/c IL-5 ko mice).
2.2.3. Infection cycle of L. sigmodontis
The life cyle of L. sigmodontis was maintained in our lab by passages of the parasite
through the cotton rat and the intermediate mite vector. Mites were maintained
on bedding material in glass flasks at a temperature of 26-28◦C and air humidity
of 80-90 %. To allow mites to have a blood meal on infected microfilariae positive
animals, the cotton rats were placed into wire cages and then placed over night onto
bedding material containing the mites. To avoid contamination of the rooms with
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mites, the cages were placed onto trays with detergent containing water, therefore
all mites were either kept in the cages or died in the water. The infected mites
in the bedding material were collected into Erlenmeyer flasks covered with a mesh
screen and then incubated for 10-14 days, until L1 larvae developed into the infec-
tive L3 larvae, used for infection of cotton rats or experimental mice. Mice were
anaesthetised with Rompun/Ketanest and placed onto bedding material containing
the mites. Anaesthetising the mice prevents them trying to get rid of the mites and
therefore increases the infection efficiency. Mites were allowed to have a blood meal
on the mice over night, the next day the mice were decontaminated from remaining
mites by placing the cages onto water with detergent over night. All materials that
came into contact with mites during the infection processes were either dunked into
water containing detergent or frozen at -20◦C to kill any mites.
Rompun/Ketanest long term anesthetic
Rompun (20 mg/ml) 100µl + 200µl PBS
Ketanest (10 mg/ml) 200µl
500µl
50µl of the Rompun/Ketanest mixture was injected intramuscularly per mouse.
PBS
20 x PBS: 160 g NaCl
23 g Na2HPO4
4 g KH2PO4
4 g KCl
ad 1000 ml nanopure water
pH adjusted to 7.4
2.2.4. Infection cycle of Acanthocheilonema viteae
The life cycle of A. viteae was maintained at the Department of Molecular Parasitol-
ogy, Humboldt University, Berlin by passages through jirds (Meriones unguiculatus)
and ticks (Ornithodorus moubata). Infected ticks containing the L3 larvae and A.
viteae-infected jirds, respectively, were kindly provided by Prof. Richard Lucius,
Humboldt University, Berlin. The infected ticks can be kept for several month in a
humid environment. Infection of jirds with A. viteae was carried out as described by
Lucius and Textor (1995). Briefly, ticks containing the L3 larvae were disrupted in
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RPMI medium, so larvae could move out of the body of the ticks into the medium.
Jirds were then injected subcutanously with 80 L3 larvae. Treatment of jirds started
when microfilariae were detectable in the blood.
2.2.5. Evaluation of microfilariae release
Mice For microfilariae count in L. sigmodontis-infected mice, blood was taken
from the tail by cutting the tip and collected into a capillary. The blood was
then blown out onto a microscope slide and 10µl blood were immediately pipetted
into 300µl of Hinkelmann solution on ice. The mixture was then incubated for
5 min at RT. The Hinkelmann solution lyses the erythrocytes and also stains the
microfilariae. After centrifugation for 5 min at 2000 rpm at RT the supernatant was
removed except for 10µl sediment. The complete sediment was analysed under a
microscope (Leica Microsystems GmbH, Wetzlar, Germany) and the microfilariae
were counted. Values were given as number of microfilariae/µl of blood.
Jirds To obtain blood from jirds containing A. viteae microfilariae, animals were
shortly anaesthetised with isoforene and bled from the retro-orbital sinus using a
glass capillary tube. Blood was collected in EDTA tubes and 2µl of EDTA blood
was mixed with 300µl Hinkelmann solution and stained and analysed as described
above for L. sigmodontis blood microfilariae.
Hinkelmann’s solution
0.5 % w/v eosin Y (2.5 g)
0.5 % v/v phenol (2.5 ml)
0.185 % v/v formaldehyde (0.925 ml)
ad 500 ml with distilled water
2.2.6. Tetracycline treatment
Tetracycline (Tet) treatment of L. sigmodontis-infected BALB/c IL-5 ko mice started
around day 60 after infection, when mice had a patent infection and blood micro-
filariae were detectable. Mice were treated daily for 36 days with intraperitoneal
(i.p.) injections of 1 mg tetracycline in 200µl PBS (50 mg Tet/kg/day).
Tet treatment of A. viteae-infected jirds also started ∼ 3 months after infection
when microfilariae were seen in blood. Animals were treated orally with tetracycline
(0.5 % w/v) in drinking water for 6 weeks. The water was changed daily.
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Figure 2.1.: Tet treatment scheme of L. sigmodontis-infected BALB/c IL-5 ko mice.
Tet = tetracycline, Mf = microfilariae. Treatment of mice started when mice had a patent
infection and Mf were detected in the blood. Mice were treated daily with i.p. injections of
tetracycline. At days 6, 15 and 36 worms were recovered from Tet treated and untreated
mice for use in microarray and qPCR expression studies.
2.2.7. Worm recovery
L. sigmodontis worms were recovered from the thoracic cavity at days 6, 15 and 36
of Tet treated and untreated BALB/c IL-5 ko mice by flushing the pleural cavity
with PBS and carefully removing worms with a pipette or forceps. Nematodes were
washed in PBS and separated by sex. Tubes containing 3 female worms were shock
frozen in liquid nitrogen and stored at -80◦C for subsequent RNA and DNA isolation.
A. viteae nematodes were recovered from jirds after 6 weeks of Tet treatment and
from untreated animals, respectively. Jirds were anaesthetised with isoforene and
bled from the retro-orbital sinus to reduce bleeding during dissection. Adult worms
were recovered from subcutaneous and intramuscular tissues and the visceral cavity.
Worms were washed in PBS, separated by sex and 2 female worms per tube were
shock frozen in liquid nitrogen and stored at -80◦C.
2.3. Molecular biology methods
2.3.1. RNA extraction
Total RNA was isolated from 2-3 (quantitative PCR) or 5-10 (microarray) female
L. sigmodontis worms per tube using the Trizol extraction method, following the
manufacturer’s protocol with some modifications. Briefly, nematodes in 800µl Tri-
zol reagent were transferred to 2 ml tubes containing 0.5 mm glass beads and ho-
mogenised in a Precellys 24 homogeniser (Peqlab, Erlangen, Germany) 4 x 10 s at
5000 rpm. Instead of chloroform, 80µl of 1-brom-3-chloro-propane was used to sep-
arate the homogenate into RNA-containing aqueous and DNA containing organic
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phases. For precipitation of RNA, linear acrylamide was used as co-precipitant with
a final concentration of 9µg/ml and 1 volume isopropanol. RNA was treated with
RNase-free DNase I for 1 h at 37◦C, followed by clean-up and concentration of the
RNA with the RNeasy Minelute kit (Qiagen) as per the manufacturer’s protocol.
Extraction of total RNA from 2 female A. viteae worms was carried out as described
above, but with the modification that 1 ml Trizol, 100µl 1-brom-3-chloro-propane
and a homogenisation programme of 2 x 30 s at 6800 rpm were used to accommodate
the larger size of A. viteae worms.
2.3.1.1. RNA concentration and quality
The concentration, purity and integrity of RNA was analysed prior to reverse tran-
scription into cDNA. Concentration of RNA1 and the 260/280 ratio2 of the RNA
was measured spectrometrically using a NanoVue (GE Healthcare, Chalfont St Giles,
UK). The ratio measured for RNA extracted in this study was around 2, which in-
dicates clean RNA without protein contamination. Furthermore, integrity of RNA
was analysed using the Experion automated gel electrophoresis system (Bio-Rad,
Munich, Germany) following the manufacturer’s instructions. Here, electrophoresis
is conducted on channels of a microchip and peaks of a fluorophore bound to very
small amounts of RNA can be measured and an electropherogram with peaks of
RNA is produced. Two distinctive peaks corresponding to 28S and 18S ribosomal
RNA indicate undegraded RNA (Figure 2.2 A). The electropherograms of the RNA
samples can be transformed into a picture of a virtual agarose gel, visualising the
bands of the ribosomal RNAs compared to an RNA ladder (Figure 2.2 B) (Fleige
and Pfaffl, 2006).
2.3.2. Reverse transcription
Depending on the concentrations after isolation, 100-500 ng of total RNA were
reverse transcribed into cDNA with oligo-dT primers using the Omniscript Reverse
transcription kit (Qiagen). For reverse transcription of mitochondrial encoded genes,
gene specific primers at a concentration of 0.5µM were used. The reaction was
incubated for 75 min at 37◦C and then stored at -20◦C.
1Depending on worm size and extraction efficiency amount of RNA extracted from 3 female L.
sigmodontis ranged from 300 ng - 2µg.
2The 260/280 ratio is used to assess purity of nucleic acid solutions. Pure DNA is indicated by
a ratio of ca 1.8 and pure RNA by a ratio of ca 2.0.
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Figure 2.2.: Quality control of RNA extracted from female L. sigmodontis worms.
L = RNA ladder, Ls = L. sigmodontis, 18S/28S = ribosomal 18S/28S RNA. Two dis-
tinct peaks for 18S and 28S ribosomal RNAs indicate undegraded RNA in this sample
(A). Virtual agarose gel showing bands corresponding to ribosomal RNAs (B).
Reverse transcription reaction
1 reaction
100-500 ng RNA in nuclease free water 13.67µl
10 x reaction buffer 2µl
oligo-dT Primer 1µl
dNTPs 2µl
Reverse Transcriptase 1µl
RNase Inhibitor (30 U/µl) 0.33µl
20µl
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2.3.3. DNA extraction
DNA from L. sigmodontis worms was precipitated from the organic phase obtained
by the Trizol extraction method described in Chapter 2.3.1 following the manufac-
turer’s instructions. Briefly, DNA was precipitated by adding 100 % ethanol. The
pellet was washed two times with 0.1 M Sodium citrate in 10 % ethanol and one time
with 75 % ethanol. Afterwards the pellet was dissolved in 100-200µl 8 mM NaOH.
Insoluble material was removed by centrifugation at 12,000 g for 10 min. The super-
natant containing the DNA was adjusted to a pH 7.5 by adding 16µl 0.1 M HEPES
per 100µl DNA.
0.1 M Sodium Citrate, 10 % EtOH
5.88 g Sodium Citrate
add nuclease free water up to 180 ml
add 20 ml 100 % EtOH
8 mM NaOH
400µl 1 M NaOH
add nuclease free water up to 50 ml
0.1 M HEPES
2.38 g HEPES
add nuclease free water up to 100 ml
In case no RNA was needed from the worms, the QIAamp DNA Mini Kit (Qia-
gen) was used for DNA extraction. Worms were homogenised with small scissors in
buffer AL and incubated with proteinase K at 56◦C over night. The manufacturer’s
tissue protocol was followed and DNA was eluted with 100-200µl buffer AE.
2.3.4. Cloning of L. sigmodontis and A. viteae sequences
2.3.4.1. Primer design
Primers were designed using the software ”Primer3” (http://frodo.wi.mit.edu/
primer3/). Parameters for quantitative PCR (qPCR) primers included a PCR
product size range of 100-130 bp, optimal primer length of 21 bp, maximum poly-
X of 3 and an optimal primer melting temperature of 60◦C. Unwanted hairpins
and self dimerisation was checked using the ”Oligonucleotide Properties Calcula-
tor” (http://www.basic.northwestern.edu/biotools/oligocalc.html). As se-
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quence information for many L. sigmodontis genes that were analysed in this study
were not available in public databases, sequences were amplified using primers de-
signed on the basis of the corresponding B. malayi sequences. Depending on se-
quence availability, cDNA sequences of B. malayi were aligned to Ascaris suum,
O. volvulus, W. bancrofti or C. elegans sequences and primers matching to con-
served parts of the gene with high sequence similarity were designed. In some cases
degenerate primers were designed with a maximum of 5 degenerate bases per primer.
L. sigmodontis sequences were than used to design L. sigmodontis specific qPCR
primer. The sequence editor software GENtle (http://gentle.magnusmanske.de/)
was used for sequence storage and management, checking primer positions and iden-
tifying sequences by alignment. New nucleotide sequence data for L. sigmodontis
genes obtained in this study are available in the GenBankTM database under the Ac-
cession No.: GU971360, GU971361, GU971362, GU971363, GU971364, GU971365,
GU971366, GU971367, GU971368, GU971369, GU971370, GU971371, GU971372
and GU971373.
2.3.4.2. Conventional PCR
For establishment of qPCR the 100-130 bp gene specific sequence to be ampli-
fied in qPCR had to be cloned from L. sigmodontis cDNA. Sequences that were
not available from public databases were amplified from L. sigmodontis and A.
viteae cDNA samples using B. malayi or degenerate B. malayi primers (Chapter
2.3.4.1). L. sigmodontis gene sequences corresponding to B. malayi succinyl-CoA
ligase (Bm1 00840), Mif-1 (Bm1 28435), Protein kinase domain containing protein
(Bm1 37575), Lipoic acid synthetase (Bm1 23910), Biopterin dependant aromatic
amino acid hydroxylase (Bm1 46865) and DNA/pantothenate metabolism flavopro-
tein (Bm1 45070) were kindly provided by Prof. Mark Blaxter, University of Edin-
burgh, Scotland. Conventional PCRs were performed in a 20µl reaction with the
reagents concentrations shown in Table 2.2 and primers listed in Table 2.3. The
following cycling conditions were used: denaturing step of 95◦C for 15 min followed
by 35 cycles of 94◦C for 30 s, annealing at 55◦C for 30 s and elongation at 72◦C for
30 s3. A final elongation step at 72◦C for 10 min followed. PCR products were stored
at 4◦C until further use. If PCRs didn’t yield the expected product with these con-
ditions annealing temperatures were lowered or MgCl2 concentrations were changed
or if this was not successful new primers were designed.
3Elongation times were extended for longer product lengths; aproximately 1 min for 1000 bp.
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Table 2.2.: Protocol for conventional PCR
1 reaction final concentrations
10 x PCR buffer with 15 mM MgCl2 2 1 x buffer, 1.5 mM MgCl2
10 x Yellow SubTM a 2µl 1 x
dNTPs (40 mM) 0.1µl 0.2 mM
Forward Primer (10µM) 2µl 1µM
Reverse Primer (10µM) 2µl 1µM
cDNA or gDNA 2µl
Hot Star Taq 0.1µl 0.25 U
nuclease free water 9.8µl
a Increases yield and specificity of PCR reaction and contains loading buffer and dye,
therefore PCR mix can be applied directly to an agarose gel.
Table 2.3.: Primer for cloning A. viteae and L. sigmodontis sequences
Gene target Primer name Primer sequence 5′ - 3′
Av cytochrome B Bmc-cytB FW GGATTGCTTTTACTGGTTATGTT
Bm-cytB RV CTAGACCTAGAACCAGTAAAATG
Ls hypothetical gene Bm-30045 F1 CATTTCTGTAGTATGTATTTCTTCGCT
Bm-30045 degaR1 TTCAAGGTYCTCCAYGCAGT
Ls acetyl-CoA hydrolase/ Bm-aCoA deg F1 GGAATCCAYACWGAAATGTTCTCAG
transferase Bm-aCoA deg R1 GWGCAATAATGGKCTTTCCR
Ls abc transporter Bm-abc deg F1 TTGTWCCWCAGGATTCMGTWCTTT
Bm-abc deg R1 AATYGTMGCYARACGATGTGCA
Ls retinoblastoma-binding Bm-rbp4 deg F1 GTACSCAYACWTCRGATGAACARAATC
protein Bm-rbp4 deg R1 CATCYTCKACMACYGCATTAT
Ls diphosphomevalonate Bm-mvd deg F2 GMTCWGGAAGTGCMTGYCG
decarboxylase Bm-mvd deg R2 ATTCGGACCRGCRTCAAAY
Ls rab5 Bm-rab5 deg F2 GGWTTCTACGGKACMCCRCAATG
Bm-rab5 deg R2 ACTYTCCTTWAGYGCCTCRAARAT
Ls actin Ov-act FW GACGCAAATCATGTTCGAGA
Ov-act RV CGGATGTCAATATCACACTTCA
a degenerate primer
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2.3.4.3. Gel electrophoresis
An agarose gel was run to determine the length of DNA4 amplified in PCR. De-
pending on the expected length of the PCR product, a 1-2 % gel was prepared by
dissolving and heating the agarose in 0.5 % TBE buffer. Initial gels were stained
with ethidium bromide, but later gels were stained with RedSafe (being biologically
safer than ethidium bromide). After polymerisation of the gel, samples were applied
into the slots of the gel and run at 120 Volt in 0.5 % TBE buffer. DNA bands were
made visible under UV light. The length of the DNA molecules was estimated by
comparing the DNA bands to a DNA size marker run on the same gel.
Tris-borate-EDTA (TBE)
10 x stock solution: 108 g Tris
55 g boric acid
9.3 g Na2EDTA 2H2O
ad 1000 ml nanopure H2O
Working solution: 0.5 x stock solution
2.3.4.4. TOPO-TA cloning
PCR products were cloned into the TOPO-TA vector (Invitrogen) for sequencing
and to generate standard plasmids to be used in qPCR. Taq Polymerase amplified
PCR products can directly be cloned into this vector as Taq Polymerase adds sin-
gle deoxyadenosine to the 3′ ends of PCR products and the linearised vector has
overhanging 3′-deoxythymidine residues. The Topoisomerase I enzyme catalyses the
ligation reaction.
TOPO-TA cloning reaction
1µl vector
1-3µl PCR product (depending on amount of PCR product)
1µl salt solution
nuclease free water up to 6µl
The reaction was incubated for 5-30 min at RT. 2µl of the cloning reaction were
then added to 50µl of One Shot Chemically Competent E.coli (Invitrogen), gently
4DNA molecules can be separated by size in an electric field due to the negative charge of nucleic
acids. Shorther molecules move faster through the agarose matrix and therefore farther than
longer molecules.
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mixed and incubated for 30 min on ice. A 30 s heat shock in a 42◦C waterbath fol-
lowed and cells were immediately transferred to ice. 250µl SOC medium was added
and the cells were incubated for 1 h on a shaker at 37◦C. 10 and 50µl of transformed
bacteria were plated onto LB-Agar plates containing ampicillin (100 µg/ml), IPTG
(0.5 mM) and X-Gal (40µg/ml), and incubated at 37◦C overnight.
2.3.4.5. Colony PCR
Colony PCR was performed to identify clones with the expected size of insert cloned
into the TOPO-TA vector. Reactions were performed in 20µl and consisted of 1 x
PCR buffer, 1 x YellowSub, 1.5 mM MgCl2, 0.2 mM dNTPs, 0.1 mM M13 forward
primer, 0.1 mM M13 reverse primer and 0.25 U HotStar Taq Polymerase. A small
amount of colony material was disolved into the PCR reaction mix using a pipet
tip. 10 white clones5 were chosen for analysis. Cycling conditions were as described
in section (conventional PCR) for conventional PCR. As M13 Primer bind to the
vector, 200 bp of the vector sequence are amplified and have to be added to the
insert length to identify the expected PCR product length on the agarose gel.
M13 Primer sequences
M13 Forward (-20) Primer: 5′-GTAAAACGACGGCCAG-3′
M13 Reverse Primer: 5′-CAGGAAACAGCTATGAC-3′
Figure 2.3.: Example for products of a Colony PCR run on an agarose gel. bp = basepair,
1-10 = clones 1-10, neg.= negative (water) control. Clones 2, 5, 6, 7, 8 and 10 show a
DNA band at the expected size.
5White colour of clones indicates insertion of DNA into the multiple cloning site of the vector. In
this case the lacZ gene is disrupted, no functional β-galactosidase enzyme can be formed and
X-Gal cannot be hydrolised into the otherwise blue colour.
37
Chapter 2. Materials and Methods
2.3.4.6. Plasmid purification
For purification of plasmids, E. coli were grown in 5 ml LB medium with 50µg/ml
ampicillin overnight in a shaker at 37◦C and 250 rpm. Bacteria were centrifuged
at 600 rpm for 10 min and the plasmids were purified from the pellet using the
DNA MiniPrep kit (Qiagen) following the manufacturer’s protocol. The plasmid
purification kit was either applied by hand or by using the automated plasmid pu-
rification system (QiaCube, Qiagen). The concentration and purity of the plasmids
was assessed spectrometrically with a nanodrop. Part of the plasmid solution was
used for sequence confirmation by sequencing (Seqlab, Go¨ttingen, Germany) and
the remaining stored at -20◦C until further use as a plasmid standard in qPCR.
2.3.5. Quantitative PCR
QPCR was performed in a 20µl volume for most genes except for Av-act and Ls-act
gDNA, which was performed in a 10µl volume. Reactions consisted of 1 x PCR
buffer, 0.2 mM dNTPs, 0.25 U Hotstar Taq Polymerase, 1/10 volume of Sybr Green
(1:1000 dilution of stock in DMSO) and 2µl DNA. QPCR for Ls-ftsZ was conducted
using 5µM of the Taqman Hybridisation Probe 6-FAM-CAGGGATGGGTGGT-
GGTACTGGAA-TAMRA instead of Sybr Green. Primer sequences, optimised
MgCl2 and primer concentrations are listed in Table 2.4. QPCR reactions were
performed in triplicate on a Rotorgene 3000 (Corbett Research, Sydney, Australia)
with the following cycling conditions: denaturing step of 95◦C for 15 min followed
by 35 cycles of 94◦C for 10 s, annealing for 20 s (see Table 2.4 for temperatures) and
72◦C for 20 s. Fluorescence was acquired at the end of the 72◦C step on the Fam
channel. After amplification, a melting curve was measured using a temperature
gradient from 62 to 99◦C to confirm specific amplification (Figure 2.4 C). For all
genes, no non-specific products were measurable. Copy numbers were calculated by
comparing crossing point data for the test samples to a standard curve obtained from
serial dilutions of the plasmid containing the specific gene (Figure 2.4 A,B). The sig-
nal for the actin gene was used to normalise each sample to correct for differences
in the amount of starting material and efficiency of RNA extraction. A regulated
gene was confirmed if the fold change as measured by qPCR was ≥ 1.3-fold. All
PCRs presented here, except the PCRs for Ls-act gDNA, Ls-hsp60 (Heider et al.,
2006) and Ls-ftsZ (Arumugam et al., 2008), were established within the scope of
this study.
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Figure 2.4.: Example for a gene specific standard (A, B) and melt curve (C) in qPCR,
CT = threshold cycle, dF/dT = rate of change in fluorescence.
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Table 2.4.: Cycling conditions for quantitative PCR
Gene target corresponding B.malayi Primer name MgCl2 Primer Annealing
accession number concentration concentration temperature
Av cytochrome c oxidase subunit 1 AF538716 Av-cox1 F1/R1 2 mM 300 nM 57◦C
Av cytochrome b AF538716 Av-cytB F2 3 mM 400 nM 57◦C
Ls abc transporter Bm1 30435 Ls-abc F1/R1 3.5 mM 500 nM 57◦C
Ls acetyl-CoA hydrolase/transferase Bm1 42975 Ls-acCoA F1/R1 3 mM 400 nM 57◦C
Ls actin (only cDNA) Bm1 34930 Ls-act FW2/RV2 3 mM 500 nM 57◦C
Ls actin (gDNA) / Av actin Bm1 34930 Ov-act F1/R1 3.5 mM 900 nM 52◦C
Ls biopterin dependant aromatic amino acid hydroxylase, Bm1 46865 Ls-cat2 F1/R1 4 mM 500 nM 57◦C
Ls cytochrome b AF538716 Ls-cytB F1/R1 2.5 mM 400 nM 57◦C
Ls cytochrome c oxidase subunit 1 AF538716 Ls-cox1 F1/R1 4 mM 500 nM 57◦C
Ls cytochrome c oxidase subunit 2 AF538716 Ls-cox2 F1/R1 4.5 mM 200 nM 57◦C
Ls diphosphomevalonate decarboxylase, Bm1 42945 Ls-mvd F1/R1 3 mM 500 nM 57◦C
Ls DNA/panthotenate metabolism flavoprotein Bm1 45070 Ls-DFP F2/R2 3.5 mM 500 nM 57◦C
Ls EF hand family protein, Troponin c Bm1 48810 Ls-tropC F1/R1 2.5 mM 500 nM 57◦C
Ls globin family protein Bm1 50430 Ls-globin F1/R1 3 mM 500 nM 57◦C
Ls heat shock protein 60 Bm1 56580 LsHspLC F2/R2 4.5 mM 300 nM 58◦C
Ls hypothetical gene Bm1 04280 Ls 04280 F1/R1 3.5 mM 500 nM 53◦C
Ls hypothetical gene Bm1 30045 Ls-30045 F1/R1 3.5 mM 500 nM 57◦C
Ls juvenile protein p120 Bm1 19955 / Bm1 00865 Ls-juvp120 F1/R1 4.5 mM 400 nM 57◦C
Ls lipoic acid synthetase Bm1 23910 Ls-lias F1/R1 4 mM 500 nM 57◦C
Ls macrophage migration inhibitory factor-1 Bm1 28435 Ls-mif1 F1/R1 3.5 mM 500 nM 57◦C
Ls med7 transcription factor Bm1 23975 Ls-med7 F1/R1 3.5 mM 400 nM 57◦C
Ls NADH dehydrogenase 4 AF538716 Ls-ND4 F1/R1 4 mM 500 nM 57◦C
Ls NADH dehydrogenase 5 AF538716 Ls-ND5 F1/R1 3 mM 400 nM 57◦C
Ls protein kinase domain containing protein Bm1 37575 Ls-c-met F1/R1 3.5 mM 500 nM 57◦C
Ls rab5 Bm1 29925 Ls-rab5 F1/R1 2.5 mM 300 nM 57◦C
Ls retinoblastoma-binding protein, putative Bm1 15930 Ls-rbp4 F1/R1 4 mM 500 nM 57◦C
Ls 60S ribosomal protein L3, putative Bm1 13895 Ls-60SL3 F1/R1 2 mM 500 nM 57◦C
Ls RNA-binding protein Bm1 37780 Ls-rbp F1/R1 2.5 mM 500 nM 55◦C
Ls succinyl-CoA ligase Bm1 00840 Ls-sucCoA F1/R1 3.5 mM 500 nM 57◦C
Ls troponin T, putative Bm1 55000 Ls-tropT F1/R1 2 mM 300 nM 57◦C
Wolbachia of Ls ftsZ AY583309 (wBm) Ls-ftsZ F1/R1 5 mM 200 nM 58◦C
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Table 2.5.: Primer sequences used for qPCR
Gene name Primer name Primer sequence 5′ - 3′
Av cytochrome c oxidase subunit 1 Av-cox1 F1 CGTTCCACTGCGGTTACTTT
Av-cox1 R1 AAGAACCAGCCAAAACAGGA
Av cytochrome b Av-cytB F2 TTGAGGGCAAATGAGGTATTG
Av-cytB R2 ACTACCTCAAATTCACCAAACCA
Ls abc transporter Ls-abc F1 AAATCCGACTGCAACTGAAGA
Ls-abc R1 TTCAAACCTCTTTCACCAACAA
Ls acetyl-CoA hydrolase/transferase Ls-acCoA F1 CCGAAAGTAGTCGATGTCCAA
Ls-acCoA R1 TGTTGCTTGGGTAAATGATCC
Ls actin (only cDNA) Ls-act FW2 ACCGATTTACGAAGGTTACGC
Ls-act RV2 TCACGTACAATTTCACGTTCG
Ls actin (gDNA) / Av actin Ov-act F1 GTGCTACGTTGCTTTGGACT
Ov-act R1 GTAATCACTTGGCCATCAGG
Ls biopterin dependant aromatic amino Ls-cat2 F1 TCGCAACAAATTGGACTTCTC
acid hydroxylase Ls-cat2 R1 TCACGACACAAACCAAATTCA
Ls cytochrome b Ls-cytB F1 TCGTTTGACTAATGTTTGATTGG
Ls-cytB R1 ACCGCAGCCCAATAGCTC
Ls cytochrome c oxidase subunit 1 Ls-cox1 F1 GGTAGTTGGTCAACCGGAAT
Ls-cox1 R1 AATGTAACCGCCCTACAACG
Ls cytochrome c oxidase subunit 2 Ls-cox2 F1 GTTGTGTTTTGCCGGTAGGT
Ls-cox2 R1 AACAAACCATTTAGCACATCCA
Ls DNA/panthotenate metabolism flavoprotein Ls-DFP F2 TGCCAGGTTTAGTAGAAGCTTTG
Ls-DFP R2 ATGCAGGCAAATCATTTCAAG
Ls diphosphomevalonate decarboxylase, Ls-mvd F1 TGCATTGGAAAGCTGGTATTT
Ls-mvd R1 TGCATCATGTGAGGTTACCAA
Ls EF hand family protein, Troponin c Ls-tropC F1 AGGGCAACGGCTACATATCTC
Ls-tropC R1 TCAATCTTTCCAGAACCATCC
Ls globin family protein Ls-globin F1 TATGCTCGTGAAACGGTCAA
Ls-globin R1 TCCATCTATTGCAGTGTGTTCC
Ls heat shock protein 60 LsHspLC F2 TACGTGAGCCAATCATGACA
LsHspLC R2 ATCATATCCAAACGCCAACTC
Ls hypothetical gene Ls-04280 F1 CGGCCTATTGGCTAAGATCA
Ls-04280 R1 AAACCCTCCAGAGTCCCAAA
Ls hypothetical gene Ls-30045 F1 TCGCTATCAGCGAAAATGC
Ls-30045 R1 CTCCATGCAGTCATCAAACG
Ls juvenile protein p120 Ls-juvp120 F1 TCAACAATTCCAAGAACAGCA
Ls-juvp120 R1 GATGTGGTTGCTGAAGCATTT
Ls lipoic acid synthetase Ls-lias F1 AGACATCACGTAAGCCACCTC
Ls-lias R1 CGCCATCTTCAATATCGTCTC
Ls macrophage migration inhibitory factor-1 Ls-mif1 F1 AAGTACGGATCCATGTGCTGT
Ls-mif1 R1 AGCCAACAGCGTGTACAATTT
Ls med7 transcription factor Ls-med7 F1 GGTCACGAAGCATTAAACCAA
Ls-med7 R1 GCTCCACCAACTCATTGTCAT
Ls NADH dehydrogenase 4 Ls-ND4 F1 TTGGCTCATGGCTATACTTCTG
Ls-ND4 R1 AACATTGAAATAACCCCGAAAA
Ls NADH dehydrogenase 5 Ls-ND5 F1 GGGGGTTTCATTATTTGTCTTA
Ls-ND5 R1 CCTGCTGCCCAAAATTAAAA
Ls protein kinase domain containing protein Ls-c-met F1 AGGTTATGCGTGCTGACCTCT
Ls-c-met R1 TCACTGCCGTTGCATACATTA
Ls rab5 Ls-rab5 F1 TGGATGACCTCTCTGGTATGG
Ls-rab5 R1 TACTGCTCCACTTCTGCCATT
Ls retinoblastoma-binding protein, putative Ls-rbp4 F1 CCTACCGATGATGCACAGTTT
Ls-rbp4 R1 CTCACCTTCGTGGTTCATCTT
Ls 60S ribosomal protein L3, putative Ls-60SL3 F1 GATTCATCTTACCGCGTTCAT
Ls-60SL3 R1 AAACTGTTACCGCTTCGACAA
Ls RNA-binding protein Ls-rbp F1 AGGAAGATGTGGCGAATTTCT
Ls-rbp R1 CCGCTGCTTCTGTTTCAAAT
Ls succinyl-CoA ligase [ADP-forming] Ls-sucCoA F1 TGGTGAATGGAGCTGGATTAG
beta-chain, mitochondrial Ls-sucCoA R1 CCGAAAGGACTCAGACACTTG
Ls troponin T, putative Ls-tropT F1 GTAGGACCGGAGGTAATCCAG
Ls-tropT R1 TTCTTTGTTGTTGGTGGTGGT
Wolbachia of Ls ftsZ Ls-ftsZ F1 CGATGAGATTATGGAACATATAA
Ls-ftsZ R1 TTGCAATTACTGGTGCTGC
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2.3.5.1. Calculation of plasmid copy numbers
The copy numbers / µl of the gene specific plasmids used for generating standard
curves can be estimated as shown in the following example:
Length of plasmid: 3956 bp (TOPO-vector) + 116 bp (insert) = 4072 bp
Molecular mass: 4072 bp x 660 Da/bp = 2.69 · 106 g/mol
DNA concentration: 222 ng/µl
Copy numbers can now be calculated with:
(222 · 10−9 g/µl x 6 · 1023 copies/mol) / (2.69 · 106 g/mol) = 4.95 · 1010 copies/µl
The same calculation is done by the dsDNA copy number calculator available at
http://www.uri.edu/research/gsc/resources/cndna.html.
2.4. Microarray
Our microrarray experiment compared gene expression profiles from Tet treated
female L. sigmodontis to the expression of untreated age-matched control worms.
The experiment was performed for three different timepoints: day 6, 15 and 36 of
Tet treatment. RNA quality control, cDNA synthesis, hybridisation of cDNA to the
B. malayi microarray chip, image analysis and normalisation of data was performed
at the core Microarray facility of Washington University School of Medicine, St.
Louis, MO and we kindly thank Dr. Michael Heinz for his support and advice.
2.4.1. Microarray fabrication
Our studies used the second-generation filarial microarray (BmV2array) developed
by the Filarial Microarray Consortium, of which our lab is a partner (http://
www.filariasiscenter.org/molecular-resources/research-materials). The
array contains 65mer oligonucleotides corresponding to 15,455 ESTs and ORFs from
B. malayi, 1,016 from O. volvulus, 878 from W. bancrofti and 804 from Wolbachia of
B. malayi (wBm). The number of different oligos corresponding to one gene varies
from 1 to more than 20. Information about the number of protein domain matches
is reported by Li et al. (2009) in a supplemental file (Summary of protein domain
matches for BmV2array elements).
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2.4.2. cDNA synthesis
First strand cDNA was generated by oligo-dT primed reverse transcription (Super-
script II, Invitrogen) utilising the 3DNA Array 900 kit (Genisphere) with Cy3 or
Cy5 specific oligo sequences attached to the oligo-dT Primer. One µl of fluorophore
specific oligo-dT primer was added to 2µg of total RNA and the solution was in-
cubated at 80◦C for 5 min and then cooled on ice for 2 min. 0.5µl RNase inhibitor
(Superase-In, Ambion), 2µl 5 x first strand buffer, 0.5µl dNTP mix (10 mM each
dATP, dCTP, dGTP and dTTP), 1µl 0.1 M DTT and 0.5µl Superscript II RNase
H - Reverse Transcriptase were added to each sample. Reverse transcription was
carried out at 42◦C for 2 h. The reaction was terminated by adding 1µl of 1 M
NaOH/100 mM EDTA and incubation at 65◦C for 10 min followed by neutralisation
with 1.2µl of 2 M Tris-HCL, pH 7.5.
2.4.3. Hybridisation
Each microarray slide for the 3 different time points was hybridised with differen-
tially labelled cDNA from tetracycline and control worms. Dye-flip replicates were
performed to exclude an impact through preferentially labelling of one fluorophore.
Each sample pair (∼ 24µl) was resuspended in formamide-based hybridisation
buffer (vial 7-Genisphere) (26µl) and Array 50dT blocker (Genisphere) (2µl). Two
hybridisations were carried out in a sequential manner. The primary hybridisation
was performed by adding 48µl of sample to the microarray under a supported glass
coverslip (Erie Scientific) at 43◦C for 16-20 h at high humidity in the dark. Prior
to the secondary hybridisation, slides were gently submerged into 2 x SSC, 0.2 %
SDS (at 43◦C) for 11 min, transferred to 2 x SSC (at RT) for 11 min, transferred
to 0.2 x SSC (at RT for 11 min) and then spun dry by centrifugation. Secondary
hybridisation was carried out using the complimentary capture reagents provided
in the 3DNA Array 900 kit (Genisphere). For each reaction, the following were
added: 3DNA capture reagent with Cy3 (2.5µl), 3DNA capture reagent with Cy5
(2.5µl), SDS-based hybridisation buffer (vial 6-Genisphere) (26µl), and nuclease
free water (21µl). The secondary hybridisation solution was incubated in the dark
at 80◦C for 10 min, then 50◦C for 15 min. Hybridisation was performed by adding
48µl secondary hybridisation solution to the slide under a supported glass coverslip
at 65◦C for 4 h at high humidity in the dark. At hybridisation termination, arrays
were gently submerged into 2 x SSC, 0.2 % SDS (at 65◦C) for 11 min, transferred to
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2 x SSC (at RT) for 11 min, transferred to 0.2 x SSC (at RT) for 11 min, and then
spun dry by centrifugation.
2.4.4. Image analysis
Slides were scanned with a Perkin Elmer ScanArray Express HT scanner to detect
Cy3 and Cy5 fluorescence. Laser power was kept constant for Cy3/Cy5 scans and
photomultiplier tube (PMT) was varied for each experiment based on optimal signal
intensity with lowest possible background fluorescence. A low PMT setting scan was
also performed to recover signal from saturated elements. Gridding and analysis
of images was performed using ScanArray v3.0 (Perkin Elmer). For determining
foreground and background intensities of each spot, the adaptive circle spot-finding
algorithm was used.
2.4.5. Data analysis
Spots that passed the criteria of an intensity unit > 200 and signal to background
ratio > 2 in one of the two channels were marked as present and were included in fur-
ther analyses. Normalisation of data was done using Lowess. The log2 transformed
values of the normalised and background subtracted ratio of intensities (treated
vs. untreated) were used for identification of significant changes in gene expression
applying Significance Analysis of Microarrays (SAM, version 3.02). SAM is a statis-
tical method adapted specifically for determining significant changes in very large
datasets like microarray expression data. A score is assigned to each gene on the ba-
sis of gene expression relative to the standard deviation of repeated measurements.
SAM estimates the percentage of genes identified by chance, which is named false
discovery rate (FDR) (Tusher et al., 2001). An example for a SAM plot with up-
and down-regulated genes is given in Figure 2.5. The one-class response type was
used with a FDR ≤ 5 % (= q-value ≤ 0.05). For each time point two hybridisations
(dye-flips) were performed. Since each oligo is spotted two times on the array we had
a total of four technical replicates. SAM imputes missing data (K-Nearest Neighbor
algorithm); therefore oligos that did not have at least 2 of the 4 technical replicates
hybridised were not identified as significantly regulated genes, due to high standard
deviations. Finally, the resulting data were filtered for genes having a minimum
2-fold gene expression change. The microarray data of the experiments reported
here have been submitted to Gene Expression Omnibus (accession GSE20976).
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Figure 2.5.: Example for a SAM plotsheet with a false discovery rate of 5.28 %. The
observed score indicates the observed relative difference d(i) of gene expression whereas
the expected score indicates the expected relative difference dE(i). The middle of the three
lines indicates the line where d(i) is identical to dE(i). The outer lines represent the delta
value which can be adjusted, resulting in larger and smaller sets of significant genes with
larger or smaller false discovery rates, respectively. Red datapoints represent up-regulated
and green points indicate down-regulated genes.
2.5. Ex vivo culture of filarial worms
2.5.1. Maintenance of LLCMK2 cells
We kindly thank Dr. Simon Townson (Northwick Park Institute for Medical Re-
search, Harrow, UK) for providing us with LLCMK2-cells6. The cells were main-
tained in 75 cm2 cell culture flasks in Minimal essential medium Eagle (MEM),
supplemented with L-glutamine, 10 % FCS and 1 % Penicillin/Streptomycin and
cultured at 37◦C and 5 % CO2. Medium was exchanged every 3-4 days and cells
were sub-cultivated once a week. Cells were washed with PBS and incubated
with Trypsin/EDTA (4 ml/flask) for ∼ 5 min at 37◦C. When cells started to de-
tach medium was added, the cells were resuspended and 1/4 of the original flask
was transferred to a new one.
6monkey kidney cells
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For cryopreservation one flask with confluent cells was used for 4 vials of frozen
cells. Cells were resuspended in standard medium and an equal volume of ice cold
freezing medium (standard medium + 20 % DMSO) was added dropwise to the
cells. Cells were frozen in cryotubes at -20◦C for 3 h and then transferred to -80◦C.
Alternatively cells were directly transferred to -80◦C using a freezing container (Mr.
Frosty, Thermo Scientific - Nalgene, Schwerte, Germany). For re-cultivation, cells
were quickly thawed, centrifuged at 1200 rpm for 5 min at 4◦C and the medium was
replaced with fresh standard medium. One vial of frozen cells was used for a 25 cm2
cell culture flask.
2.5.2. Feeder cell layer
LLCMK2 cells were used as feeder cells for ex vivo culture experiments with filarial
worms. 1/4 flask of confluent grown cells was seeded to one 6-well plate (for female
worms) or 48-well plate (for male worms) 2 days before adding the worms.
2.5.3. Isolation and selection of worms
L. sigmodontis worms less than 14 months old were isolated from cotton rats with
a patent infection. A. viteae were isolated from jirds with a patent infection, as
described in Chapter 2.2.7. The worms were washed in PBS and single worms were
then transferred into cavities of a 12-well plate (female worms) and 48-well plates
(male worms), respectively, containing medium. Integrity of the worms was than
evaluated under an inverse microscope (Leica Microsystems). Single intact female
worms were then transferred to cavities of a 6-well plate with a LLCMK2 feeder cell
layer or without cells, respectively. Female worms were cultivated on 6-well plates
and male worms on 48-well plates. In the survival assay (Chapter 3.7.1), worms were
cultivated in 4 ml medium with half of the medium changed every 3 days. In all
other drug treatment experiments the female worms were cultivated in 3 ml medium
containing the drug with a complete medium change every 2 days.
2.5.4. Drug treatment
The media containing the drugs were freshly prepared with the standard medium
used for cultivation of worms (MEM + 10 % FCS + 1 % Penicillin/Streptomycin)
prior to drug treatment. Succinylacetone was either directly dissolved in the medium
to a final concentration of 3 mM or prepared as 300 mM stock solution in DMSO
and diluted 1:100 in the medium. Stock solutions in DMSO were prepared for
wALADin1 (100 mM and 50 mM) and 5-ALA (500 mM) and diluted 1:100 in the
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Table 2.6.: Motility score description for L. sigmodontis cultured ex vivo
Score Description
0 Worm is stretched, no movement
1 Minor movement observed by eye, alternated by no movement,
worm ist stretched
2 Slow movement, worm is stretched
3 Moderate movement, worm is slightly stretched; some worms are
completely stretched at one side, but the other side shows active
motility
4 Active movement, not as closely knotted as ’5’
5 Very active movement, worm is knotted
medium. All media contained a final concentration of 1 % DMSO. Media containing
the final concentrations of drugs (3 mM SA, 500µM wALADin1, 1 mM wALADin1,
5 mM 5-ALA) were then sterile filtered.
2.5.5. Motility scoring
Motility was scored as a measure for viability. We used a scoring system from
0-5, with 5 = best motility and 0 = no motility. Table 2.6 describes the phenotypes
observed for each score. Depending on the drugs used in the experiment, worm
behaviour might be observed which was different from this scoring scheme and was
therefore recorded separately. The worm movement was also documented using a
Sony DCR-HC46E video camcorder and video material was edited using Final Cut
Pro 6.0 for Macintosh. Examples for L. sigmodontis and A. viteae motility scoring
0-5 are given on videos 1 and 2 (for overview of videos see appendix Table A.1).
2.5.6. Microfilariae count
Old medium was collected at each day of medium change for microfilariae count.
The medium was centrifuged at 1200 rpm for 5 min at 4◦C. Medium was discarded
and microfilariae were taken up in 200µl of medium. Microfilariae and early stages
were directly counted under a Neubauer counting chamber (LO-Laboroptik GmbH,
Friedrichsdorf, Germany). Differentiation between living and dead microfilariae was
possible, as larvae can move within the counting chamber.
47
Chapter 2. Materials and Methods
2.5.7. MTT assay
On the last day of culture, a biochemical evaluation of the worm viability was
performed using the MTT7 assay. As a control for dead worms, worms frozen in
liquid nitrogen and heat shocked for 10 min at 70◦C were included in the assay.
Worms were washed in PBS and then incubated for 30 min in 0.5 mg MTT/ml PBS
at 37◦C. Afterwards, single worms were transferred to 200µl DMSO and incubated
for 1 h to solubilise the blue formazan product. The plate was gently agitated to
disperse the blue colour and the absorption of the formazan was measured at a
microplate spectrophotometer (Spectra Max, Molecular Devices, Sunnyvale, USA)
at 490 nm. For adsorption values over 1, the samples were diluted in DMSO and
measured again.
7The yellow compound MTT [3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide] is
reduced by the mitochondrial enzyme succinate dehydrogenase of living tissues to produce the
blue precipitate MTT formazan. Inhibition of formazan formation is correlated with worm
damage or death.
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3.1. Wolbachia are effectively depleted from L.
sigmodontis
An effective depletion of Wolbachia in our experiments was confirmed by qPCR
that detects Wolbachia ftsZ copies (1 ftsZ = 1 Wolbachia). At day 6 of Tet treat-
ment Wolbachia ftsZ copies were reduced by 99.3 %. On day 36 a further decrease of
Wolbachia levels was measured, with 99.8 % reduction of bacterial DNA (Figure 3.1).
Figure 3.1.: Wolbachia are depleted from L. sigmodontis after Tet treatment. To confirm
the depletion of Wolbachia due to Tet treatment ftsZ copies were measured by qPCR
of gDNA extracted from treated and control worms. PCR reactions were performed in
triplicate. Copy numbers were normalised to copies of filarial actin from the same sample.
Each square represents gDNA levels from 3 female worms. Lines are median values.
Our microarray experiment aimed to study gene expression changes of L. sigmod-
ontis genes in response to depletion of Wolbachia rather than of Wolbachia genes
itself. Therefore oligo-dT primer were used for cDNA synthesis. Nevertheless, some
hybridisation of Wolbachia oligos was detected, very likely due to binding of the
oligo-dT primer to A-rich regions of the Wolbachia genes. Microarray analysis re-
vealed significantly down-regulated Wolbachia oligos (except 3 up-regulated oligos
at day 36) with a much higher fold change (Table 3.1 and 3.2) than most of the
filarial down-regulated oligos. Whereas the mean fold change of all Wolbachia genes
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down-regulated at day 6, 15 and 36 (FDR ≤ 5 % and minimum 2-fold change) was
8.8, the mean fold change of the significantly down-regulated filarial genes was only
2.9. Thus, successful depletion of Wolbachia was also confirmed by the results of
the microarray.
Table 3.1.: Regulated Wolbachia genes at day 6 and 15 of Tet treatment with fold change
≥ 2 and FDR ≤ 5 %
Oligo ID FDR % Fold Model Annotation
change name
Down-regulated oligos day 6
BMX14298 2.01 0.21 Wbm0531 Ribosomal protein S16
bm.01655 0.00 0.04 BMC11139 16S ribosomal RNA gene
BMX14105 0.00 0.19 Wbm0338 50S ribosomal protein L2
BMX14468 1.76 0.25 Wbm0700 50S ribosomal protein L27
BMX14524 1.76 0.09 Wbm0756 NifU homolog involved
in Fe-S cluster formation
BMX14070 3.35 0.22 Wbm0302 Ribosomal protein L28
BMX14288 1.76 0.26 Wbm0521 Ribosomal protein S21
BMX14110 4.61 0.19 Wbm0343 Translation elongation
factor EF-Tu, GTPase
BMX13119 0.00 0.05 TC3121 no match
BMX13089 0.00 0.05 TC3089 no match
bm.00809 0.00 0.06 BMC03273 no match
bm.03319 0.00 0.10 BMC05922 no match
bm.02869 1.76 0.17 BMC03240 no match
BMX12409 1.76 0.18 WB-contig 1624 no match
bm.03228 0.00 0.08 BMC01096 no match
BMX12657 0.00 0.08 WB-contig 453 no match
bm.00929 0.00 0.05 BMC03698 no match
bm.03514 0.00 0.07 BMC12386 no match
bm.01569 0.00 0.06 BMC07973 no match
Down-regulated oligos day 15
BMX14113 0.00 0.06 Wbm0346 30S ribosomal protein S12
BMX14105 0.00 0.08 Wbm0338 50S ribosomal protein L2
BMX14007 0.00 0.30 Wbm0239 hypothetical protein
BMX14537 0.00 0.10 Wbm0769 Membrane protease subunit,
stomatin/prohibitin homolog
BMX13825 0.00 0.11 Wbm0053 Outer membrane protein
BMX14070 0.00 0.12 Wbm0302 Ribosomal protein L28
BMX14288 0.00 0.09 Wbm0521 Ribosomal protein S21
BMX14110 0.00 0.04 Wbm0343 Translation elongation
factor EF-Tu, GTPase
bm.03228 0.00 0.04 BMC01096 no match
bm.00929 0.00 0.03 BMC03698 no match
bm.00809 3.47 0.04 BMC03273 no match
BMX12657 0.00 0.07 WB-contig 453 no match
bm.03514 0.00 0.07 BMC12386 no match
BMX12409 0.00 0.15 WB-contig 1624 no match
bm.01569 0.00 0.06 BMC07973 no match
BMX13089 0.00 0.03 TC3089 no match
BMX13119 0.00 0.03 TC3121 no match
bm.03319 0.00 0.07 BMC05922 no match
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Table 3.2.: Regulated Wolbachia genes at day 36 of Tet treatment with fold change ≥ 2
and FDR ≤ 5 %
Oligo ID FDR % Fold Model Annotation
change name
Up-regulated oligos day 36
BMX14282 2.79 3.32 Wbm0515 hypothetical protein
BMX14078 2.48 2.01 Wbm0310 Short-chain alcohol
dehydrogenase family enzyme
BMX14443 2.79 2.05 Wbm0675 Stress-induced morphogen, BolA
Down-regulated oligos day 36
BMX14128 1.52 0.13 Wbm0362 Predicted membrane protein
bm.01655 0.00 0.11 BMC11139 16S ribosomal RNA gene
BMX14113 3.13 0.30 Wbm0346 30S ribosomal protein S12
BMX14105 0.00 0.10 Wbm0338 50S ribosomal protein L2
BMX14468 1.52 0.24 Wbm0700 50S ribosomal protein L27
BMX14225 3.13 0.40 Wbm0459 ATP synthase subunit C
BMX14475 1.52 0.12 Wbm0707 Cold shock protein
BMX14415 2.48 0.38 Wbm0647 DNA-directed RNA
polymerase beta’ chain
BMX14537 0.52 0.11 Wbm0769 Membrane protease subunit,
stomatin/prohibitin homolog
BMX14010 1.52 0.26 Wbm0242 NADH dehydrogenase beta subunit
BMX14393 0.52 0.18 Wbm0625 NADH:ubiquinone
oxidoreductase chain J
BMX14070 3.13 0.28 Wbm0302 Ribosomal protein L28
BMX14400 0.00 0.05 Wbm0632 Ribosomal protein L36
BMX14103 1.52 0.09 Wbm0336 Ribosomal protein S16
BMX14298 1.52 0.09 Wbm0531 Ribosomal protein S16
BMX14288 0.00 0.16 Wbm0521 Ribosomal protein S21
BMX13917 1.52 0.06 Wbm0147 Thiol-disulfide isomerase,
thioredoxin family
BMX14421 1.52 0.13 Wbm0653 Translation elongation
factor EF-Tu, GTPase
BMX14110 0.00 0.05 Wbm0343 Translation elongation
factor EF-Tu, GTPase
BMX14007 0.00 0.28 Wbm0239 hypothetical protein
BMX13995 0.00 0.09 Wbm0225 hypothetical protein
bm.01569 3.59 0.18 BMC07973 no match
bm.03514 4.28 0.27 BMC12386 no match
bm.00929 3.59 0.19 BMC03698 no match
bm.03319 0.00 0.04 BMC05922 no match
bm.03228 0.00 0.03 BMC01096 no match
BMX12409 0.00 0.02 WB-contig 1624 no match
bm.00809 1.84 0.09 BMC03273 no match
BMX13089 1.52 0.08 TC3089 no match
BMX12657 0.00 0.05 WB-contig 453 no match
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3.2. Hsp60 is not up-regulated after Wolbachia
depletion
Expression of L. sigmodontis hsp60 was measured during Tet treatment as an indi-
cator for a possible stress response in the worms due to Tet treatment or depletion
of Wolbachia. Expression of hsp60 showed no alteration over the treatment time
compared to the control (Figure 3.2).
Figure 3.2.: Hsp60 is not up-regulated in L. sigmodontis after Wolbachia depletion. To
control for a possible stress response during Tet treatment, expression of filarial hsp60
was measured by qPCR. PCR reactions were performed in triplicate. Copy numbers were
normalised to cDNA copy numbers of filarial actin from the same sample. Each square
represents cDNA levels from 3 female worms. Lines are median values.
3.3. Differentially expressed L. sigmodontis genes
after depletion of endosymbiotic Wolbachia
The microarray experiment was conducted to identify genes of L. sigmodontis that
show differential expression upon depletion of intracellular Wolbachia. This study
represents the first attempt to use the B. malayi microarray to study gene expression
changes in L. sigmodontis. Binding of L. sigmodontis cDNA to the oligonucleotides
on the chip covered approximately 20 % of the spots (average percentage of all 6
slides, not including oligos derived from Wolbachia gene sequences). Within the
thresholds of a q-value ≤ 0.05 (= False Discovery Rate ≤ 5 %) and a minimum fold
change of 2, we detected most of the oligos corresponding to regulated genes at day
36 of Tet treatment (142 up- and 193 down-regulated). Fewer oligos passed the
thresholds at day 6 (1 up- and 57 down-regulated) and the fewest at day 15 (3 up-
and 5 down-regulated).
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Figure 3.3.: KEGG classification of L. sigmodontis genes, that are regulated in response
to Wolbachia depletion at days 6, 15 and 36 of tetracycline treatment. Numbers of func-
tionally annotated genes with q ≤ 0.05 and fold change ≥ 2 are shown. Red represents
up-regulation and green down-regulation.
3.3.1. KEGG analysis
KEGG analysis (Kanehisa and Goto, 2000) classified the differentially regulated
genes into functional groups and highlighted pathways that were most affected by
the depletion of Wolbachia. The regulated oligos included hypothetical and unknown
genes and also genes that cannot be assigned a gene ontology term by KEGG. Figure
3.3 comprises the classification of 40 % of the significantly regulated oligos. Detailed
information of all regulated genes can be found in the appendix in Tables B.1, B.2
and B.3. Hypothetical and unknown proteins made up over 30 % of the down-
regulated and over 40 % of the up-regulated genes at day 36 of Tet treatment, with
q ≤ 0.05 and fold change ≥ 2.
From the KEGG analysis and genome annotation, genes involved in genetic infor-
mation processing including translation, transcription and genes coding for proteins
involved in folding/sorting and degradation were predominantly down-regulated at
day 36 of Tet treatment. Translation proteins included the 60S ribosomal pro-
teins L3, (Bm1 13895), L12 (Bm1 07030), L18a (Bm1 23030), L21 (Bm1 47445),
L27 (Bm1 28975), 40S ribosomal protein S7 (Bm1 09900) and 50S ribosomal pro-
tein L21 (Bm1 46405). Besides these ribosomal proteins, different translation fac-
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tors were down-regulated including EF-1 guanine nucleotide exchange domain con-
taining protein (Bm1 27955), translation elongation factor eEF-2 homolog eft-1
(Bm1 44395), initiation factor 2-associated protein (Bm1 37925), WD40 associated
region in TFIID subunit family protein (Bm1 47705) and eukaryotic translation ini-
tiation factor 4E type 3 (Bm1 32915). Down-regulated genes involved in protein
degradation were also identified: Hsp70 (Bm1 43675) and proteasome A-type and
B-type family proteins (Bm1 55200 and Bm1 30555).
Down-regulated genes that play a role in transcription included transcription
factor-like GATA zinc finger family protein (Bm1 44270) and other zinc finger fam-
ily proteins (Bm1 41325, Bm1 55855, Bm1 43055, Bm1 24215), which often play a
role in transcription regulation, but can also have other regulatory functions that in-
volve binding to RNA and proteins. Different genes involved in splicing were down-
regulated at day 36, such as U2 small nuclear ribonucleoprotein A (Bm1 15860),
THO complex subunit 3 (Bm1 12545) and putative splicing factor SF2 (Bm1 45785).
In contrast, other genes involved in splicing were up-regulated, like a protein sim-
ilar to RNA helicase p68 (DDX5; BMC06625), and ATP-dependent RNA helicase
DDX5/DBP2 (Bm1 52675).
Several genes belonging to the cytoskeleton were differentially expressed. Up-
regulated oligos at day 36 of Tet treatment included genes belonging to thin fil-
aments of musculature: troponin C (Bm1 48810), troponin T (Bm1 55000) and
tropomyosin (Bm1 01235). Furthermore, proteins that bind to proteins of the cy-
toskeleton and that are involved in their regulation were seen to be differentially
expressed: a calponin homolog (Bm1 49080) and gelsolin (Bm1 33155) were up-
regulated at day 36, whereas a coronin gene (Bm1 03260) and the gex interacting
proteins 4 (Bm1 41495) and 10 (Bm1 31280) were down-regulated at day 36. At
day 6 of Tet treatment the actin-binding genes profilin family protein (Bm1 21620)
and actin-depolymerization factor 1 (Bm1 22990) were found to be down-regulated.
Several cuticle collagens were up-regulated at day 36 (Bm1 36555, Bm1 17485,
Bm1 13245, Bm1 27595). At day 15 of Tet treatment one collagen gene was up-
regulated (Bm1 01465) and another down-regulated (Bm1 17480).
Genes belonging to energy metabolism displayed the most noticeable group of
up-regulated genes. This finding is described in detail in Chapter 3.5.
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3.4. Validation of a sub-set of regulated genes by
qPCR
QPCR was used to confirm the up- and down-regulation trends of a subset of genes
found to be differentially expressed in the microarray. 20 genes that had either
multiple regulated oligos, a strong fold change, or were interesting in regard to
filaria-Wolbachia symbiosis were chosen. This selection included genes from differ-
ent functional classes: structural proteins (Troponin T and C), proteins of metabolic
pathways (Succinyl-CoA ligase beta chain, Acetyl-CoA hydrolase/transferase, Lipoic
acid synthase, DNA/panthonate metabolism flavoprotein, Diphosphomevalonate de-
carboxylase, Aromatic aminoacid hydrolase), a transcription factor (Med7 transcrip-
tion factor), secreted proteins (Mif1, Juv-p120) and proteins involved in transport
and trafficking (Globin family protein, ABC transporter, Rab5 GDP/GTP exchange
factor). Two hypothetical genes were also included (Bm1 30045, Bm1 04280), since
they showed a strong up-regulation in the microarray. From this list, 60 % of the
differentially expressed genes were confirmed by qPCR. Expression changes of the
up-regulated genes agreed well with the microarray results, whereas only a few of
the selected down-regulated genes were validated (Table 3.3).
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Table 3.3.: qPCR results to validate expression changes in L. sigmodontis after Wolbachia depletion
Fold changea
BLAST Match B. malayi locus Annotation ID Time Microarray qPCRb
Up-regulated genes
Globin family protein Bm1 50430 14992.m10859 d36 4.8 (1)c 2.1d
Troponin C Bm1 48810 TC2796, BMW00285.523, d36 2.4 (4) 1.8
BMC12124, BMW01217.101
Troponin Te Bm1 55000 BMC00075 d6 2.4 (1) 1.3
BMC00075, TC2790 d36 2.4 (2) 1.7
Mif1 Bm1 28435 BMC00238 d36 2.2 (1) 1.3
Hypothetical proteine Bm1 30045 BMC00075 d15 2.7 (1) 1.3
BMC02980,14950.m01825, d36 8.1 (3) 2.0
WB-contig 1411
Hypothetical protein Bm1 04280 12962.m00049, TC3117, d36 6.9 (3) 1.8
WB-contig 256
Succinyl-CoA ligase beta chain Bm1 00840 12498.m00044 d36 4.6 (1) 0.89
Acetyl-CoA hydrolase/transferase Bm1 42975 14975.m04536 d36 2.1 (1) 1.4
ABC transporter Bm1 30435 14952.m01388 d36 2.0 (1) 0.95
RNA binding protein Bm1 37780 BMC00185, 14972.m07250 d36 3.0 (2) 2.0
Similar to c-met receptor Bm1 37575 BMC00090 d36 2.1 (1) 1.1
Down-regulated genes
Med7 transcription factor Bm1 23975 TC3295, TC3326 d36 0.32 (2) 1
Retinoblastoma binding protein Bm1 15930 BMC08875, 14224.m00309 d6 0.34 (2) 0.52
Secretory protein Juv-p120 Bm1 19955/ Bm1 00865 14478.m00108/14478.m00109 d36 0.43 (2) 0.53
Lipoic acid synthase Bm1 23910 14696.m00211 d36 0.44 (1) 0.94
DNA/panthotenate metabolism flavoprotein Bm1 45070 BMC03590 d36 0.48 (1) 0.9
Diphosphomevalonate decarboxylase Bm1 42945 14975.m04530 d36 0.28 (1) 0.84
Aromatic aminoacid hydrolase Bm1 46865 14981.m02410 d36 0.13 (1) 1.4
60S ribosomal protein L3 Bm1 13895 14039.m00115, WB-contig 530 d36 0.38 (2) 1.3
Rab5 GDP/GTP exchange factor Bm1 29925 14950.m01801 d36 0.31 (1) 0.88
a Fold change: treated versus untreated.
b Median of six samples containing three worms.
c Indicates the number of oligonucleotides on the microarray that were regulated.
d Bold: validated expression changes.
e Genes were regulated at two time points in microarray.
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3.4.1. Fluorescence intensities among up- and
down-regulated genes
As we observed a clear difference of expression validation between up- and down-
regulated genes (Table 3.3) we further analysed the microarray data for possible
reasons leading to this discrepancy. A comparison of the microarray fluorescence in-
tensities of the spots corresponding to the genes selected for qPCR validation shows
significantly higher fluorescence signals for the genes which were validated in qPCR
(average of 5181) than those which were not validated (average of 832) (p = 0.0051,
Mann-Whitney test) (Table 3.4).
Table 3.4.: Microarray fluorescence intensities (FI) of genes measured in qPCR
BLAST match B. malayi locus Time Mean FIa
Up-regulated genes
Globin family protein Bm1 50430 d36 355b
Troponin C Bm1 48810 d36 4552
Troponin T Bm1 55000 d6 3486
d36 4552
Mif1 Bm1 28435 d36 2394
Hypothetical protein Bm1 30045 d15 4602
d36 3686
Hypothetical protein Bm1 04280 d36 2709
Succinyl-CoA ligase beta chain Bm1 00840 d36 402
Acetyl-CoA hydrolase/transferase Bm1 42975 d36 628
ABC transporter Bm1 30435 d36 1634
RNA binding protein Bm1 37780 d36 31744
Similar to c-met receptor Bm1 37575 d36 2881
Down-regulated genes
Med7 transcription factor Bm1 23975 d36 606
Retinoblastoma binding protein Bm1 15930 d6 816
Secretory protein Juv-p120 Bm1 19955/ Bm1 00865 d36 2645
Lipoic acid synthase Bm1 23910 d36 574
DNA/panthotenate metabolism flavoprotein Bm1 45070 d36 316
Diphosphomevalonate decarboxylase Bm1 42945 d36 387
Aromatic aminoacid hydrolase Bm1 46865 d36 410
60S ribosomal protein L3 Bm1 13895 d36 686
Rab5 GDP/GTP exchange factor Bm1 29925 d36 428
a Mean fluorescence intensities of all spots of the gene on the microarray corresponding to the channel
with the higher signal (for down-regulated genes: control, for up-regulated genes: Tet treated).
b Bold: Fluorescence intensities of genes with validated expression changes in qPCR, compare
Table 3.3.
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3.4.2. Expression patterns of validated regulated genes
In this section selected genes with a validated expression change and their expression
patterns on days 6, 15 and 36 of Tet treatment are described in more detail.
Globin family protein Globins are heme and oxygen binding proteins which
are widely distributed amongst nematode species (Hoogewijs et al., 2008). One of
these globin family proteins was up-regulated in L. sigmodontis after Tet treatment.
In our microarray experiment one oligo (BMX8086) corresponding to the globin
Bm1 50430 was 4.8-fold up-regulated and qPCR analysis for 3 time points of Tet
treatment revealed that expression of this gene gradually increased with duration
of Tet treatment and was 2.1-fold up-regulated at day 36 (p = 0.0022) (Figure 3.5
A). The C. elegans homolog of this up-regulated globin is the protein ZK637.13,
the canonical globin 1 (E = 3e-37). The crystal structure of the C. elegans Glb-1
demonstrates the characteristic 3 over 3 alpha helical sandwich structure and the
incorporated heme molecules (Figure 3.4).
Figure 3.4.: The up-regulated B. malayi globin family protein Bm1 50430 is homologous
to the C. elegans globin 1 gene (ZK637.13), one out of a total of 33 C. elegans globin genes.
The C. elegans Glb-1 molecule consists of two subunits, interacting mainly through the
E and F helices (orange and cyan). Heme is shown in red. Figure is taken from Geuens
et al. (2010).
RNA binding protein Two oligonucleotides corresponding to the B. malayi
RNA binding protein Bm1 37780 were 3-fold up-regulated at day 36 of Tet treatment
(Table 3.3). This up-regulation has been confirmed using qPCR with L. sigmodontis
specific primers. The observed fold change at day 36 was 2 (p = 0.0043) with the
expression already starting to increase at day 6 of treatment (Figure 3.5 B). This
gene is one of 15 B. malayi RNA binding proteins with an RNA recognition motif
(RRM) domain. A BlastP search using the Bm1 37780 aminoacid sequence revealed
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the homology to the Ascaris suum Cleavage stimulation factor subunit 2 (CstF-2)
tau variant (E-value = 7e-43).
Figure 3.5.: Up-regulated genes after Wolbachia depletion. PCR reactions were per-
formed in triplicate. Copy numbers were normalised to cDNA copy numbers of filarial
actin from the same sample. Each square represents gene expression from 3 female worms.
Lines are median values, # denotes a significant difference of gene expression compared
to the control, as determined with Mann-Whitney-U test (p ≤ 0.05).
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Troponin T and C Our microarray experiment revealed subunits of the tro-
ponin complex up-regulated after Tet treatment. Troponin is a globular molecule,
consisting of the three subunits T, C and I. Troponin T (Bm1 55000) was signifi-
cantly up-regulated at day 6 (1 oligo) of Tet treatment as evidenced by microarray
analysis. This gene was also up-regulated at day 36 (2 oligos) (Table 3.3). QPCR
analysis confirmed that expression of Troponin T increased from day 6 to 36 of
Tet treatment, with a significant 1.5-fold (p = 0.0152) up-regulation at day 15 and
1.7-fold (p = 0.0087) up-regulation at day 36 (Figure 3.5 C). Consistent with this
result, another subunit of the troponin complex showed increased expression after
Tet treatment of L. sigmodontis : 4 oligos corresponding to the B. malayi troponin C
gene (Bm1 48810) were ∼ 2.5-fold up-regulated at day 36 in microarray and 1.7-fold
in qPCR analysis, although it was not significant (p = 0.0649). Similar to the ex-
pression pattern observed for troponin T, expression of troponin C increased with
duration of Tet treatment (Figure 3.5 D). The best C. elegans blastx match to the
L. sigmodontis mRNA sequence is the troponin C pat-10 gene (E-value = 6e-80,
93 % similarity).
Hypothetical proteins 30045 and 04280 Two hypothetical genes were chosen
for further validation of the differential expression detected by microarray analy-
sis. Here, multiple oligos corresponding to the genes Bm1 30045 and Bm1 04280
showed that expression increased 8.1 and 6.9-fold, respectively (Table 3.3). An
up-regulation of the genes after 36 day of Tet treatment compared to untreated
control worms could be confirmed by qPCR, although the expression change was
much lower. Expression of Bm1 04280 significantly increased 1.8-fold (p = 0.0211)
and expression of Bm1 30045 increased 2-fold, although not significantly. The hypo-
thetical protein (Bm1 04280) was identified by BLAST as small nuclear RNA U2-1
(91 % similarity to A. suum snRNA U2-1, E = 9e-58).
Juvenile protein p120 (Juv-p120) The protein Juv-p120 is the major excretory-
secretory product of juvenile L. sigmodontis. In our microarray experiment we found
two oligos corresponding to juv-p120 2.3-fold down-regulated at day 36 of Wolbachia
depletion (Table 3.3). This result was confirmed by qPCR analysis with a decrease
of 1.9-fold (p = 0.0411) after Tet treatment compared to the untreated control. As
in the microarray analysis, down-regulation of juv-p120 was not observed at days 6
and 15 of treatment (Figure 3.6 A).
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Retinoblastoma binding protein Two oligos corresponding to the retinoblas-
toma-binding protein Bm1 15930 were 2.9-fold down-regulated in L. sigmodontis
at day 6 of Tet treatment, as evidenced by our microarray analysis (Table 3.3).
QPCR analysis verified the decrease in expression (1.9-fold) at day 6 of treatment,
although it was not significant (p = 0.0649). Same as seen in the microarray analysis,
expression levels at day 15 and 36 of Tet treatment were the same as in untreated
worms (Figure 3.6 B). The L. sigmodontis sequence used for qPCR also has a great
homology to a second retinoblastoma binding protein (Bm1 57630) encoded by B.
malayi. One oligo corresponding to this genes was also down-regulated at day 6
of treatment as shown by microarray analysis (Table B.1). Blast searches revealed
homology to the highly related mammalian retinoblastoma binding proteins Rbbp4
and Rbbp7, components of a histone deacetylase complex (Nicolas et al., 2000).
However, a blastx search with the Ls sequence used for qPCR identified the best
homology to Ascaris suum Rbbp4 (E = 3e-100, 94 % identity) and the Rbbp4 of
several mammalian species (E ≤ 3e-76).
Figure 3.6.: Down-regulated genes after Wolbachia depletion. PCR reactions were per-
formed in triplicate. Copy numbers were normalised to cDNA copy numbers of filarial
actin from the same sample. Each square represents gene expression from 3 female worms.
Lines are median values, # denotes a significant difference of gene expression compared
to the control, as determined with Mann-Whitney-U test (p ≤ 0.05).
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3.5. Expression of mitochondrial encoded
respiratory chain enzymes
3.5.1. Expression of mitochondrial encoded genes in L.
sigmodontis after Wolbachia depletion
Evident from the microarray results was the fact that mitochondrial encoded genes
of the respiratory chain were up-regulated after Wolbachia depletion. The Brugia
mitochondrial genome encodes 12 subunits of the respiratory chain, which belong
to the complexes NADH dehydrogenase, cytochrome bc1, cytochrome c oxidase
and ATP synthase (Figure 3.7). The microarray analysis resulted in 24 oligos cor-
responding to 9 mitochondrial encoded subunits of the respiratory chain with a
significant up-regulation and a minimum 2-fold change in expression. When oligos
with < 2-fold significant change were included, 28 oligos corresponding to 10 of the
12 mitochondrial encoded subunits were found to be up-regulated (Table 3.5).
Figure 3.7.: Mitochondrial encoded subunits of the respiratory chain of Brugia malayi.
Shown are the 12 mitochondrial encoded subunits (red) belonging to 4 of the respira-
tory chain complexes. Except subunits ND4L and ND6 (light red) all subunits were
up-regulated at day 36 of tetracycline treatment in L. sigmodontis. Cofactors essential in
the respiratory chain complexes are shown in grey.
To validate the differential expression seen in the microarray, qPCR was performed
for the respiratory chain subunits cytochrome c oxidase subunit 1 and 2 (cox1 and
cox2), cytochrome b (cytB) and NADH dehydrogenase subunit 4 and 5 (ND4 and
ND5). The qPCR confirmed an increase in expression at day 36 for these 5 genes.
Expression of Ls-cox1 increased 1.6-fold (p = 0.0008), Ls-cox2 1.7-fold (p = 0.001),
Ls-cytB 1.8-fold (p = 0.0029), Ls-ND4 1.9-fold (p = 0.0025) and Ls-ND5 1.8-fold
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(p = 0.0293) compared to expression in untreated control worms (Figure 3.8). As
in the microarray, change of expression on days 6 and 15 of Tet treatment was not
detected by qPCR.
Table 3.5.: Mitochondrial encoded subunits of the respiratory chain complexes up-
regulated at day 36 of tetracycline treatment as evident from microarray analysis
Fold change microarrayc
Annotationa Annotation ID Oligo IDb Oligo Mediand
Cytochrome c oxidase subunit 1 TC2778 BMX12792 3,5 2,7
TC7739 BMX10990 2,89
WB-contig 182 BMX12477 2,72
BMW00283.860 BMX11370 2,7
BMC12170 bm.01757 2,7
BMC06165 bm.03325 2,47
TC2780 BMX12794 2,32
BMC12111 bm.03436 2,22
Cytochrome c oxidase subunit 2 BMC12116 bm.03438 2,82 2,61
BMC00030 bm.03171 2,81
BMC00071 bm.03174 2,4
BMC06256 bm.03082 2,31
Cytochrome c oxidase subunit 3 BMC01393 bm.00380 27,36 2,37
BMC00359 bm.03045 3,05
BMC12260 bm.03485 1,68
BMC00256 bm.03201 1,64
Cytochrome b WB-contig 187 BMX12481 2,93 2,22
BMC11632 bm.03368 2,22
WB-contig 207 BMX12492 2
NADH dehydrogenase subunit 1 TC2803 BMX12812 2,36 2,36
NADH dehydrogenase subunit 2 BMC00485 bm.03545 2,54 2,43
WB-contig 1474 BMX12282 2,43
BMW01358.408 BMX11795 2,2
NADH dehydrogenase subunit 3 TC3244 BMX13241 2,64 2,24
BMW00166.284 BMX11305 1,83
NADH dehydrogenase subunit 4 WB-contig 383 BMX12609 1,94 1,94
NADH dehydrogenase subunit 5 TC3096 BMX13096 2,15 2,15
ATPase subunit 6 TC2809 BMX12816 2,51 2,51
a Brugia malayi mitochondrion (GenBank Accession No. AF538716).
b Significantly regulated oligonucleotides with q ≤ 0.05.
c Treated versus untreated.
d For subunits represented by multiple oligos, the median fold-change was calculated.
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Figure 3.8.: Expression of mitochondrial encoded subunits of the respiratory chain of
L. sigmodontis increased at day 36 of Tet treatment. To confirm up-regulation of res-
piratory chain genes qPCR for cytochrome c oxidase subunit 1 (A), cytochrome c oxi-
dase subunit 2 (B), cytochrome b (C), NADH-dehydrogenase subunit 4 (D) and NADH-
dehydrogenase subunit 5 (E) was performed for days 6, 15 and 36 of tetracycline treatment.
PCR reactions were performed in triplicate. Copy numbers were normalised to cDNA copy
numbers of filarial actin from the same sample. Each square represents gene expression
from 3 female worms. Lines are median values, # denotes a significant difference of gene
expression compared to the control, as determined with Mann-Whitney-U test (p ≤ 0.05).
Graphs are representative of 2 experiments.
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3.5.2. Expression of mitochondrial encoded genes in A.
viteae after Tet treatment
To exclude a direct effect of tetracycline on the worms as the cause of up-regulation
of respiratory chain genes, experiments with the Wolbachia-free filaria A. viteae were
performed. Transcript levels of cytochrome c oxidase subunit 1 and cytochrome b
from 6 weeks orally Tet treated A. viteae were not different to transcript levels of
untreated control worms (Figure 3.9). Therefore, under these conditions, tetracy-
cline had no measurable effect directly on the mitochondria.
Figure 3.9.: Expression of mitochondrial-encoded subunits of the respiratory chain of
A. viteae is not altered after Tet treatment. QPCR was performed with cDNA for cy-
tochrome c oxidase subunit 1 (A) and cytochrome b (B) from untreated and 6 weeks orally
Tet treated worms. PCR reactions were performed in triplicate. Copy numbers were nor-
malised to copy numbers of A. viteae actin from the same sample. Each square represents
gene expression from 2 female worms. Lines are median values. Graphs are representative
of 2 experiments.
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3.6. Mitochondrial DNA (mtDNA) content after
Tet treatment in L. sigmodontis and A.
viteae
Mitochondria are dynamic organelles and their number per cell can change for exam-
ple depending on the energy demands of the cell. To ascertain whether Tet treatment
or Wolbachia depletion has an impact on mtDNA content we measured the levels of
DNA of mitochondrial encoded genes from Tet treated worms and compared them
to mtDNA levels of untreated worms. Genomic DNA of the nuclear encoded gene
actin was measured to control for the amount of DNA extracted from the worms.
MtDNA levels were significantly elevated in L. sigmodontis at day 15 (p = 0.0236
(cox1), p = 0.0013 (cytB)) and day 36 (p = 0.0168 (cox1), p = 0.0063 (cytB)) of Tet
treatment. The gDNA amount of the nuclear encoded gene actin also increased at
day 15 and 36 of Tet treatment, although this increase was not significant. However,
the pattern of mt and nuclear gDNA levels during Tet treatment in L. sigmodontis
are comparable. MtDNA content of Tet treated A. viteae was measured to control for
possible changes in mitochondrial copy numbers due to a direct effect of tetracycline.
MtDNA levels were not elevated after 6 weeks of oral Tet treatment in A. viteae,
nevertheless actin copy numbers, which were used to control for the total amount
of DNA extracted from the worms, showed a 5-fold decrease after Tet treatment (p
= 0.0089).
One possible reason for the lower actin gDNA copies seen in A. viteae worms
after Tet treatment could be an impairment in embryogenesis due to Tet treatment.
Fewer embryos and microfilariae in the worms could lead to a decrease of actin copy
numbers. In a further experiment the microfilariae numbers in blood of A. viteae-
infected jirds were counted after 6 weeks of oral Tet treatment and compared to
untreated A. viteae-infected jirds. Additionally, we examined whether uteri from
worms that were isolated from Tet treated and untreated jirds were filled with
embryonic stages and microfilariae. No decrease of microfilariae numbers in blood
was detected after Tet treatment (Figure 3.12). All worms, both the untreated and
Tet treated worms, had uteri filled with embryos.
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Figure 3.10.: MtDNA content during Tet treatment of L. sigmodontis. QPCR was
performed with mitochondrial DNA of cytochrome c oxidase subunit 1 (A) and cytochrome
b (B) from untreated and 6, 15 and 36 days Tet treated L. sigmodontis. Copy numbers
were compared to gDNA copies of the nuclear encoded actin gene (C). PCR reactions
were performed in triplicate. Each square represents gene expression from 3 female worms.
Lines are median values, # denotes a significant difference of gene expression compared
to the control, as determined with Mann-Whitney-U test (p ≤ 0.05).
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Figure 3.11.: MtDNA content during Tet treatment of A. viteae. QPCR was performed
with mtDNA of cytochrome c oxidase subunit 1 (A) and cytochrome b (B) from untreated
and 6 weeks orally Tet treated A. viteae. Copy numbers were compared to gDNA copies
of the nuclear encoded actin gene (C). PCR reactions were performed in triplicate. Each
square represents gene expression from 2 female worms. Lines are median values, #
denotes a significant difference of gene expression compared to the control, as determined
with Mann-Whitney-U test (p ≤ 0.05).
Figure 3.12.: Numbers of microfilariae in blood of A. viteae-infected Tet treated jirds.
Microfilariae were counted before and after 6 weeks orally Tet treatment and compared to
microfilariae numbers in untreated jirds. Columns represent mean and standard deviation
of microfilariae numbers from 4 - 6 jirds.
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3.7. Inhibition of heme biosynthesis of Wolbachia
from L. sigmodontis
3.7.1. Survival of L. sigmodontis ex vivo is enhanced by
the presence of feeder cells
To perform experiments with L. sigmodontis ex vivo we first established appropriate
culture conditions which allowed us to cultivate the worms over a longer period of
time. Several publications report the positive effects of feeder cells on filaria cultured
ex vivo (Townson et al., 1986; Falcone et al., 1995; Townson et al., 2006) Notably,
LLCMK2 feeder cells supported the survival of Onchocerca gutturosa ex vivo. In
order to test the suitability of these cells for cultivation of L. sigmodontis we com-
pared the survival of L. sigmodontis in the presence of the LLCMK2 feeder cells and
without cells, respectively. The motility of the worms was assessed as measurement
for viability. The feeder cells clearly improved the survival of L. sigmodontis (p =
0.0392)(Figure 3.13 A). The median survival of female worms in the presence of cells
was 58 days (range 29 - 64) and 26 days without feeder cells (range 8 - 33). The ini-
tial drop in motility of L. sigmodontis cultured in the presence of feeder cells results
from a few worms (6/24) which were apparently damaged during removal from the
pleural cavity and separation by sex. Therefore, in further experiments worms were
cultured 1-2 days before starting drug treatment in order to sort out unhealthy or
damaged worms.
With the conditions established in this experiment L. sigmodontis could be cul-
tured for a minimum of 14 days with no obvious impairment of the worms and are
therefore suitable for ex vivo experiments and testing of long term effects of drugs.
3.7.2. Inhibition of Wolbachia ALAD effects the survival
and microfilariae release of L. sigmodontis
Our previous experiments reported the up-regulation of heme proteins after deplet-
ing Wolbachia bacteria from L. sigmodontis. We now aimed to demonstrate the
dependency of filaria on the cofactor heme, which might be delivered by Wolbachia
to the worms. L. sigmodontis were cultured in the presence of succinylacetone (SA),
a known inhibitor of ALAD, the second enzyme of the heme biosynthesis pathway
(Figure 4.3). Any effects of the drug on the worms were assessed by evaluating the
motility of the worms and counting the microfilariae released into the medium.
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Figure 3.13.: Survival of L. sigmodontis ex vivo. L. sigmodontis were obtained from a
cotton rat with a patent infection. Single female worms were incubated in a cavity of a
6-well plate in 5 ml MEM + 10 % FCS + 1 % Penicillin/Streptomycin either on a feeder
cell layer (LLCMK2 cells) or without feeder cells (A). Single male worms were cultivated
in a cavity of a 24-well plate in 1.5 ml medium in the presence of or without feeder cells
(B). Half of the medium was exchanged every 2 - 3 days and worms were transferred to
new plates every 14 days. Motility of worms was assessed using a score from 0 - 5 with
0 = no motility and 5 = best motility (see description of scores in Table 2.6). Error bars
represent SEM of 24 worms.
SA significantly effected the motility of the worms. An initial effect was seen at
day 3 of treatment and motility gradually worsened until day 14. At this last time
point, control worms were still actively moving and knotted (mean motility score 4.6)
whereas SA treated worms were stretched and only slowly moving (mean motility
score 1.9) (Figure 3.14 A). Additionally, microfilariae numbers of SA treated worms
were significantly decreased from day 6 on compared to untreated control worms
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(Figure 3.14 B). An impairment of microfilariae motility could already be seen at
day 2 of SA treatment.
Figure 3.14.: Effect of succinylacetone (SA) on motility and microfilariae release of L.
sigmodontis ex vivo. Single female worms were cultured on a LLCMK2 cell layer in 3 ml
MEM + 10 % FCS + 1 % Penicillin/Streptomycin (control) or in medium containing 3 mM
SA. Medium was completely exchanged every 2 days. Motility of worms was assessed daily
using a score from 0 - 5 with 0 = no motility and 5 = best motility (see description of scores
in Table 2.6) Data points present mean and standard deviation of a minimum of 9 worms
(A). Microfilariae in the old medium were counted every two days at the day of medium
exchange. Bars represent median and interquartile range of a minimum of 9 worms (B).
SA is a heme biosynthesis inhibitor which not only inhibits the Wolbachia ALAD
but also the human enzyme. In contrast, the substance wALADin1 specifically
inhibits the Wolbachia ALAD without interfering with the human enzyme. This
substance has been identified by large scale screening of a substance library in order
to identify anti-Wolbachia drugs (Christian Lentz, unpublished data). Using the
L. sigmodontis ex vivo culture we assessed the impact of wALADin1 on worm vi-
ability. Using a much lower concentration of wALADin1 (500µM and 1 mM) than
of SA (3 mM) the effect of wALADin was much stronger. We observed a dras-
tic effect on the worms at a time point early as 2 hours after start of treatment.
The worms treated with wALADin1 showed a characteristic phenotype: they were
moving slower but without being stretched, rather having a contracted or cramped
appearance. The condition of these worms worsened during the course of treatment,
however the contracted/cramped phenotype changed into a stretched appearance.
The effect of wALADin1 was dose dependent. With a concentration of 1 mM no
motility was observed from day 8 on, whereas worms treated with 500µM wAL-
ADin1 were moving until day 14, the last time point of culture, although very
weakly (motility score ”1”).
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Figure 3.15.: Effect of the ALAD inhibitor wALADin1 on survival and microfilariae
release of L. sigmodontis ex vivo. Single female worms were cultured on a LLCMK2 cell
layer in 3 ml MEM + 10 % FCS + 1 % Penicillin/Streptomycin (control) or in medium
containing 3 mM SA, 500µM and 1 mM wALADin1. All media contained 1% DMSO.
Medium was completely exchanged every 2 days. Motility of worms was assessed daily
using a score from 0 - 5 with 0 = no motility and 5 = best motility (A). Enzymatic activity
of worms was assessed at day 14 using the MTT viability assay (B). Live microfilariae
released into the medium were counted every two days at the day of medium exchange,
n.d. = not detected (C). Shown are means of 6 worms. # indicates a significant difference
compared to the control, as determined with Mann-Whitney-U test (p ≤ 0.05).
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In this experiment the SA treated worms, which served as a positive control for
the effect of heme inhibition on the worms, showed impaired motility late in the
treatment, compared to what was seen in the previous experiment. At day 14 the
worms were still moving with a motility ”score 3” (Figure 3.15 A). One parameter
that differed was the presence of 1 % DMSO in the medium, which served as solvent
for all drugs in this experiment, whereas SA was directly dissolved in the medium
in the experiment presented in Figure 3.14 A.
The effect of the drugs on motility of L. sigmodontis worms at days 0, 3, 9 and
14 (corresponding to the experiment shown in Figure 3.15 A) is also documented on
videos 3 - 6 (for overview of videos see appendix Table A.1).
The biochemical evaluation of worm viability was carried out at day 14, the last
time point of treatment. Viability was measured as the ability of the mitochondrial
succinate dehydrogenase to reduce the yellow MTT into a blue formazan product.
500µM wALADin1 reduced the viability of the worms to 30 % of control level,
whereas worms treated with 1 mM wALADin1 had no enzyme activity. Viability of
SA treated worms was reduced by 50 % compared to the control worms (Figure 3.15
B). These results matched well to the motility states of the worms at day 14.
wALADin1 strongly affected release of motile microfilariae by the worms. At a
concentration of 1 mM no motile microfilariae were detectable beginning at day 2.
Also, with the lower wALADin1 concentration motile microfilariae numbers were
significantly reduced starting at day 2 (p = 0.022) and not detectable at day 12
(Figure 3.15 C).
3.7.3. Effects of heme biosynthesis inhibitors on the
Wolbachia-free filaria A. viteae
To exclude unspecific effects of the heme biosynthesis inhibitors SA and wALADin1,
we performed inhibition experiments with A. viteae. A. viteae does not contain
Wolbachia and (except ferrochelatase) no heme biosynthesis enzymes have been
found in the genome. Any effects of SA and wALADin1 on the worms are therefore
considered unspecific effects.
We were able to cultivate A. viteae in MEM + 10 % FCS + 1% Penicillin / Strep-
tomycin in the presence of LLCMK2 feeder cells for 14 days without an impairment
in motility. The addition of 3 mM SA did not effect the motility of the worms (Fig-
ure 3.16 A) and viability of worms measured in the MTT assay was not decreased
compared to the control worms (Figure 3.16 C). We therefore conclude, that the
effects of SA we have seen on L. sigmodontis are due to the inhibition of the ALAD
enzyme.
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On the other hand, the motility of A. viteae was impaired by treatment with
wALADin1. An initial strong effect could be observed directly after adding medium
containing the drug. Worms treated with 1 mM wALADin1 did not recover during
the course of treatment, which is also reflected by the results of the MTT viability
assay (Figure 3.16 C). Nevertheless, the lower concentration of wALADin1 (500µM)
had an initial effect on the worms, starting at the first day of treatment, but con-
dition of worms did not worsen during the course of treatment as it was seen with
treatment of L. sigmodontis. Additionally, the MTT assay at day 14 did not detect
an impairment of viability of worms treated with 500µM wALADin (Figure 3.16 A
and C). Hence, although there is an unspecific effect of wALADin on the worms, the
effect of wALADin on A. viteae is a different than on L. sigmodontis. Movement of
A. viteae worms during treatment with wALADin1 and SA at days 0, 3, 9 and 14
(corresponding to the experiment shown in Figure 3.16 A) is also documented on
videos 7 - 11 (for overview of videos see appendix Table A.1).
The substrate of ALAD in the heme biosynthesis pathway is 5-aminolevulinic acid
(5-ALA). Upon inhibition of the ALAD enzyme a accumulation of 5-ALA is possible
and might be a cause for the effect on the worms we observed. We therefore aimed
to evaluate the effect of 5-ALA on the worms motility and viability. 5 mM 5-ALA
had a very strong initial effect observed directly after addition of the drug. The first
addition of the drug at day 0 resulted in a complete paralysis of the worm (motility
score ”0”). However, this drastic effect was not long lasting and worms were moving
with a motility score of 3.5 until day 14 (Figure 3.16 B). The MTT assay did not
reveal an effect of 5-ALA on the enzyme activity, it even was above control level
(Figure 3.16 C). The effect of 5-ALA on motility of A. viteae worms at days 0, 3 and
14 (corresponding to the experiment shown in Figure 3.16 B) is also documented on
video 12 (for overview of videos see appendix Table A.1).
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Figure 3.16.: Effect of succinylacetone (SA) and wALADin1 on the viability of A. viteae
ex vivo. Single female worms were isolated from jirds and cultured on a LLCMK2 cell
layer in 3 ml MEM + 10 % FCS + 1 % Penicillin/Streptomycin (control) or in medium
containing 3 mM SA, 5-ALA, 500 µM and 1mM wALADin1. Media (except 3 mM SA
and medium group) contained 1 % DMSO. Medium was completely exchanged every 2
days. Motility of worms was assessed daily using a score from 0 - 5 with 0 = no motility
and 5 = best motility (A and B). Arrows indicate the effect of 5-ALA on the worm’s
motility at 1.5 h after medium exchange and addition of fresh drug. Enzymatic activity
of worms was assessed at day 14 using the MTT viability assay (C). Shown are means of
6 worms. # indicates a significant difference compared to the control, as determined with
Mann-Whitney-U test (p ≤ 0.05).
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4. Discussion
4.1. Suitability of the B. malayi microarray for
hybridisation with L. sigmodontis cDNA
4.1.1. Cross-hybridisation
In our study we used the B. malayi microarray chip to measure changes in gene
expression in L. sigmodontis after depletion of Wolbachia. Due to cDNA from a
different filarial species hybridising to the chip, it is expected that only a limited
number of L. sigmodontis genes with enough sequence similarity to the correspond-
ing oligos are detected by the array. The oligos on the microarray have a length of
65 nucleotides, which means that binding of L. sigmodontis genes is only possible if
enough similarity in this restricted part of the sequence is present. The more oligos
corresponding to one gene present on the array, the higher the chance that one of the
oligos can bind the L. sigmodontis cDNA. Here, 20 % of the oligos corresponding to
filarial genes showed a signal above background level and were included in the anal-
ysis. This number is low compared to percentage of detection seen in experiments
using cDNA of B. malayi where ∼ 70 % of hybridisation signals were above threshold
(Li et al., 2005). Experiments using the B. malayi microarray chip with L. sigmod-
ontis cDNA are therefore not expected to provide a complete picture of the gene
expression status. However, we showed that within the genes that have enough ho-
mology to the oligos on the chip, a comparison of RNA levels from untreated with
treated worms is possible and can serve as tool for identification of differentially
regulated genes. Additionally, genes that hybridised in our experiment possibly rep-
resent evolutionary conserved genes with greater biologic importance. Compared
with differential display, a method previously used to find differentially regulated
genes (Heider et al., 2006), the B. malayi microarray provided greater speed and
more information on gene expression changes in L. sigmodontis. The tool box to
study the molecular mechanism of the Wolbachia-filaria symbiosis is restricted and
the establishment of experimental set ups for its study is important. Our microarray
experiment showed that the sequence information available for B. malayi is of great
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use to promote investigations of symbiosis using the well established filarial model
organism L. sigmodontis.
4.1.2. Reproducibility of microarray data
A subset of differentially expressed genes was ,,cherry picked“ from the microarray
data to be validated by qPCR with samples from a different experiment. Including
the mitochondrial encoded genes, we performed qPCR for 25 genes and confirmed
63 % of the genes regulated in response to the loss of Wolbachia. QPCR results of the
up-regulated genes better agreed with the microarray data than the down-regulated
genes. An increased variability of low-intensity spots has been reported and it has
been speculated that this may lead to a worse validation of down-regulated genes
compared to up-regulated genes (Morey et al., 2006). Indeed, most of the selected
genes with a validated expression change in qPCR had higher fluorescence intensities
in the microarray than genes whose differential expression change could not be
confirmed. The selected down-regulated genes had a lower fluorescence intensity
than most of the selected up-regulated genes. Interestingly, for the spots of the
two out of 9 selected down-regulated genes with a confirmed differential expression,
higher intensities could be ascertained than for all of the 7 not validated genes (Table
3.4). To achieve a greater reproducibility of the data further studies could use more
restricted criteria for the analysis of this microarray with a minimal intensity unit
higher than 200.
Our data and the data of Ghedin et al. (2009) show that genes of many distinct
pathways are affected by endosymbiont depletion, therefore it cannot be excluded
that the gene used for normalisation is also affected by the disruption of symbiosis.
Of note, the mitochondrial encoded NADH-dehydrogenase subunit 1 gene used by
Ghedin et al. (2009) for normalisation after Wolbachia depletion in B. malayi was
up-regulated in our microarray experiment after 36 days of Tet treatment (Table
3.5). Therefore caution should be used when using this gene for normalising gene
expression.
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4.2. Differentially expressed genes after
Wolbachia depletion
4.2.1. General expression patterns after Wolbachia
depletion
We detected most of the regulated genes at day 36, with Wolbachia copies reduced
by 99.8 %, fewer genes at day 6 and the fewest genes at day 15. This resembles
a bimodal pattern that has been observed before for phosphate permease (Heider
et al., 2006) and was explained by an early response due to dying of embryonic stages,
which have been shown to be more sensitive to the loss of Wolbachia (Langworthy
et al., 2000), and the later peak due to the adult worms responding to disruption of
symbiosis. A bimodal expression pattern of genes belonging to signalling pathways
was also reported by Ghedin et al. (2009), although this was seen at an earlier time
point with the first up-regulation at day one of Tet treatment and the second at day
6. As they cultured the worms ex vivo in tetracycline containing medium, the earlier
gene expression response might be due to a more direct exposure of the worms to
tetracycline.
The regulation of genes in this pattern supports that the gene expression changes
result from disruption of symbiosis and do not result from a general stress response
due to the dying bacteria within the worm. We also showed that most of the Wol-
bachia had already died by day 6 of Tet treatment (Figure 3.1) and were eliminated
from the worms by day 36. Further evidence to support that the regulation was not
simply a stress response is that hsp60 was not up-regulated for any time point as
measured by qPCR (Figure 3.2). Gene expression changes seen at this time point
are therefore more probably the result of lack of supply by Wolbachia and attempt
of the worm to adapt to this situation than a general stress response.
Although we used oligo-dT primer to reverse transcribe L. sigmodontis mRNA,
we also detected some hybridisation to Wolbachia oligos. These Wolbachia genes
were strongly down-regulated and reflected successful bacterial depletion in our ex-
periment. If one compares the significantly down-regulated Wolbachia genes at the
3 different time points, it can be noticed that the same genes come up at day 6,
15 and 36 (Tables 3.2 and 3.1). Likely, this is not because these are the only genes
down-regulated, but because these are the only ones which had A-rich regions (to
be reverse transcribed by oligo-dT primers) and because they were expressed high
enough to be detected and to exceed the minimal fluorescence intensity to be in-
cluded in the analysis.
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4.2.2. Cytoskeletal proteins
B. malayi has 67 genes which encode several cuticle collagens. They are expressed
differentially during development, therefore each larval stage contains a character-
istic composition of collagens (Scott and Ghedin, 2009). We detected several cuti-
cle collagens up-regulated at day 36 of Tet treatment and one up- and one down-
regulated collagen at day 15. Ghedin et al. (2009) found collagens predominantly
down-regulated in wBm depleted B. malayi, but these were not the same genes
that we found to be differentially expressed. Only collagen col-34 (Bm1 36555) was
both up-regulated in B. malayi (day 7) and in our microarray analysis (day 36).
Cuticle biosynthesis occurs prior to molting at the end of the embryonic and each
larval stage (Page and Johnstone, 2007), thus a change in the expression of cuti-
cle collagens might reflect the impairment of larval development after Wolbachia
depletion.
Troponin C, troponin T and tropomyosin were up-regulated in the microarray.
The globular molecule troponin is, together with actin and tropomyosin, part of the
thin filament of the muscle apparatus and responsible for regulation of contraction.
Troponin consist of 3 subunits: troponin T, which binds to tropomyosin, troponin
C, which binds calcium and thereby produces a conformational change in troponin
I and Troponin I, which binds to the actin thin filaments (Hooper et al., 2008). We
confirmed the up-regulation of the troponin genes by qPCR (Figure 3.5 C and D).
Besides their role in locomotion, troponin and tropomyosin are important regulators
for ovarian contraction in Caenorhabditis elegans (Ono and Ono, 2004) and differen-
tial expression of these genes might result from the block in embryogenesis seen after
disruption of symbiosis (Hoerauf et al., 1999, 2003). Furthermore, mutations in sev-
eral genes for regulatory components of the muscle filaments affect embryonic and
larval development in C. elegans. Specifically, mutations in the pat-10 gene, which
encodes the up-regulated troponin C, lead to paralysed, arrested embryos late in
development (Terami et al., 1999). This coincides with the phenotype observed in
filarial worms after Wolbachia depletion. Also, the actin binding proteins profilin,
gelsolin, coronin, actin-depolymerization factor 1 and calponin were differentially
expressed after Wolbachia depletion. Together, these observations might either be
a result of the disturbed symbiosis or even might reflect an interaction of Wolbachia
proteins with the host cytoskeleton.
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4.2.3. Transcriptional regulation
Our microarray analysis identified a retinoblastoma binding protein to be down-
regulated in L. sigmodontis at day 6 of Wolbachia depletion. A decrease in expres-
sion at day 6 has been confirmed by qPCR analysis. This protein is a orthologue
to the mammalian protein RbAp48 which plays a role in regulation of chromatin
remodelling during transcription. RbAp48 binds the retinoblastoma protein (Rb)
and the histone deacetylase 1 (HDAC1) and is thereby involved in the repression of
the transcription factor E2F-1. E2F-1 activates the transcription of S phase genes,
promoting the progression of cell cycle from G1 to S phase (Nicolas et al., 2000)(Fig-
ure 4.1). Consistent with that result, another protein, PurA, which can bind to the
transcription factor E2F-1 and thereby inhibits transcription of E2F-1 responsive
genes (Darbinian et al., 1999), was down-regulated at day 6 in the microarray. Ho-
mologues of Rb and RbAp48 in C. elegans are the proteins Lin-35 and Lin-53 and
they also seem to function in transcriptional repression and developmental regula-
tion (Harrison et al., 2006). RbAp48 targets the chromatin remodelling complex
to nucleosomes by binding histones. Consistent with that, several genes encoding
histones were also differentially expressed in our microarray and after Wolbachia de-
pletion in B. malayi (Ghedin et al., 2009). Wolbachia encode several Ank proteins
which have been implicated in diverse functions to establish intracellular lifestyle of
bacteria within the host. In Anaplasma phagocytophilum an Ank protein has been
observed in association with condensed chromatin of the host cell and a role in reg-
ulation or modification of host cell gene transcription has been suggested (Caturegli
et al., 2000). The differential expression of a histone binding protein, which is in-
volved in the deacetylation of chromatin during transcriptional regulation indicates
that Wolbachia bacteria as well might be able to modify host cell gene expression.
Landmann et al. (2009) proposed an impaired histone deposition as the mechanism
for Wolbachia induced CI in insects, thus Wolbachia possibly influence chromatin
remodelling for transcriptional regulation of host genes.
It is unknown how Wolbachia synchronises its replication with the filarial cell cy-
cle. The differential expression of the proteins RbAp48 and PurA after Wolbachia
depletion, which regulate an important transcription factor for cell cycle control,
might be an indication for an interaction of Wolbachia with host cell cycle regula-
tion.
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Figure 4.1.: Regulation of transcription of E2F responsive genes is altered after Wolbachia
depletion. The transcription factor E2F-1 activates the transcription of S-phase genes (A).
The complex of Rb, histone deacetylase 1 (HDAC1) and RbAp48 as well as Pur alpha
(PurA) are repressors of E2F-1 and inhibit G1/S cell cycle progression. RbAp48 and Pur
alpha (green) are down-regulated at day 6 of Wolbachia depletion in L. sigmodontis (B).
4.2.4. Post-transcriptional processing and protein synthesis
Several genes involved in post-transcriptional processing were differentially expressed
in L. sigmodontis after Wolbachia depletion. One of these genes, an RNA binding
protein (Bm1 37780), has been validated by qPCR to be up-regulated at day 36
of Tet treatment (Figure 3.5 B). This gene contains an RRM domain, which are
very abundant protein domains in eukaryotes, but are also found in prokaryotes and
viruses. The structural motif allows high RNA binding and specific recognition. It
has multiple biological functions, mostly associated with post-transcriptional gene
regulation (Maris et al., 2005). The gene up-regulated in our experiments has high
homology to the subunit 2 of the cleavage stimulation factor (CstF2 tau variant),
that is involved in cleavage and polyadenylation of the 3’ site of pre-mRNAs (Salis-
bury et al., 2006). The maturation of the pre-mRNAs ensures stability and function
of the transcripts, therefore an expression change in post-transcriptional modifica-
tion processes might affect the copy numbers of RNA transcripts of many genes.
This might in part explain why we and Ghedin et al. (2009) observed differential
expression of many different gene classes, especially considering that we used oligo-
dT primer to reverse transcribe mature mRNA into cDNA.
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We detected a considerable number of genes involved in splicing to be differen-
tially expressed after Wolbachia depletion. Cis- and trans-splicing in nematodes
requires several small nuclear RNAs (snRNA) which are associated with proteins in
a complex called spliceosome (Hannon et al., 1991). One of the hypothetical proteins
(Bm1 04280) that we confirmed by qPCR to be up-regulated at day 36 of Tet treat-
ment had BLAST hits to the small nuclear RNA U2-1. Furthermore, our microarary
data revealed the DDX5 RNA helicase up-regulated at day 36, whereas 2 splicing
factors and the U2 small nuclear ribonucleoprotein A were down-regulated at this
point of time. A U6 snRNA-associated protein (Lsm4) was down-regulated at day 6.
Results of other studies support an alteration of the splicing process after Wolbachia
depletion: differential display previously identified the early up-regulation (day 3 to
day 15) of the small nuclear RNA U6-3 after Wolbachia depletion in L. sigmodontis
(Klemm, Pfarr and Hoerauf, unpublished data) and in the study of Ghedin et al.
(2009) several splicing factors were up-regulated in B. malayi at day 14 of Wolbachia
depletion. The up-regulation and at the same time the down-regulation of splicing
factors and spliceosome associated proteins is not necessarily an inconsistent finding,
as splicing factors can have repressor and activator functions and can even reverse
their effects on a substrate depending on changes in the splicing process during
development (Barberan-Soler et al., 2011). A differential expression might reflect
an adaption of the worm to the impaired developmental processes after Wolbachia
depletion. A change in general processes like post-transcriptional regulation might
also reflect the disturbed homeostasis after disruption of the mutualistic symbiosis.
Another possible explanation of these results is supported by a recent study of Sug-
imoto et al. (2010) that showed that Wolbachia influences the alternative splicing of
a sex determination gene and thereby induces sexual alterations in a moth. Thus,
the differential expression of splicing related genes seen in L. sigmodontis after en-
dosymbiont depletion might indicate an interaction of Wolbachia molecules in this
process. Whether nematode Wolbachia alter the expression of specific genes at the
mRNA level to establish its intracellular lifestyle is a topic that needs further re-
search.
Our microarray analysis revealed translation genes to be predominantly down-
regulated at day 36 of Tet treatment. Similarly, in the study of Ghedin et al.
(2009) differential regulation of genes involved in translation was observed after
depleting wBm, although they found them to be up-regulated at days 7 and 14 of
Tet treatment. They explained this finding by a general stress response induced due
to a shortage of essential nutrients which are otherwise supplied by Wolbachia. An
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early increase in protein synthesis could reflect the attempt of the worm to provide
necessary proteins and thereby counteract the loss of supply from Wolbachia. At a
later time point, as seen in our results, the protein synthesis machinery might be
down-regulated again, reflecting the failure to compensate for the loss of Wolbachia.
4.2.5. Immunoregulatory proteins
The major L. sigmodontis excretory/secretory protein Juv-p120, produced by juve-
nile female worms (Hintz et al., 1998), was down-regulated at day 36 of Tet treatment
in our experiments (and confirmed by qPCR) as well as at day 14 in Wolbachia de-
pleted B. malayi (Ghedin et al., 2009). In B. malayi an early up-regulation of this
protein has been observed, which coincides with the slight increase of expression we
observed by qPCR at day 6, before expression decreases 2-fold at day 36. Juv-p120 is
highly decorated with dimethylaminoethanol (DMAE) (Houston et al., 2008). The
major secretory product of A. viteae, ES-62, is conjugated with phosphorylcholine
(PC), which inhibits pro-inflammatory responses of the mammalian host. DMAE
contains only two methyl groups, whereas PC contains 3. It is hypothesised that
the DMAE decorated Juv-p120 may function immunologically in a manner similar
to PC (Hewitson et al., 2009). Further, our microarray analysis detected galectin-1
(Bm1 24940) to be down-regulated at day 6 of Tet treatment. This protein is one
of the most prominent excretory-secretory products of adult B. malayi (Hewitson
et al., 2008). Galectin is thought to participate in filarial down-regulation of host
immune responses, as it is able to inhibit Th1 and Th2 inflammatory responses
in humans and affects regulation of regulatory T-cells (Garn et al., 2007; Toscano
et al., 2006). A change in the expression of immunomodulatory molecules suggests
a change in the immunological environment of the worm after Wolbachia depletion.
4.2.6. Hypothetical proteins
The many hypothetical proteins that were up- and down- regulated after Wolbachia
depletion are also of interest, because they may represent proteins with important
functions for symbiosis and parasitic life style. 20 % of total genes encoded by B.
malayi and ca. 2000 of the hypothetical genes are only found in B. malayi and
may encode filarial-specific gene products (Ghedin et al., 2007). Assigning functions
to the hypothetical proteins that have a role in symbiosis will be of great interest,
because they might have evolved since the establishment of the filaria-Wolbachia
symbiosis and might have key roles in maintaining the homeostasis. Up-coming
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interactome studies by other filarial research groups will surely shed light on this
issue by identifying interactions of Wolbachia proteins with filarial proteins.
4.3. Heme proteins of the respiratory chain are
up-regulated after Wolbachia depletion
The most striking result in our study was the up-regulation of nearly all mitochon-
drial encoded genes of the respiratory chain at day 36 of Tet treatment (Table 3.5,
Figure 3.8). Distinct localisation patterns of filarial mitochondria and Wolbachia
have been reported (Pfarr et al., 2008) which would limit a direct interaction be-
tween the mitochondria and the vesicles containing Wolbachia. A trend towards
up-regulation of these respiratory chain subunits during Tet treatment was also
reported in Wolbachia depleted B. malayi (Ghedin et al., 2009), where increased
transcript levels were detected at day 14 of Tet treatment. As tetracycline acts
by inhibiting the bacterial 30S ribosomal subunit (Brodersen et al., 2000) and mi-
tochondria have proteobacterial ancestors, an impairment on mitochondrial protein
synthesis due to an inhibition by tetracycline is possible and has been reported (Mc-
Kee et al., 2006). To exclude this possibility, jirds infected with the Wolbachia-free
filaria A. viteae were treated for 6 weeks with tetracycline in drinking water. The
treatment time used was the same previously demonstrated to achieve a sustained
depletion of Wolbachia from L. sigmodontis to levels equivalent to 36 days of intra-
peritoneal treatment in mice (Arumugam et al., 2008). As expression of respiratory
chain genes did not change after Tet treatment in A. viteae (Figure 3.9), we conclude
that the up-regulation of the mitochondrial respiratory chain subunits is specific to
Wolbachia depletion from worms dependent on this endosymbiont.
One possible reason for the change in the expression of these mitochondrial sub-
units is their requirement for heme and riboflavin (Figure 3.7), cofactors that may
be provided by the Wolbachia (Foster et al., 2005). Specifically, the complexes cy-
tochrome c oxidase and cytochrome bc1 need heme as a prosthetic group. Genome
analysis revealed that Wolbachia possess all but one enzyme required to synthesise
this essential cofactor (Figure 4.4). The missing gene is protoporphyrinogen, a gene
that is absent in many alpha-proteobacteria, but very likely complemented by an-
other gene (Foster et al., 2005). However, B. malayi lack most of the genes needed to
produce heme and therefore must take it up from the environment or are dependent
on their intracellular Wolbachia bacteria. Furthermore, riboflavin, another cofactor
that also can be synthesised by Wolbachia, is essential in the NADH-dehydrogenase
complex (Figure 3.7). No enzymes for riboflavin synthesis have been detected in
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the B. malayi genome (Foster et al., 2005). We hypothesise that due to a lack of
essential cofactors it is not possible to form functional respiratory chain complexes.
As a consequence, the nematode cells attempt to correct for their lack by increasing
the transcription of respiratory chain subunits (Figure 4.2).
Another heme-binding protein of the globin family (Bm1 50430), the orthologue
of the canonical globin 1 of C. elegans (ZK637.13), was also up-regulated after Wol-
bachia depletion and validated by qPCR (Figure 3.5 A). C. elegans expresses 33
globin genes with high diversity in gene structure, amino acid sequence and ex-
pression profiles, and the B. malayi genome encodes 13 different globin variants.
Nonvertebrate globins are much more heterogeneous than globins from vertebrates
and have, besides the conventional oxygen storage and transport, a wealth of diverse
functions (Geuens et al., 2010; Hoogewijs et al., 2007). As this protein is encoded
by the nucleus, the up-regulation of heme-dependent proteins was not limited to
mitochondrial proteins.
Wolbachia-containing filarial nematodes may be dependent on the heme provided
by Wolbachia and needed for mitochondrial and nuclear encoded heme-requiring
proteins. A loss of function of the heme containing enzymes required for ecdysone
signalling has been hypothesised to contribute to the developmental defects after
Wolbachia depletion (Tzertzinis et al., 2010). Furthermore, deficiency of mitochon-
drial respiratory chain due to loss of heme may also account for the developmental
impairments, as seen in C. elegans (Tsang et al., 2001).
4.3.1. Tet treatment differentially affects mitochondrial
copy number in L. sigmodontis and A. viteae
The number of mitochondria in a cell can change depending on energy needs during
development (Lemire, 2005). We therefore analysed whether a change of mitochon-
dria per cell in L. sigmodontis might be a cause for the elevated mRNA levels after
Wolbachia treatment. Copy number of the mitochondrial encoded genes were ele-
vated at days 15 and 36 of Tet treatment, nevertheless, copies of the nuclear encoded
actin showed the same pattern after treatment (Figure 3.10). Therefore, we conclude
that the numbers of mitochondria per cell are not increased after Tet treatment and
that this is not an explanation for the increased mRNA levels we observed. We
also performed the same analysis with untreated and 6 weeks orally Tet treated A.
viteae. We did not observe a change of mtDNA copies, but we observed an unex-
pected drop of actin copy numbers to 5-fold under the control level (Figure 3.11).
Previous experiments have shown that Tet treatment does not affect development in
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Figure 4.2.: Wolbachia depletion leads to up-regulation of mitochondrial encoded heme
containing enzymes of the respiratory chain of L. sigmodontis. We hypothesise that filarial
worms are dependent on heme and riboflavin, provided by Wolbachia, to form a functional
respiratory chain. After depletion of Wolbachia with tetracycline, loss of the cofactors
leads to deficiencies in respiratory chain function, which the nematode attempt to correct
by increasing transcription of genes for the respiratory chain.
the Wolbachia-free filaria A. viteae. We also did not see a difference in microfilariae
number in blood of untreated and Tet treated A. viteae-infected jirds (Figure 3.12).
A difference in embryo content within the worms could have led to differences in
gDNA amounts extracted from the worms.
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In mammalian cells, tetracycline analogues can induce apoptosis, which is demon-
strated by growth inhibition and DNA fragmentation, a typical hallmark of apop-
tosis (Onoda et al., 2006). It could be possible that decreased gDNA copies in A.
viteae are due to degraded DNA as a consequence of apoptosis induced by tetracy-
cline. To address this question, further experiments could investigate whether DNA
is degraded after Tet treatment in A. viteae compared to L. sigmodontis. Further-
more, determining the amount of cytochrome c would help answer this question,
as cytochrome c is released during apoptosis. Regarding our findings, it is advised
not to use gDNA copy numbers for normalising gene expression in Tet treatment
experiments, as this would lead to misinterpretations.
Clearly, our experiment showed that L. sigmodontis and A. viteae are differentially
affected by tetracycline. One explanation for a different effect of tetracycline on in-
fected versus uninfected species is given by Ballard and Melvin (2007). They showed,
that Tet treatment led to an increase in mtDNA density in Wolbachia-uninfected
Drosophila, whereas in Wolbachia-containing individuals this was not seen. They
hypothesised that tetracycline enters both the mitochondria and the Wolbachia bac-
teria and therefore tetracycline concentration is diluted in the mitochondria. The
effects of tetracycline on the mitochondria would therefore be less prominent in
Wolbachia-infected compared to uninfected individuals. This argument might also
explain why Wolbachia-infected and uninfected filaria were differentially affected by
tetracycline in our study. Tetracycline reaches the Wolbachia in our experiments,
evident by a 99.3 % reduction of bacterial copy number (Figure 3.1). Nevertheless,
there is no knowledge of pumps or ABC transporters that actively transport tetra-
cycline into the bacterium or help getting it out, respectively. Tetracycline might
also reach the Wolbachia by passive transport. Such possible unspecific effects of
tetracycline would be overestimated in uninfected compared to Wolbachia-infected
species and would not devalue the effects on filaria that are caused by loss of the
Wolbachia endosymbiont.
4.4. Ex vivo cultivation of L. sigmodontis
In order to clarify a possible dependency of filarial nematodes on Wolbachia heme
biosynthesis, we first established appropriate culture conditions for ex vivo drug
treatment experiments with L. sigmodontis. Comparable to the results seen with O.
gutturosa (Townson et al., 1986) LLCMK2 feeder cells greatly enhanced the survival
of worms compared to worms cultured in medium only. That way, it is possible to
perform experiments over 14 days without damaging the worms. An established ex
88
Chapter 4. Discussion
vivo cultivation of this well established model organism for filariasis (Hoffmann et al.,
2000) has considerable advantages, as pharmacokinetic issues are reduced compared
to in vivo experiments in mice. Uptake of substances, accumulation within the worm
and anti-filarial efficiency can be tested ex vivo to preselect substances prior to in
vivo studies. Furthermore, experiments involving substances which would be toxic
for mice are possible.
4.4.1. Inhibition of heme biosynthesis specifically impairs
Wolbachia-containing filaria
The importance of heme biosynthesis for filarial survival has recently been shown
ex vivo in a study by Wu et al. (2009). The inhibition of heme biosynthesis led to
immobility of B. malayi worms. C. elegans do not synthesis heme, but are able to
take up heme from the environment (Hieb et al., 1970; Rao et al., 2005). Although
the B. malayi were cultured in the presence of hemin, they were not able to make
use of this environmental source of heme. In addition, 10 % FCS was added to
the medium in the studies by Wu et al. (2009) as well as in our experiments and
might be sufficient as an external source of heme, assuming that filaria could take it
up. However, succinylacetone (SA), the inhibitor of aminolevulinic acid dehydratase
(ALAD), also slightly affected larval growth of C. elegans, therefore one cannot fully
exclude that unspecific effects of SA have contributed to the impaired motility of B.
malayi worms. We addressed this question in our study by treating L. sigmodontis
as well as the Wolbachia-free filaria A. viteae with SA. A significant impairment of
SA on the feeder cells could be excluded (data not shown), as this would have led
to an additional disadvantage of survival of SA treated worms. As seen with B.
malayi we observed a reduction in motility of L. sigmodontis when cultured in the
presence of 3 mM SA. However, the effect was not as detrimental as in the study by
Wu et al. (2009). Whereas female B. malayi were immotile after 8 days of treat-
ment, female L. sigmodontis were moving, although more slowly, until the end of
the observation period at day 14 (Figure 3.14 A). Differences in permeability of
the cuticles of B. malayi and L. sigmodontis and different sensitivities and ages of
worms may account for these distinct observations. Furthermore, the presence of
feeder cells in our worm culture very likely not only promotes the survival of the
control but also the SA treated worms. Nevertheless, the effect of SA on L. sigmod-
ontis was significant, which is also clearly reflected by the biochemical evaluation of
viability (Figure 3.15 B). In contrast, the Wolbachia-free A. viteae worms were not
affected by SA treatment, as demonstrated by assessment of motility and enzymatic
viability assay (Figure 3.16 A and C). Thus, SA reduces viability in two Wolbachia
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containing filaria, but not in a Wolbachia-free species. We believe this effect is due
to inhibition of Wolbachia heme biosynthesis, leading to loss of function of essential
heme containing proteins.
Several questions remain open, e.g. regarding the function of ferrochelatase (FC),
which is the only heme biosynthesis enzyme found in Wolbachia-containing filaria
as well as in the Wolbachia-free filaria A. viteae. FC catalyses the last step of heme
biosynthesis, the conversion of protoporphyrin IX into heme. Complementation as-
says in E. coli show that this filarial enzyme is functional. Furthermore, the heme
auxotroph C. elegans transfected with Bm-FC are able to utilise the heme precursor
protoporphyrin IX (Slatko et al., 2010). Thus, it is possible that filarial nematodes
obtain protoporphyrin IX from the environment and convert it into heme. It may
be a second source of heme additional to the provision of heme by Wolbachia. As
developmental processes require heme dependent functions like ecdysone mediated
molting and energy metabolism and because embryos are affected first by Wolbachia
depletion, filarial nematodes might require additional heme from Wolbachia in times
of high needs of this cofactor. Inhibiting Wolbachia heme biosynthesis in the pres-
ence of protopophyrin IX might elucidate whether filaria are able to take up and
utilise this heme precursor. Also, further experiments should address the possibil-
ity that filarial worms obtain heme or protoporphyrin IX from red blood cells, as
haematophagy seems to play a role for maturation of L. sigmodontis (Attout et al.,
2005). Determining the heme content within the worms (e.g. in Wolbachia deple-
tion experiments) could also give more informations about the heme metabolism.
Measuring of heme concentration is possible by reconstitution of peroxidase activity
with heme and an apoenzyme (Thomas and Weinstein, 1990) or with a colorimetric
assay that measures the heme that is converted into an uniform coloured form in an
aqueous alkaline solution (QuantiChromTM Heme Assay Kit, BioAssay Systems,
Hayward, USA). This would control for an eventual utilisation of heme precursors,
decrease of heme after Wolbachia depletion or for the efficiency of heme biosynthesis
inhibitors.
4.4.2. In search of a Wolbachia-specific heme biosynthesis
inhibitor
Genome information, previous and our studies showed the potential of the Wolbachia
heme biosynthesis as a target for drugs against filariasis. Therefore, efforts are being
made to find drugs that specifically inhibit Wolbachia heme biosynthesis enzymes
but not the human enzyme. wALADin1 showed a drastic dose dependent effect on
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vitality of L. sigmodontis. Lower concentrations than used for SA, which was used as
a control, were needed to achieve a greater reduction in motility and in the enzymatic
viability assay (Figure 3.15 A and C). An unspecific effect was observed, as evidenced
by the impact of the drug on the Wolbachia-free A. viteae. Nevertheless, comparing
the effect of 500µM wALADin1 on motility of L. sigmodontis and A. viteae it was
clear that the drug acts differently on the both filarial species. Whereas motility of L.
sigmodontis gradually worsens over time of treatment, motility of A. viteae is slightly
impaired initially, but then does not worsen until the end of treatment (Figure 3.16
A). Also, viability of A. viteae was at control level after 14 days treatment with
500µM wALADin1 (Figure 3.15 C), but the same concentration strongly reduced
the motility of L. sigmodontis (Figure 3.15 C). Thus, wALADin1 seems to effectively
block heme biosynthesis in L. sigmodontis, but a different additional effect on filaria
can be observed. Lower concentrations of wALADin1 might still effectively block
heme biosynthesis without an additional side effect. Further experiments will also
elucidate whether wALADin1 has unspecific effects on mammalian cells.
ALAD inhibitors might have an additional anti-filarial effect by a different mecha-
nism: The substrate of ALAD is 5-aminolevulinic acid (5-ALA), which has structural
similarities to the neurotransmitters GABA and glutamic acid (Figure 4.3) and can
act as GABA agonist (Meyer et al., 1998).
Figure 4.3.: Structural similarity of 5-aminolevulinic acid (ALA) with the neurotrans-
mitters GABA and glutamic acid. Figure taken from Meyer et al. (1998).
Blocking the enzyme would lead to the accumulation of 5-ALA. GABA agonists
have been shown to reduce spontaneous contractions of A. viteae (Christ et al.,
1990). The same observations were made in our experiments when treating A.
viteae with the GABA agonist 5-ALA. Paralysis of worms occurs directly after
adding the substance to the medium, but worms quickly recover from the blockade
of contraction (Figure 3.16 B). These results suggest that 5-ALA can function as an
GABA agonist in filaria, leading to a blockade of spontaneous contractions of the
worms. The mode of action might resemble those of ivermectin. Ivermectin disrupts
neurotransmission processes by binding to glutamate-gated chloride channels, which
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also control the muscles responsible for the excretory-secretory apparatus (Moreno
et al., 2010).
Thus, the anti-filarial effect, exhibited by ALAD inhibitors in L. sigmodontis
can have two possible causes: 1) Inhibition of Wolbachia heme biosynthesis leads
to deficiency of essential heme enzymes, eventually leading to death of the worm.
2) Inhibition of ALAD leads to accumulation of 5-ALA, leading to disfunctions of
regulation of nerve system and paralysis of worms (Figure 4.4). Further experiments
by Christian Lentz are underway to titrate wALADin1 concentrations, testing the
efficiency of wALADin1 derivatives and evaluating the potential of the anti-filarial
effect in vivo using the L. sigmodontis BALB/c mouse model.
Figure 4.4.: Inhibition of Wolbachia heme biosynthesis using succinylacetone (SA) and
wALADin1. Inhibition of Wolbachia ALAD might lead to death of filarial worms by
preventing synthesis of heme, which would lead to deficiency of essential enzymes (green)
and also by accumulation of the GABA agonist 5-ALA, thereby leading to disfunctions of
neuromuscular regulation (red). Figure adapted from Wu et al. (2009).
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4.5. Conclusions
In summary, our microarray analysis of L. sigmodontis after Wolbachia depletion
has shown that:
1. the B. malayi microarray can be used to detect changes in gene expression
and provided more molecular information about the L. sigmodontis genes than
differential display,
2. although not a direct match to the results from the B. malayi microarray
hybridised with cDNA from B. malayi worms treated with tetracycline, dif-
ferential regulation of genes of interest such as cuticular collagens, juvenile
protein p120 and energy metabolism were in agreement,
3. processes of transcriptional regulation as well as mRNA processing were altered
and might indicate that Wolbachia can influence host gene expression,
4. expression of immunosuppressive proteins decreased, thus indicating a change
in the immunological environment of the worm,
5. mitochondria were sensitive to the loss of Wolbachia resulting in the up-
regulation of subunits of the respiratory chain complexes. The latter find-
ings support the hypothesis that filaria are dependent on heme provided by
Wolbachia,
6. Wolbachia heme biosynthesis inhibition experiments in L. sigmodontis con-
firmed the importance of heme provided by Wolbachia to filaria and supports
targeting heme biosynthesis as antifilarial therapy,
7. the second enzyme of the pathway, ALAD, may be a particularly good target
as accumulation of the substrate 5-ALA has an additional anti-filarial effect.
The ex vivo culture now allows one to look at the function of interesting genes
identified in this study, as successfully shown for ALAD. It also can be extended to
perform RNAi experiments (using established dsRNA methods (Pfarr et al., 2006)
or siRNA or shRNA) to answer open questions regarding the Wolbachia-filaria sym-
biosis, e.g. a knock-down of the L. sigmodontis ferrochochelatase in the presence of
the heme precursor protoporphyrin IX could clarify a possible involvement of this
filarial gene in heme metabolism. The results of this study can be used for further
discovery of drugs that will help to combat filariasis in humans.
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Filarial infections, caused by Brugia malayi, Wuchereria bancrofti and Onchocerca
volvulus are a worldwide health problem in developing countries, causing elephanti-
asis or dermatitis and blindness. 1.3 billion people live at risk of infection. Current
mass drug administration programmes with ivermectin, diethylcarbamazine and al-
bendazole prevented many cases of disease, nevertheless, as they are only microfila-
ricidal they have to be given over many years to stop transmission. Targeting the
essential Wolbachia endobacteria with doxycycline has been proven to be an effective
therapy, as worm development and survival of adult worms is greatly reduced with-
out the endosymbiont. However, doxycycline is contraindicated for a large portion
of the at risk population.
My work aimed to analyse the molecular interactions between filaria and their
endosymbiotic Wolbachia in order to promote target identification for new drugs
against filariasis. The B. malayi microarray was used in a cross-species hybridisa-
tion experiment to identify genes that are differentially expressed in Litomosoides
sigmodontis after depletion of Wolbachia and therefore might have a role in sym-
biosis. The microarray data were filtered for regulated genes with a false discovery
rate ≤ 5 % and a ≥ 2-fold change. Most of the genes were differentially expressed at
day 36 of tetracycline treatment, when 99.8 % of Wolbachia were depleted. Several
classes of genes were affected, including genes for general processes like translation,
transcription, post-transcriptional processing and folding/sorting of proteins and
also genes involved in motility, structure and signalling pathways. L. sigmodontis
specific quantitative PCR validated ∼ 60 % of the genes found to be regulated in the
microarray.
Interestingly, most of the mitochondrial encoded subunits of respiratory chain
complexes containing heme and riboflavin were up-regulated. No change in the
expression of these genes was seen in tetracycline treated Wolbachia-free Acan-
thocheilonema viteae. As Wolbachia synthesise heme and filaria do not, we hypoth-
esise that without the endosymbionts no functional heme-containing enzymes can
be formed, leading to loss of energy metabolism which then results in up-regulation
of the mitochondrial encoded subunits in an attempt to correct the deviation from
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homeostasis. A nuclear encoded heme-binding protein of the globin family was also
up-regulated, therefore the differential expression of heme proteins after Wolbachia
depletion was not limited to the mitochondria. Using a filarial ex vivo culture,
established as part of my thesis work, we confirmed that Wolbachia-containing
L. sigmodontis worms were sensitive to inhibition of the heme biosynthesis path-
way, whereas Wolbachia-less worms were not affected by the same treatment. The
results indicate that filarial nematodes are dependent on the heme provided by their
essential Wolbachia and support further targeting the Wolbachia heme synthesis
pathway for the discovery of new anti-filarial drugs.
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Die durch die Filarien Brugia malayi, Wuchereria bancrofti und Onchocerca volvulus
verursachte Onchozerkose und Lymphatische Filariose stellt ein weltweites Gesund-
heitsproblem in den Entwicklungsla¨ndern dar und kann zu Dermatitis, Erblindung
oder Elephantiasis fu¨hren. Weltweit sind 1.3 Milliarden Menschen dem Risiko einer
Infektion ausgesetzt. Derzeitige Massenbehandlungen mit Ivermectin, Diethylcar-
bamazin und Albendazol haben bereits viele Krankheitsfa¨lle verhindern ko¨nnen,
jedoch wirken sie nur auf die Mikrofilarien, so dass diese Medikamente u¨ber viele
Jahre verabreicht werden mu¨ssen, um eine Transmission zu stoppen. Eine neue Be-
handlungsstrategie mit Doxyzyklin hat sich als sehr effektiv erwiesen, da es das
endosymbiontische Bakterium Wolbachia angreift, welches fu¨r die Wurmentwick-
lung und das U¨berleben der adulten Filarien essenziell ist. Doxyzyklin ist jedoch fu¨r
einen großen Anteil der Bevo¨lkerung kontraindiziert.
Ziel der vorliegenden Arbeit war es, die molekularen Interaktionen zwischen Fila-
rien und ihrem Endosymbionten Wolbachia zu analysieren, um symbiotische Mecha-
nismen und damit Angriffspunkte fu¨r die Entwicklung von neuen Medikamenten
gegen Filariosen zu identifizieren. Der B. malayi Microarray wurde fu¨r die Detektion
von Genen genutzt, die in der nahe verwandten Nagetier-Filarie L. sigmodontis nach
Depletion der Wolbachien eine vera¨nderte Expression aufweisen. Diese Gene ko¨nnten
auf symbiotische Abha¨ngigkeiten zwischen Filarien und Wolbachia-Bakterien hin-
weisen. Die Microarray-Daten wurden nach Genen mit einem ≥ 2-fachen Unter-
schied in der Expression und einer falsch-positiven Rate von ≤ 5 % gefiltert. Nach 36
Tagen Tetrazyklinbehandlung, ein Zeitpunkt an dem die Wolbachien-Zahl zu u¨ber
99 % reduziert war, konnten die meisten regulierten Gene nachgewiesen werden.
Viele verschiedene Genklassen waren betroffen, unter anderem Gene fu¨r allgemeine
Prozesse wie Translation, Transkription, posttranskriptionale Prozessierung und Fal-
tung/Sortieren von Proteinen sowie Gene fu¨r Motilita¨t, Struktur und Signalwege.
L. sigmodontis spezifische quantitative PCR besta¨tigte ∼ 60 % der im Microarray
regulierten Gene.
Interessanterweise wiesen fast alle mitochondrial kodierten Untereinheiten der At-
mungskettenkomplexe, welche Ha¨m und Riboflavin enthalten, eine hochregulierte
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Genexpression auf. Bei der Wolbachia-freien Filarie Acanthocheilonema viteae konn-
te nach Tetrazyklinbehandlung keine Expressionsa¨nderung dieser Gene nachgewiesen
werden. Da Wolbachien im Gegensatz zu den Filarien Ha¨m synthetisieren ko¨nnen,
vermuten wir, dass ohne das Endobakterium keine funktionellen Komplexe fu¨r die
Atmungskette gebildet werden ko¨nnen. Dies wu¨rde zu einem Defekt im Energie-
metabolismus und dadurch zu einer Hochregulierung der Untereinheiten der At-
mungskette fu¨hren, um die Abweichung der Homeostase auszugleichen. Die Ex-
pressionsa¨nderung nach Depletion der Wolbachien beschra¨nkte sich nicht auf mi-
tochondrial kodierte Ha¨mproteine, da auch fu¨r ein nuklear kodiertes Ha¨mprotein
aus der Globin-Familie eine Hochregulierung des Transkripts nachgewiesen werden
konnte. Mittels einer ex vivo Filarienkultur, die im Rahmen dieser Arbeit etabliert
wurde, konnte besta¨tigt werden, dass Wolbachia-enthaltende Filarien sensitiv auf
eine Inhibition der Ha¨m-Synthese reagieren, wohingegen Wolbachia-freie Filarien
von der gleichen Behandlung nicht beeintra¨chtigt waren. Die Ergebnisse deuten da-
rauf hin, dass Filarien von dem von ihren essenziellen Wolbachien zur Verfu¨gung
gestelltem Ha¨m abha¨ngig sind und unterstreichen die Bedeutung des Wolbachia
Ha¨m-Synthesewegs als effektiven Angriffspunkt fu¨r die Entwicklung neuer Medika-
mente gegen Filariosen.
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A. Appendix
Table A.1.: List of videos of L. sigmodontis and A. viteae ex vivo culture experiments.
Videos are available on enclosed DVD.
Video
No.
Description of contents
Motility scoring
1 Examples of L. sigmodontis motility scoring 0 - 5
2 Examples of A. viteae motility scoring 0 - 5
L. sigmodontis ex vivo culture: control, 500µM/1 mM wALADin1, 3 mM SA
3 Day 0
4 Day 3
5 Day 9
6 Day 14
A. viteae ex vivo culture: control, 500µM/1 mM wALADin1, 3 mM SA
7 Day 0, before treatment
8 Day 0, 1.5 h after addition of drug
9 Day 3
10 Day 9
11 Day 14
A. viteae ex vivo culture: control and 5 mM 5-ALA
12 Day 0 (before treatment and 1.5 h after addition of drug), day 3 and 14
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B. Appendix
Table B.1.: Up- and down-regulated filarial genes at day 6 of tetracycline treatment
Oligo ID FDR
%
Fold
change
Model Name
or EST
B. malayi
locus
Annotation or blast match
Up-regulated genes
bm.00032 2,79 2,38 BMC00075 Bm1 55000 troponin-T
Down-regulated genes
bm.01065 2,79 0,49 BMC04361 Bm1 46680 26S proteasome subunit P45 family protein
BMX577 1,76 0,44 12902.m00230 Bm1 03910 40S ribosomal protein S27, putative
BMX3571 4,15 0,47 14652.m00402 Bm1 22990 actin-depolymerizing factor 1, putative
BMX9144 1,76 0,37 15470.m00007 Bm1 57025 ADP-ribosylation factor 1, putative
BMX3068 3,35 0,48 14469.m00103 Bm1 19880 Autoantigen NGP-1, putative
BMX6459 4,94 0,39 14972.m07843 Bm1 40640 conserved hypothetical protein
BMX4090 1,76 0,44 14782.m00009 Bm1 19520 conserved hypothetical protein
BMX10446 3,35 0,40 AW191516 Bm1 13830 eukaryotic initiation factor 4A
BMX6796 4,15 0,39 14975.m04474 Bm1 42660 fizzy-related protein, putative
BMX7493 1,76 0,49 14981.m02382 Bm1 46715 Gaba, putative
bm.02929 2,79 0,32 BMC07434 Bm1 24940 galectin, putative
BMX4949 4,61 0,45 14954.m01743 Bm1 31380 glycogen synthase kinase 3 alpha, putative
BMX6316 4,15 0,49 14972.m07666 Bm1 39805 GMC oxidoreductase family protein
BMX2838 0,00 0,23 14361.m00189 Bm1 18395 Hepatic leukemia factor, putative
BMX7231 4,61 0,49 14979.m04549 Bm1 45200 High mobility group protein 1.2, putative
bm.00432 1,76 0,50 BMC01644 Bm1 25620 high mobility group protein, putative
bm.01720 1,76 0,33 BMC11925 Bm1 45075 HMG box family protein
BMX5096 4,61 0,47 14961.m04954 Bm1 32310 Innexin family protein
BMX5537 4,15 0,44 14967.m01540 Bm1 35075 Innexin inx-3, putative
BMX5161 2,53 0,46 14961.m05031 Bm1 32700 Leucine carboxyl methyltransferase family protein
BMX3761 4,15 0,36 14704.m00452 Bm1 24150 mbt repeat family protein
BMX2325 4,15 0,45 14157.m00017 Bm1 03265 N-terminal acetyltransferase complex ARD1 sub-
unit homolog, putative
BMX8645 3,35 0,48 15081.m00161 Bm1 53755 NADH-ubiquinone oxidoreductase subunit
B14.5b, putative
BMX5408 0,00 0,30 14961.m05354 Bm1 34295 Neurotransmitter-gated ion-channel ligand bind-
ing domain containing protein
BMX8754 4,15 0,45 15161.m00148 Bm1 54505 oxidoreductase, zinc-binding dehydrogenase fam-
ily protein
BMX9886 4,15 0,44 AA841464 Bm1 14590 Probable U6 snRNA-associated Sm-like protein
LSm4, putative
BMX3351 3,35 0,49 14590.m00346 Bm1 21620 Profilin family protein
BMX2627 4,15 0,50 14276.m00250 Bm1 17085 proteasome subunit alpha type 4, putative
BMX136 1,76 0,50 12512.m00025 Bm1 00955 Protein kinase domain containing protein
BMX16 2,79 0,47 12417.m00015 Bm1 00130 Protein kinase domain containing protein
BMX7409 4,94 0,37 14980.m02764 Bm1 46210 Protein kinase domain containing protein
bm.02416 2,79 0,40 BMC11777 Bm1 14145 protein phosphatase PP2A regulatory subunit, pu-
tative
BMX6123 1,76 0,47 14972.m07434 Bm1 38675 PurA ssDNA and RNA-binding protein
bm.01810 1,76 0,38 BMC03608 Bm1 32095 Ras-related protein Rab-6B, putative
BMX9089 2,79 0,35 15424.m00007 Bm1 56635 RE63138p, putative
bm.02415 1,76 0,31 BMC08875 Bm1 15930 retinoblastoma-binding protein, putative
BMX2440 1,76 0,32 14224.m00309 Bm1 15930 retinoblastoma-binding protein, putative
bm.02856 1,76 0,45 BMC11307 Bm1 57630 retinoblastoma-binding protein., putative
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BMX2977 3,35 0,38 14412.m00158 Bm1 19325 RNA and export factor binding protein 2, putative
bm.00326 2,53 0,46 BMC01082 Bm1 24070 RNA recognition motif domain containing protein
bm.01654 1,76 0,28 BMC11108 Bm1 46695 RNA recognition motif.
bm.02941 2,53 0,44 BMC00658 Bm1 17780 signal recognition particle 54 kDa protein
(SRP54), putative
BMX3352 2,01 0,43 14590.m00348 Bm1 21630 transcription elongation factor B polypeptide 1,
putative
BMX4463 4,15 0,44 14930.m00346 Bm1 28480 translation elongation factor aEF-2, putative
BMX1320 4,94 0,44 13409.m00048 Bm1 08695 trehalose-6-phosphate synthase, putative
BMX7233 2,79 0,50 14979.m04551 Bm1 45210 Ubiquitin-like protein SMT3, putative
BMX6196 4,15 0,35 14972.m07521 Bm1 39100 V-ATPase subunit C family protein
bm.02489 2,79 0,48 BMC06799 Bm1 39100 V-ATPase subunit C family protein
BMX8923 2,53 0,48 15268.m00008 Bm1 55505 hypothetical protein
BMX2358 3,35 0,39 14181.m00071 Bm1 15420 hypothetical protein
BMX6102 4,94 0,37 14972.m07406 Bm1 38535 hypothetical protein
BMX3239 4,15 0,45 14542.m00051 Bm1 20915 hypothetical protein
BMX3136 1,76 0,47 14500.m00155 Bm1 20270 hypothetical protein
BMX3270 1,76 0,38 14559.m00034 Bm1 21110 hypothetical protein
BMX2107 4,15 0,41 14038.m00030 Bm1 13865 hypothetical protein
BMX9338 4,15 0,28 AA110565 hypothetical protein W02A2.9
BMX7420 3,35 0,36 14980.m02778 Bm1 46275 Hypothetical UPF0185 protein ZK652.3 in chro-
mosome III, putative
Table B.2.: Up- and down-regulated filarial genes at day 15 of tetracycline treatment
Oligo ID FDR
%
Fold
change
Model Name
or EST
B. malayi
locus
Annotation or blast match
Up-regulated genes
BMX208 4,95 2,00 12577.m00007 Bm1 01465 cuticular collagen Bmcol-2
BMX12229 4,36 2,73 BMC00075 Bm1 30045 hypothetical protein
bm.01661 4,36 2,91 BMC11473 no match
Down-regulated genes
BMX6517 0,00 0,15 14973.m02591 Bm1 40960 Chymotrypsin/elastase isoinhibitors 2 to 5, puta-
tive
BMX13295 0,00 0,47 TC3302 Bm1 17480 cuticle collagen
BMX2838 0,00 0,47 14361.m00189 Bm1 18395 Hepatic leukemia factor, putative
BMX1993 0,00 0,06 13945.m00125 Bm1 13070 conserved hypothetical protein
BMX12963 0,00 0,20 TC2959 no match
Table B.3.: Up- and down-regulated filarial genes at day 36 of tetracycline treatment
Oligo ID FDR
%
Fold
change
Model Name
or EST
B. malayi
locus
Annotation or blast match
Up-regulated genes
bm.00007 0,84 2,30 BMC00011 40S ribosomal protein S6
bm.00532 0,00 5,96 BMC02077 5S ribosomal RNA gene
BMX4795 2,48 2,02 14952.m01388 Bm1 30435 ABC transporter, putative
BMX6847 4,28 2,12 14975.m04536 Bm1 42975 Acetyl-CoA hydrolase/transferase family protein
bm.02799 2,79 2,05 BMC09181 Bm1 28250 amidase, putative
BMX12198 1,84 6,15 WB-
contig 1369
Ascaris lumbricoides small nuclear RNA (snRNA)
U1-1, U1-2, U1-3, U1-4 genes
BMX12816 1,84 2,51 TC2809 AF538716 ATP synthase F0 subunit 6
BMX11446 2,48 2,21 BMW00445.38 Bm1 52675 ATP-dependent RNA helicase DDX5/DBP2
bm.00104 1,34 2,31 BMC00238 Bm1 28435 Bm-Mif-1, identical
BMX7866 3,13 2,49 14990.m07940 Bm1 49080 Calponin homolog OV9M., putative
bm.03088 1,34 2,22 BMC06828 Bm1 36555 collagen col-34, putative
bm.03416 4,28 2,18 BMC11971 Bm1 13245 Cuticle collagen C09G5.5, putative
bm.03300 2,48 2,03 BMC04762 Bm1 13245 Cuticle collagen C09G5.5, putative
BMX12481 0,00 2,93 WB-contig 187 AF538716 cytochrome b
BMX12492 3,59 2,00 WB-contig 207 AF538716 cytochrome b
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bm.03368 2,48 2,22 BMC11632 AF538716 cytochrome b
BMX12792 2,79 3,50 TC2778 AF538716 cytochrome c oxidase subunit I
BMX10990 0,84 2,89 TC7739 AF538716 cytochrome c oxidase subunit I
BMX12477 0,84 2,72 WB-contig 182 AF538716 cytochrome c oxidase subunit I
bm.03325 1,34 2,47 BMC06165 AF538716 cytochrome c oxidase subunit I
BMX12794 3,13 2,32 TC2780 AF538716 cytochrome c oxidase subunit I
BMX11370 0,84 2,70 BMW00283.860 AF538716 cytochrome c oxidase subunit I
bm.03436 2,48 2,22 BMC12111 AF538716 cytochrome c oxidase subunit I
bm.01757 0,84 2,70 BMC12170 AF538716 cytochrome c oxidase subunit I
bm.03171 1,34 2,81 BMC00030 AF538716 cytochrome c oxidase subunit II
bm.03082 2,79 2,31 BMC06256 AF538716 cytochrome c oxidase subunit II
bm.03174 1,34 2,40 BMC00071 AF538716 cytochrome c oxidase subunit II
bm.03438 0,00 2,82 BMC12116 AF538716 cytochrome c oxidase subunit II
bm.03045 0,00 3,05 BMC00359 AF538716 cytochrome c oxidase subunit III
bm.00380 0,00 27,36 BMC01393 AF538716 cytochrome c oxidase subunit III
BMX12806 0,84 2,48 TC2796 Bm1 48810 EF hand family protein, Troponin C (tnc-1)
BMX11372 0,52 2,60 BMW00285.523 Bm1 48810 EF hand family protein, Troponin C (tnc-1)
bm.03443 1,34 2,26 BMC12124 Bm1 48810 EF hand family protein, Troponin C (tnc-1)
BMX11740 1,24 2,25 BMW01217.101 Bm1 48810 EF hand family protein, Troponin C (tnc-1)
BMX5583 2,79 2,86 14968.m01464 Bm1 35360 EGF-like domain containing protein
BMX12421 1,34 2,10 WB-
contig 1637
Bm1 33155 gelsolin, putative
BMX8086 0,00 4,78 14992.m10859 Bm1 50430 Globin family protein
bm.01805 2,48 2,03 BMC02156 Bm1 26160 Ground-like domain containing protein
bm.00432 1,34 2,26 BMC01644 Bm1 25620 high mobility group protein, putative
bm.01434 3,13 2,08 BMC06812 Bm1 32130 Hsp20/alpha crystallin family protein
bm.03350 3,59 2,01 BMC09956 Bm1 15210 conserved hypothetical protein
bm.03546 0,00 2,99 BMC00600 AF538716 large subunit ribosomal RNA, mitochondrial
BMX12812 1,34 2,36 TC2803 AF538716 NADH dehydrogenase subunit 1
bm.03545 1,84 2,54 BMC00485 AF538716 NADH dehydrogenase subunit 1
BMX11795 3,59 2,20 BMW01358.408 AF538716 NADH dehydrogenase subunit 2
BMX12282 1,34 2,43 WB-
contig 1474
AF538716 NADH dehydrogenase subunit 2
BMX13241 2,48 2,64 TC3244 AF538716 NADH dehydrogenase subunit 3
BMX13096 3,13 2,15 TC3096 AF538716 NADH dehydrogenase subunit 5
BMX11838 1,34 2,28 BMW01496.504 Bm1 17485 Nematode cuticle collagen N-terminal domain con-
taining protein
BMX11969 2,79 2,00 WB-
contig 1102
Bm1 27595 nematode cuticle collagen, N-terminal domain
bm.03038 2,48 2,33 gi|443682|gb|L27686.1|
ONGIGGORF
Onchocerca volvulus retinoid binding protein pre-
cursor, mRNA
BMX12596 3,59 2,14 WB-contig 369 Bm1 41305 phosphatidylserine decarboxylase proenzyme, pu-
tative
BMX9936 3,13 2,07 AA841929 Bm1 18520 Protein kinase domain containing protein, CDK
family
bm.02455 1,84 2,09 BMC00090 Bm1 37575 Protein kinase domain containing protein, similar
to c-met
BMX10922 3,59 2,28 N89547 putative RNA binding protein (bm-rbp-1)
bm.03194 0,84 3,63 BMC00185 Bm1 37780 RNA binding protein
BMX5979 3,59 2,41 14972.m07250 Bm1 37780 RNA binding protein, identical
bm.00761 1,84 2,32 BMC03055 Bm1 37185 Saposin-like type B, region 1 family protein
BMX8848 3,13 2,30 15217.m00022 Bm1 55060 SET domain containing protein
bm.02729 3,59 2,08 BMC06625 similar to RNA helicase p68 (DDX5)
BMX11224 1,34 2,79 BMW00034.265 AF538716 small subunit ribosomal RNA, mitochondrial
BMX634 0,00 7,02 12962.m00049 Bm1 04280 snRNA U2-1 gene, snRNA U2-2 pseudogenes, and
snRNA U2-1
BMX13116 0,00 7,32 TC3117 Bm1 04280 snRNA U2-1 gene, snRNA U2-2 pseudogenes, and
snRNA U2-1
BMX12521 0,00 6,22 WB-contig 256 Bm1 04280 snRNA U2-1 gene, snRNA U2-2 pseudogenes, and
snRNA U2-1
BMX120 1,84 4,64 12498.m00044 Bm1 00840 succinyl-CoA ligase [ADP-forming] beta-chain,
mitochondrial, putative
BMX5661 3,13 2,12 14971.m02813 Bm1 35865 TGF-beta induced apoptosis protein 2, putative
BMX11378 1,34 2,85 BMW00296.538 Bm1 09630 Transcription factor
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BMX13174 1,84 2,27 TC3177 Bm1 06445 Transthyretin-like family protein
BMX12574 2,79 2,01 WB-contig 339 Bm1 01235 Tropomyosin, putative
bm.00032 0,84 2,78 BMC00075 Bm1 55000 Troponin T
BMX12801 1,84 2,07 TC2790 Bm1 55000 Troponin T
bm.00553 0,00 6,16 BMC02185 no match
BMX4544 2,48 3,43 14938.m00329 Bm1 13985 Zinc finger, C2H2 type family protein
bm.03154 1,34 2,06 BMC12254 no match
BMX5835 1,84 2,11 14972.m07082 Bm1 36960 conserved hypothetical protein
BMX1246 3,13 2,04 13367.m00045 Bm1 08200 conserved hypothetical protein
BMX5031 2,48 2,28 14958.m00358 Bm1 31905 Conserved hypothetical protein, putative
bm.00738 0,00 9,52 BMC02980 Bm1 30045 hypothetical protein
BMX4726 0,00 7,56 14950.m01825 Bm1 30045 hypothetical protein
BMX6509 2,48 2,15 14973.m02582 Bm1 40920 hypothetical protein
BMX977 1,84 2,07 13253.m00068 Bm1 06495 hypothetical protein
BMX12074 3,13 2,01 WB-
contig 1229
hypothetical protein
bm.03139 1,34 2,39 BMC00307 hypothetical protein
BMX12229 0,00 7,19 WB-
contig 1411
Bm1 30045 hypothetical protein
BMX663 3,59 2,23 13016.m00022 Bm1 04515 hypothetical protein
BMX176 1,34 2,95 12548.m00028 Bm1 01160 hypothetical protein
BMX6250 4,28 3,12 14972.m07589 Bm1 39435 hypothetical protein
BMX11863 3,13 3,21 BMW01588.491 hypothetical protein
BMX2148 2,48 2,46 14052.m00190 Bm1 14110 hypothetical protein
BMX11622 0,00 2,54 BMW00915.413 hypothetical protein
BMX13363 0,52 2,61 TC3370 hypothetical protein
bm.01661 0,00 3,50 BMC11473 hypothetical protein
bm.03409 3,59 4,82 BMC11908 Bm1 15895 hypothetical protein
BMX12514 0,00 5,47 WB-contig 247 Bm1 03790 hypothetical protein
BMX860 1,34 2,22 13186.m00013 Bm1 05750 hypothetical protein
BMX664 4,28 3,64 13022.m00018 Bm1 04540 hypothetical protein
BMX5153 2,48 3,83 14961.m05023 Bm1 32660 hypothetical protein
BMX1916 0,00 4,77 13891.m00014 Bm1 12555 hypothetical protein
BMX7604 1,84 2,31 14982.m02250 Bm1 47370 hypothetical protein
BMX12188 1,84 2,59 WB-contig 136 Bm1 11040 hypothetical protein
bm.00050 1,34 2,07 BMC00114 Bm1 47225 hypothetical protein, putative
bm.02312 1,34 2,40 BMC07204 Bm1 04980 Hypothetical RING finger protein F54G8.4 in
chromosome III, putative
BMX730 1,84 2,27 13081.m00126 Bm1 04980 Hypothetical RING finger protein F54G8.4 in
chromosome III, putative
BMX4160 3,13 2,01 14830.m00076 Bm1 26585 Hypothetical UPF0205 protein C40H1.5 in chro-
mosome III precursor, putative
bm.01554 2,48 2,45 BMC07907 no match
BMX11823 2,48 2,79 BMW01444.86 no match
bm.03330 1,34 2,92 BMC06439 no match
bm.03432 0,84 2,83 BMC12091 no match
bm.03316 0,00 2,83 BMC05768 no match
bm.03233 0,84 2,53 BMC01489 no match
bm.01474 2,48 2,59 BMC07089 no match
bm.00248 2,79 2,57 BMC00802 no match
BMX10049 1,34 2,76 AI043369 no match
BMX11412 0,52 2,74 BMW00374.174 no match
BMX11927 2,79 2,12 WB-
contig 1051
no match
bm.03269 2,48 2,30 BMC02796 no match
BMX12848 1,34 2,30 TC2843 no match
BMX10707 3,59 2,01 CD570734 no match
BMX11787 1,34 2,02 BMW01339.1 no match
BMX11857 2,48 2,05 BMW01563.274 no match
BMX11405 2,79 2,06 BMW00355.11 no match
BMX11194 3,59 2,06 BMBC gene 64.1319 no match
bm.03424 1,34 2,58 BMC12074 no match
BMX11862 2,48 2,38 BMW01584.43 no match
BMX11569 3,59 2,23 BMW00757.255 no match
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bm.00760 1,34 2,09 BMC03051 no match
BMX11687 1,84 2,10 BMW01104.236 no match
bm.03147 1,34 2,11 BMC07069 no match
bm.01018 0,00 9,57 BMC04151 no match
BMX11926 0,00 7,65 WB-
contig 1050
no match
BMX11761 1,34 2,24 BMW01276.443 no match
BMX12927 0,00 4,12 TC2922 no match
BMX11067 4,28 2,12 W00314 no match
BMX12251 1,34 2,31 WB-
contig 1438
no match
BMX12274 1,34 3,35 WB-
contig 1466
no match
BMX10628 2,48 2,08 CB328940 no match
bm.00033 0,00 3,60 BMC00077 no match
bm.01634 0,00 3,42 BMC10048 no match
BMX10005 0,00 2,93 AA842849 no match
BMX11510 2,48 2,16 BMW00613.288 no match
BMX11537 1,34 2,04 BMW00684.508 no match
bm.03351 0,00 3,22 BMC09976 no match
Down-regulated genes
BMX9813 1,52 0,18 AA840846 16S rRNA gene, bacterial
bm.03452 2,48 0,47 BMC12165 Bm1 09900 40S ribosomal protein S7, putative
BMX13179 1,52 0,31 TC3182 Bm1 46405 50S ribosomal protein L21, mitochondrial precur-
sor
bm.03243 4,28 0,36 BMC01716 Bm1 07030 60S ribosomal protein L12
bm.00263 2,48 0,43 BMC00864 Bm1 23030 60S ribosomal protein L18a
bm.00397 1,52 0,34 BMC01506 Bm1 47445 60S ribosomal protein L21, putative
BMX4542 2,79 0,45 14937.m00494 Bm1 28975 60S ribosomal protein L27, putative
BMX2112 1,52 0,37 14039.m00115 Bm1 13895 60S ribosomal protein L3, putative
BMX12710 2,79 0,39 WB-contig 530 Bm1 13895 60S ribosomal protein L3, putative
BMX12573 3,13 0,50 WB-contig 338 Bm1 24260 6330505F04Rik protein, putative
BMX1007 2,79 0,48 13261.m00257 Bm1 06670 Acid phosphatase F26C11.1, putative
BMX3428 1,52 0,43 14610.m00102 Bm1 22105 acyl-CoA desaturase, putative
BMX856 2,79 0,33 13183.m00075 Bm1 05725 Acyltransferase family protein
bm.00853 3,59 0,48 BMC03403 Bm1 19050 ADIPOR-like receptor C43G2.1, putative
BMX2534 1,52 0,42 14246.m00079 Bm1 16495 ADP-sugar pyrophosphatase , putative
BMX8610 2,48 0,37 15062.m00043 Bm1 53535 alanyl-tRNA synthetase family protein
BMX196 4,28 0,48 12568.m00015 Bm1 01370 alpha-1,3-mannosyltransferase, putative
BMX3477 2,48 0,46 14623.m00077 Bm1 22410 ATP-dependent RNA helicase DDX18
bm.02069 3,59 0,50 BMC05925 Bm1 46895 Autophagocytosis associated protein, C-terminal
domain containing protein
bm.02386 0,00 0,23 BMC10217 bacterial adhesin
BMX4479 1,52 0,41 14931.m00329 Bm1 28580 bifunctional aminoacyl-tRNA synthetase, putative
BMX7517 0,00 0,13 14981.m02410 Bm1 46865 Biopterin-dependent aromatic amino acid hydrox-
ylase family protein
bm.01896 1,52 0,10 BMC09332 Bm1 51990 BRM protein, putative
BMX3794 3,59 0,49 14710.m00262 Bm1 24355 calcium ATPase, putative
BMX7234 4,28 0,46 14979.m04553 Bm1 45220 CG7038-PA, putative
BMX2989 4,28 0,38 14417.m00066 Bm1 19385 CG7192-PB, ESCRT-I complex subunit MVB12
BMX13366 1,52 0,44 TC3373 Bm1 52920 Chain B, Crystal Structure Of The D1d2 Sub-
Complex From The Human Snrnp Core Domain
BMX8276 3,13 0,48 14992.m11086 Bm1 51525 chromosome 14 open reading frame 153, putative
BMX3771 2,48 0,39 14705.m00192 Bm1 24215 CHY zinc finger family protein
BMX723 3,13 0,31 13074.m00011 Bm1 03260 coronin 2A, putative
BMX5114 2,48 0,49 14961.m04976 Bm1 32425 CRAL/TRIO domain containing protein
bm.01302 2,79 0,49 BMC06039 Bm1 13860 Cyclin, N-terminal domain containing protein
BMX13369 1,84 0,50 TC3376 Bm1 52100 cyclophilin-type peptidyl-prolyl cis-trans
isomerase-13, Bmcyp-13
BMX11137 3,59 0,47 BMB gene 13.435 Bm1 21700 cyclophilin-type peptidyl-prolyl cis-trans
isomerase-4, Bmcyp-4
BMX13028 1,84 0,37 TC3026 Bm1 02045 cysteine-rich protein 1, putative
BMX301 0,84 0,35 12628.m00036 Bm1 02045 cysteine-rich protein 1, putative
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BMX7969 4,28 0,50 14990.m08067 Cytochrome c oxidase assembly protein CtaG /
Cox11 containing protein
BMX12230 1,52 0,29 WB-
contig 1412
Bm1 31675 Death domain containing protein
BMX6842 2,48 0,28 14975.m04530 Bm1 42945 diphosphomevalonate decarboxylase family pro-
tein
BMX7438 1,52 0,46 14980.m02798 Bm1 46365 DIRP family protein
bm.02690 2,48 0,48 BMC03590 Bm1 45070 DNA / pantothenate metabolism flavoprotein
bm.02962 2,79 0,43 BMC07387 Bm1 27955 EF-1 guanine nucleotide exchange domain con-
taining protein
BMX8031 4,28 0,45 14990.m08149 Bm1 50100 EST embl—AI107989—AI107989 comes from the
3’ UTR, putative
BMX13481 2,48 0,47 TC3493 Bm1 32915 Eukaryotic translation initiation factor 4E type 3,
putative
BMX3080 1,52 0,42 14478.m00108 Bm1 19955 excretory/secretory protein Juv-p120 precursor,
putative
BMX3081 3,59 0,44 14478.m00109 Bm1 00865 excretory/secretory protein Juv-p120 precursor,
putative
BMX3809 2,79 0,36 14712.m00229 Bm1 24435 exodeoxyribonuclease III family protein
bm.01844 2,79 0,49 BMC02897 Bm1 38160 Fatty acid desaturase family protein
BMX7078 0,84 0,27 14977.m05104 Bm1 44270 GATA zinc finger family protein
bm.01994 1,84 0,43 BMC11004 Bm1 39355 GDP-fucose protein O-fucosyltransferase 2 precur-
sor, putative
BMX11652 2,79 0,48 BMW01009.534 Bm1 31280 Gex interacting protein protein 10, isoform a, pu-
tative
BMX6596 1,52 0,34 14973.m02692 Bm1 41495 Gex interacting protein protein 4, isoform c, puta-
tive
BMX7403 1,52 0,35 14980.m02757 Bm1 46175 Glutamate receptor 2 precursor.-related
bm.02518 3,13 0,45 BMC04064 Bm1 25005 Glutamate-rich WD-repeat protein 1, putative
BMX7383 1,52 0,40 14980.m02727 Bm1 46035 Gro-1 operon protein 2, putative
BMX2449 3,59 0,30 14227.m00028 Bm1 15980 guanine nucleotide-binding protein G(o), alpha
subunit, putative
BMX6627 4,28 0,19 14974.m00799 Bm1 41670 Haemolysin-III related family protein
bm.02396 1,84 0,50 BMC07369 Bm1 10400 haloacid dehalogenase-like hydrolase domain con-
taining 2, putative
bm.00164 3,13 0,48 BMC00470 Bm1 43675 heat shock 70 kDa protein, putative
BMX12036 0,52 0,31 WB-
contig 1184
Bm1 43675 heat shock 70 kDa protein, putative
BMX671 1,52 0,43 13032.m00029 Bm1 04585 Hepatocellular carcinoma-associated antigen 59
family protein
bm.01606 1,52 0,37 BMC08827 Bm1 20285 histone H2A
BMX4000 3,13 0,47 14768.m00181 Bm1 25575 hrp36.1, putative
BMX6519 2,48 0,39 14973.m02593 Bm1 40970 Hsp20/alpha crystallin family protein
BMX5997 4,28 0,49 14972.m07280 Bm1 37925 initiation factor 2-associated protein., putative
BMX11365 3,13 0,50 BMW00275.499 Bm1 38165 Lanthionine synthetase C-like protein
bm.03203 3,59 0,35 BMC00271 AAN62757.1 larval allergen
BMX6540 1,84 0,38 14973.m02621 Bm1 41125 LBP / BPI / CETP family, N-terminal domain
containing protein
BMX3718 2,79 0,44 14696.m00211 Bm1 23910 lipoic acid synthetase, mitochondrial precursor,
putative
BMX13070 1,52 0,47 TC3070 Bm1 17915 Mak16 protein
BMX13288 0,84 0,23 TC3295 Bm1 23975 MED7 protein
BMX13319 3,13 0,50 TC3326 Bm1 23975 MED7 protein
bm.00413 3,13 0,50 BMC01584 Bm1 54980 Mediator protein 18, putative
BMX5430 1,52 0,41 14962.m00668 Bm1 34420 MGC52693 protein, putative
BMX7873 1,84 0,45 14990.m07948 Bm1 49110 MGC86306 protein
bm.01727 4,28 0,44 BMC11946 Bm1 41590 Mitochondrial import inner membrane translocase
subunit Tim17 family protein
BMX12258 1,52 0,23 WB-
contig 1447
NADH:ubiquinone dehydrogenase, putative
BMX334 3,59 0,23 12665.m00135 Bm1 02270 OTU-like cysteine protease family protein
BMX1400 3,59 0,31 13458.m00087 Bm1 09210 Partner of SLD five, PSF1 family protein
BMX1224 3,13 0,41 13358.m00040 Bm1 08075 Paxneb protein, putative
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bm.01734 3,59 0,45 BMC11983 Bm1 54480 Peptidyl-tRNA hydrolase domain containing pro-
tein
BMX7134 1,84 0,50 14979.m04429 Bm1 44615 Phosphatidylcholine:ceramide cholinephospho-
transferase 3, putative
BMX13266 3,13 0,49 TC3271 Bm1 22915 Phospholipase/Carboxylesterase family protein
BMX4461 2,79 0,45 14930.m00344 Bm1 28470 Probable DNA replication complex GINS protein
PSF2, putative
bm.02654 2,48 0,32 BMC07408 Bm1 40665 probable homocysteine S-methyltransferase, puta-
tive
BMX6492 2,79 0,40 14972.m07881 Bm1 40820 Probable inner membrane protein OXA1L2, puta-
tive
bm.03394 2,79 0,33 BMC11783 Bm1 38970 Probable nucleolar GTP-binding protein 1
bm.02841 1,84 0,43 BMC09283 Bm1 30555 Proteasome A-type and B-type family protein
BMX8873 2,79 0,44 15233.m00030 Bm1 55200 Proteasome A-type and B-type family protein
BMX12704 1,84 0,38 WB-contig 523 Bm1 50865 Protein KIAA0174, putative
BMX6027 3,13 0,41 14972.m07316 Bm1 38095 Protein kinase domain containing protein
BMX11817 3,59 0,36 BMW01427.519 Bm1 51830 Protein kinase domain containing protein
BMX13426 3,59 0,50 TC3435 Bm1 56705 protein x 0004, putative
BMX5139 3,59 0,48 14961.m05007 Bm1 32580 Protein-tyrosine phosphatase containing protein
BMX7218 3,13 0,50 14979.m04531 Bm1 45110 PX domain containing protein
BMX4706 0,00 0,31 14950.m01801 Bm1 29925 Rab5 GDP/GTP exchange factor, putative
bm.03070 3,13 0,41 BMC04800 radical SAM domain protein
BMX6503 2,48 0,47 14972.m07894 Bm1 40885 Ras family protein
BMX3765 1,84 0,33 14704.m00458 Bm1 24180 Ras-related protein Rap-2c, putative
bm.00500 2,79 0,46 BMC01914 Bm1 38100 Rhodanese-like domain containing protein
BMX9069 3,13 0,41 15398.m00011 Bm1 56480 RhoGAP domain containing protein
bm.01962 1,52 0,29 BMC11877 Bm1 52810 Ribosome biogenesis protein BMS1 homolog, pu-
tative
bm.00181 3,59 0,47 BMC00539 Bm1 47790 RNA polymerase Rpc34 subunit family protein
bm.02854 3,13 0,50 BMC06741 Bm1 56655 RNA-binding protein., putative
BMX95 1,52 0,36 12481.m00076 Bm1 00700 RNA, U transporter 1, putative
BMX2219 4,28 0,46 14089.m00011 Bm1 14575 Salivary glue protein Sgs-4 precursor, putative
bm.03019 2,48 0,47 BMC03755 Bm1 49815 SCAMP family protein
BMX9465 1,84 0,36 AA241571 Bm1 23870 SEC14-like protein 4
bm.02497 2,48 0,39 BMC04147 Bm1 32220 Serine/threonine protein phosphatase PP1-alpha
catalytic subunit, putative
BMX1673 1,52 0,44 13663.m00019 Bm1 11010 Serologically defined colon cancer antigen 1, puta-
tive
BMX7340 3,59 0,41 14980.m02677 Bm1 45785 SF2, putative, splicing factor
BMX7372 3,59 0,39 14980.m02713 Bm1 45965 Skb1 methyltransferase family protein
bm.02997 3,13 0,50 BMC02742 Bm1 12960 SMC family, C-terminal domain containing pro-
tein
BMX13360 3,13 0,40 TC3367 Bm1 47485 T-complex protein 1, epsilon subunit, putative
BMX6820 2,48 0,42 14975.m04505 Bm1 42820 TAR-binding protein, putative
BMX8733 2,79 0,49 15150.m00062 Bm1 54355 TPR Domain containing protein
bm.02843 3,59 0,49 BMC06557 Bm1 44395 translation elongation factor eEF-2 homolog eft-1,
putative
BMX6995 3,59 0,48 14977.m05008 Bm1 43805 Trehalase family protein
BMX4707 1,84 0,24 14950.m01802 Bm1 29930 tRNA-specific adenosine deaminase 2, putative
BMX12651 3,13 0,38 WB-contig 445 Bm1 02060 Tropomyosin family protein (tmy-1)
BMX6907 2,48 0,34 14977.m04907 Bm1 43315 Troponin C, isoform 2, putative
BMX12520 2,48 0,47 WB-contig 255 Bm1 43315 Troponin C, isoform 2, putative
BMX9052 2,79 0,47 15378.m00019 Bm1 56355 Tubulin-tyrosine ligase family protein
BMX13242 2,79 0,42 TC3245 Bm1 15860 U2 small nuclear ribonucleoprotein A
BMX1337 1,52 0,43 13415.m00440 Bm1 08805 ubiquinone biosynthesis O-methyltransferase fam-
ily protein
bm.02261 3,59 0,48 BMC09009 Bm1 56725 Ubiquitin carboxyl-terminal hydrolase family pro-
tein
BMX4535 3,13 0,49 14937.m00485 Bm1 28920 Ubqln2 (Ubiquilin-2) protein, putative
BMX5760 3,13 0,29 14972.m06992 Bm1 36515 UBX domain containing protein
BMX7735 2,79 0,44 14990.m07764 Bm1 48215 Vacuolar h atpase protein 16, putative
BMX12381 3,59 0,49 WB-
contig 1591
Bm1 32805 Vacuolar protein sorting-associated protein 45, pu-
tative
bm.03336 1,52 0,43 BMC06819 Bm1 14040 venom allergen antigen-like protein 1, putative
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bm.02180 2,79 0,44 BMC00560 Bm1 45520 Vps53-like, N-terminal family protein
BMX3281 4,28 0,49 14563.m00109 Bm1 21170 WD domain containing protein
BMX7654 2,79 0,49 14990.m07660 Bm1 47705 WD40 associated region in TFIID subunit family
protein
bm.02264 2,48 0,42 BMC00091 Bm1 55855 Zinc finger, C2H2 type family protein
BMX6570 0,00 0,25 14973.m02657 Bm1 41325 Zinc finger, C2H2 type family protein
BMX6860 4,28 0,44 14975.m04552 Bm1 43055 Zinc finger, C2H2 type family protein
bm.02710 2,79 0,33 BMC02626 Bm1 55855 Zinc finger, C2H2 type family protein
BMX1113 1,84 0,49 13313.m00085 Bm1 07340 zinc metalloproteinase toh-2 precursor , putative
BMX4758 2,48 0,46 14950.m01863 Bm1 30230 Hypothetical 19.4 kDa protein ZC395.10 in chro-
mosome III, putative
BMX1056 2,79 0,46 13281.m00013 Bm1 06970 Hypothetical 28.7 kDa protein in RNR3-ARC15
intergenic region, putative
bm.02648 3,59 0,38 BMC09182 Bm1 45770 Hypothetical 31.4 kDa protein T19C3.2 in chro-
mosome III, putative
bm.00360 1,52 0,45 BMC01287 Bm1 13740 Hypothetical 37.7 kDa protein ZK686.3 in chro-
mosome III, putative
BMX8602 3,59 0,41 15053.m00051 Bm1 53480 Hypothetical 45.1 kDa protein C16C10.6 in chro-
mosome III, putative
BMX102 0,00 0,32 12485.m00052 Bm1 00740 hypothetical protein
BMX5927 0,00 0,31 14972.m07192 Bm1 37490 hypothetical protein
BMX8980 4,28 0,49 15315.m00009 Bm1 55900 hypothetical protein
BMX3235 0,52 0,29 14541.m00148 Bm1 20895 hypothetical protein
BMX1475 4,28 0,17 13499.m00138 Bm1 09715 hypothetical protein
BMX2912 3,59 0,25 14387.m00357 Bm1 18885 hypothetical protein
BMX6477 4,28 0,47 14972.m07865 Bm1 40740 hypothetical protein
BMX4150 1,52 0,25 14824.m00119 Bm1 26530 hypothetical protein
BMX2530 4,28 0,50 14245.m00086 Bm1 16475 hypothetical protein
BMX4294 2,48 0,23 14907.m00579 Bm1 27405 hypothetical protein
BMX6730 3,13 0,40 14975.m04393 Bm1 42280 hypothetical protein
BMX1421 1,84 0,42 13466.m00197 Bm1 09370 hypothetical protein
BMX8293 1,52 0,40 14992.m11105 Bm1 51615 hypothetical protein
BMX1985 2,48 0,46 13939.m00060 Bm1 13005 hypothetical protein
BMX12969 3,59 0,44 TC2966 Bm1 24320 hypothetical protein
bm.01122 3,59 0,41 BMC04958 Bm1 03285 hypothetical protein
BMX4396 4,28 0,41 14921.m00197 Bm1 28045 hypothetical protein
BMX2994 1,52 0,42 14419.m00094 Bm1 19415 hypothetical protein
BMX8270 3,13 0,40 14992.m11075 Bm1 51480 hypothetical protein
BMX3256 3,13 0,33 14553.m00038 Bm1 21020 hypothetical protein
BMX2312 2,79 0,34 14146.m00015 Bm1 15130 hypothetical protein
BMX766 1,84 0,49 13130.m00010 Bm1 05200 hypothetical protein
BMX7856 2,48 0,49 14990.m07928 Bm1 49020 hypothetical protein
BMX2479 1,52 0,48 14232.m00275 Bm1 16160 hypothetical protein
BMX3608 3,59 0,47 14658.m00022 Bm1 23225 hypothetical protein
BMX4004 2,48 0,34 14768.m00186 Bm1 25600 hypothetical protein
BMX12748 4,28 0,46 WB-contig 989 Bm1 55905 hypothetical protein
BMX8367 2,79 0,34 14992.m11195 Bm1 52065 hypothetical protein
BMX376 1,52 0,33 12698.m00332 Bm1 02525 hypothetical protein
BMX1990 4,28 0,49 13943.m00028 Bm1 13045 hypothetical protein
BMX5467 1,52 0,35 14963.m01802 Bm1 34660 Hypothetical UPF0054 protein TTE0972, putative
BMX9784 1,52 0,35 AA661405 no match
BMX12288 3,59 0,42 WB-
contig 1482
no match
BMX12963 1,52 0,16 TC2959 no match
BMX12270 2,79 0,26 WB-
contig 1461
no match
BMX12155 4,28 0,50 WB-
contig 1325
no match
BMX11586 1,52 0,24 BMW00827.474 no match
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